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Abstract 	  
	  
Inflammation is implicated in a wide array of diseases and is associated with the ageing 
process: ‘inflammageing’ is the low-grade inflammation that occurs as an organism 
ages. I was particularly interested in age-related inflammation of the brain, thought to be 
mediated by microglia, the immune cells of the central nervous system (CNS). To this 
end, I carried out RNA sequencing of microglia from young (6 months) and aged mice 
(23 months). I found that microglia from aged mice have a very distinct transcriptome 
signature. Interestingly, pathways associated with mTOR signalling and inflammation 
were upregulated. Given the evidence that mTOR is a key modulator of ageing, I 
investigated its role in inflammation in microglia. Using a mouse model in which Rheb, 
a positive regulator of mTORC1, was knocked out in Csf1r-expressing cells (microglia 
and macrophages), I found that in vivo LPS stimulation caused a significant increase in 
the transcription of inflammatory genes in microglia from mTORC1-deficient mice 
compared to controls. The effect was further exaggerated in mTORC1-deficient aged 
mice, suggesting a role for mTORC1 in the priming of aged microglia. However, these 
transcriptome changes were not translated into protein; indeed, Csf1r-Cre; Rheb f/f mice 
showed reduced overall inflammation, as measured by sickness behaviour in the open-
field test and by plasma cytokine levels. On the other hand, long-term treatment with 
rapamycin in vivo showed a very distinct phenotype, with reduced inflammation 
following LPS stimulation in young mice but no effect in aged ones. This PhD thesis 
sheds new light on pathways regulating microglia in ageing and has clinical 
implications for pathologies in which inflammation plays a major role. 
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1 Introduction 
1.1 Life expectancy 
World life expectancy has more than doubled over the past two centuries, rising from 25 
to 65 years in men and 25 to 70 years in women, resulting in a 2.5 year increase in 
lifespan per decade, as depicted in Fig. 1.11. This figure represents global life 
expectancy, whereas for example, in the U.K., the average life expectancy is much 
higher, ranging from 79.1 years for men to 82.8 years for women2. The United Nations 
(UN) has estimated that by 2050 the number of people over 60 years of age will exceed 
the number of people under 60 years of age in the western world3. 
Figure 1.1 Female lifespan expectancy recorded from 1840. The linear regression trend 
is depicted by a bold black line and the extrapolated trend by a dashed grey line. The horizontal 
black and grey lines show asserted ceilings on life expectancy, with a short vertical line 
indicating the study year of publication1.  
1.2 Ageing 
Ageing is defined as the gradual decline and functional deterioration of the body, 
leading to increased vulnerability to death4. While lifespan is clearly increasing, as 
described in Fig 1.1, the number of people ageing and therefore affected by age-related 
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diseases is also increasing. This is because ageing is a major risk factor for a number of 
chronic illnesses such as diabetes and cardiovascular diseases5, as well as cancer (Fig. 
1.2). Ageing is also a primary risk factor for a number of neurodegenerative 
pathologies, such as Alzheimer’s5. 
Figure 1.2 The average number of cases of all cancers (excluding non-melanoma 
skin cancer). The graph shows incidence rates of cancer per 100,000 (blue and pink lines for 
males and females, respectively) and cancer-related deaths/year (blue and pink bars). Data refer 
to cases in the United Kingdom from 2011 to 2013. Graph adapted from Cancer Research UK.  
The correlation between age and illness has also been shown for dementia, as depicted 
by Fig. 1.3 in the world Alzheimer’s report in 2015, which showed that the incidence of 
dementia exponentially increases with age, doubling with every 6.3-year increase in 
age6. 
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Figure 1.3 Estimated age–specific annual incidence of dementia in different 
regions across the globe. Incidence is given per 1000 persons per year on the x-axis, with 
each region depicted by a coloured line. Age groups are shown in years on the y-axis. High- and 
low-income countries are represented by the blue and red lines, respectively. Data was obtained 
from the World Alzheimer’s report 20156. 
It is clear that the burden of chronic illnesses is strongly correlated with age; it is 
therefore a major aim of ageing research to understand how we age and to try and treat 
age-related illnesses to potentially reduce this burden. “Researchers are learning about 
the molecular basis of ageing and finding clues about how to treat diseases in the 
process” Katherine Bourzac, Nature Outlook, 20127.  
1.3 The Hallmarks of Ageing  
In 2000 Hanahan and Weinberg described the six hallmarks of cancer, defining the key 
characteristics acquired by cancer cells, categorising the cancer research field into 
subfields that are still of extreme importance today8. A similar breakthrough publication 
was published in Cell in 2012 entitled “The Hallmarks of Ageing”, whereby the authors 
attempted to define the common denominators of ageing as shown in Fig. 1.4. The 
hallmarks were categorised into nine groups: 1) genomic instability – the accumulation 
of different types of DNA damage over time; 2) telomere attrition – the progressive loss 
of sequences from the ends of chromosomes as we age; 3) epigenetic alterations, such 
as histone modifications, DNA methylation and chromatin remodelling; 4) loss of 
proteostasis – the progressive loss of stability of the cell’s proteome, which leads to the 
accumulation of misfolded or aggregated proteins; 5) deregulated nutrient sensing – 
deregulation of many pathways that sense changes in the availability of nutrients, such 
as the Insulin Growth Factor (IGF), mammalian target of rapamycin (mTOR), AMP-
activated kinase (AMPK) or sirtuin-regulated pathways; 6) mitochondrial dysfunction – 
which may lead to an increased production of reactive oxygen species (ROS), known to 
accompany ageing and promoting the deterioration of mitochondria and other cell 
organelles; 7) cellular senescence – whereby cells exit the cell cycle and change their 
phenotype; 8) stem cell exhaustion – where tissues lose their ability to regenerate, this 
also includes the reduction of both haematopoiesis and the production of adaptive 
immune cells (Immunosenescence); 9) altered intercellular communications, such as 
“inflamm-ageing”, the low grade pro-inflammatory phenotype that accompanies ageing 
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in mammals4. Inflamm-ageing will be the focus of my PhD thesis and will therefore be 




Figure 1.4 The Hallmarks of Ageing - schematic showing “The Nine Hallmarks of 
Ageing”, adapted from Lopez –Otin et al.4. 
1.3.1 Inflamm-ageing 
 
A consequence of ageing is the increase in the inflammatory response that can often 
lead to tissue damage9. This damage can itself drive further inflammation in the form of 
cytokine secretion and ROS production. This perpetual cycle of damage and cytokine 
release can lead to chronic inflammation with age. This phenomenon was first described 
as inflamm-ageing in 2000 by Franceschi et al.10. In this paper, the authors proposed 
that “inflamm-ageing” is the combination of a progressive increase in pro-inflammatory 
status and a decreased ability to cope with a number of stressors. Furthermore, they 
postulated that the persistent pro-inflammatory phenotype that ensues over time is the 
first phenomenon that eventually leads to increased susceptibility to age-related 
illnesses. They suggest that genetic factors (loss of robust gene variants or gain of 
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diseases with an inflammatory pathogenesis, for example Alzheimer’s disease or many 
types of cancer9.  
1.3.2 Factors that contribute to inflamm-ageing  
 
A number of potential factors contribute to the induction of a more pro-inflammatory 
phenotype, for example impaired autophagy or inflammasome activation.  
Autophagy is the mechanism by which a cell digests its own cytoplasmic contents, it 
can be a survival pathway in the absence of nutrients but it is also required for the stead-
state removal of damaged organelles, which are eventually degraded in lysosomes. This 
process has been shown to decline with age11 and the accumulation of damaged 
organelles can lead to the activation of intracellular sensors such as inflammasomes, 
leading to increased inflammation. Inflammasomes are multiprotein complexes with 
different core components (Nod-like receptors – NLRs or AIM2) that assemble in 
response to a number of different danger signals and lead to the activation of caspase-1; 
once active, caspase-1 cleaves the inactive pro-IL-1 into its active form IL-1β, 
contributing to overall inflammation. For example, the NLRP3 inflammasome can be 
activated by ROS that are generated by an accumulation of dysfunctional 
mitochondria12. The NLRP3 inflammasome, in particular, has been associated with a 
number of age-related illnesses, such as Alzheimer’s disease13. The accumulation of 
amyloid beta in the Alzheimer’s brain is linked to a defective neuronal autophagy 
mechanism14; its accumulation activates the NLRP3 inflammasome in microglia cells, 
leading to the production of IL-1β, which contributes to neuroinflammation in 
Alzheimer’s disease13,15. In fact, NLRP3 -/- and Casp1 -/- mice, crossed with models of 
familial Alzheimer’s disease, were largely protected from spatial memory loss and had 
an enhanced capacity to clear amyloid β13, implicating the NLRP3 inflammasome as a 
key player in the pathogenesis of Alzheimer’s disease. Caspase-1 has also been shown 
to cleave pro-IL-18 into it’s active form IL-18 and therefore, it’s production must also 
be considered as a consequence of NLRP3 inflammasome activation16. 
1.3.3 Senescence Associated Secretory Phenotype (SASP) 
 
The factors described in the previous paragraph are also key stressors that can drive 
cellular senescence.  The senescence programme initiates cell-cycle arrest in order to 
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prevent cells from dividing and spreading damage to daughter cells. Once a certain 
threshold of damage is reached within the cell, the senescence programme is activated17. 
Senescent cells are characterized by the secretion of a number of factors, which have 
been collectively called the Senescence Associated Secretory Phenotype (SASP)17. The 
SASP was recently characterized by Coppe et al. using antibody arrays to measure the 
secretome of human fibroblast and epithelial cells that had been exposed to genotoxic 
stess18. They found that the secretome of senescent cells was complex and contained 
multiple factors that related to inflammation, including many interleukins, chemokines 
and growth factors18. There is a lot of interest on fully elucidating the SASP, as these 
factors may have an impact on surrounding cells that lead to multiple pathologies, for 
example cancer19. 
1.4 Ageing interventions  
1.4.1 Caloric restriction  
 
It was published for the first time in 1935 that restricting the number of calories, while 
retaining “adequate levels of all other constituents”, resulted in the extension of lifespan 
in white rats20, although it was not until the early 1990s that further studies showed that 
this was also evident in other model organisms such as yeast, worms, flies and mice21.  
In 2009 this was further supported by a report in Science which showed that caloric 
restriction (CR) could also extend lifespan in Rhesus monkeys22. This study was 
conducted over a 20-year period and included both male and female Rhesus monkeys. 
Monkeys were only enrolled in the study once they had reached adulthood and during 
the study they were continually monitored for signs of illnesses. The cause of death for 
each monkey was assessed by a pathologist; this allowed the authors to assess not only 
the effect of CR on lifespan but also to determine its impact on age-related illnesses. 
They found that monkeys, whose calories were not restricted, had three times the rate of 
death from age-related diseases, compared to monkeys who had calories restricted since 
adulthood. The authors identified long-term health benefits in monkeys on a calorie-
restricted diet, including a 50% reduction in the incidence of cancer and heart disease, 
as well as reduced brain atrophy, a sign normally associated with ageing. Strikingly, CR 
monkeys seemed to be completely protected from diabetes, with all experimental 
monkeys maintaining glucose homeostasis throughout their lifespan. Overall, CR 
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appeared to promote survival, reduce age-related illnesses and improve overall 
metabolic function22.  
 
Both the extension of lifespan and prevention of age-related illnesses are now widely 
accepted outcomes of CR.  In recent years, it has been proposed that CR may exert 
some of these anti-ageing properties by relieving oxidative stress and reducing chronic 
inflammation, two processes that increase with age. Evidence suggests that CR can in 
fact suppress the activation of the nuclear factor kappa beta (NF-κB) transcription 
factor23, a major player in the pro-inflammatory response, while promoting the 
activation of the peroxisome proliferator-activator receptor family (PPARs) of 
transcription factors24. The activity of PPARs have been shown to decline with age and 
recently PPARα and PPARγ, in particular, have been shown to inhibit inflammatory 
cytokine production and promote an anti-inflammatory phenotype24. 
 
Downregulation of mitogen-activated protein kinase (MAPK) family members ERK, 
JNK and p38 MAPK, modulation of the forkhead box O (FOXO) transcription factors 
and activation of sirtuins have all been linked to the anti-inflammatory effects of CR. It 
has been proposed that these mechanisms could at least in part explain the effects on 
health and lifespan exerted by CR25.  
1.4.2 mTOR inhibition  
 
The link between dietary restriction and the mTOR pathway in extending lifespan has 
become clearer in the past ten years. mTOR is a serine/threonine kinase that plays an 
essential role in cell growth and response to nutrients. A full description of mTOR, and 
the two complexes containing it, mTORC1 and mTORC2, is provided on pages 22-27 
of this introduction, here I only report evidence that mTOR inhibition is beneficial in 
lifespan extension.  
 
In 2006, Kaeberlein et al.26 conducted a large-scale experiment using 564 strains of 
Saccharomyces cerevisiae, each containing a single gene deletion. They identified ten 
strains out of 564 that showed a 30% increase in lifespan compared to wild-type (WT) 
yeast. Of these ten genes, six were related to the yeast homolog of mTOR known as 
TOR and the Sch9 pathway. The Sch9 gene encodes a protein kinase homologous to the 
mammalian protein kinase B/AKT and p70S6 kinase. In yeast, Sch9 is important for 
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regulating cell growth in response to nutrients27. Calorie restriction failed to extend 
lifespan in the TOR-deleted yeast strain, further suggesting that TOR is a target of CR26. 
These findings were further supported by a number of studies in which mTOR was 
genetically inhibited in other model organisms. For instance, Hansen et al.28 found that 
reducing levels of ribosomal proteins, S6 kinase or translation initiating factors, all 
downstream targets of TOR, extended lifespan in Caenorhabditis elegans29. Like in the 
yeast study, the authors found that reducing the levels of these factors by RNA 
interference in calorie-restricted worms did not extend lifespan further29.  Overall, these 
studies lead to the view that inhibition of TOR in lower organisms and mTOR in 
mammals, specifically the mTORC1 complex, was responsible for the extended lifespan 
caused by CR, although the effect on mTORC1 mediated by CR is likely to be very 
complex and warrants further investigation30. 
 
Given that genetic inhibition of mTOR was shown to extend lifespan in a number of 
model organisms, as shown in Tab. 1.1, there is significant interest in targeting mTOR 
as an anti-ageing intervention. In 2012, a study was published showing that mTOR 
inhibition with the drug rapamycin could extend lifespan in mice31. This pivotal study 
was carried out by the National Institute on Ageing Interventions Testing Program and 
tested rapamycin at three independent sites. Rapamcyin extended the median and 
maximum lifespan of both males and females at all three sites involved in the 
experiment. Rapamycin was encapsulated and incorporated into the diet and was given 
to mice starting from 600 days of age. The authors found that this lead to a 9% increase 
in male lifespan and a 14% increase in female lifespan31.   
 
There are a number of potential mechanisms that have been suggested to extend lifespan 
via mTOR inhibition. One of the primary functions of mTORC1 is to promote cell 
growth and proliferation in response to nutrients, an effect mediated by regulation of 
both the initiation and elongation steps of protein translation, through its downstream 
targets S6K and the eukaryotic translation initiation factor 4E-binding protein 1 (4E-
BP1)32.  
 
A global reduction in protein translation could be beneficial in ageing. For example, it 
could be particularly important when considering age-related pathologies in which 
protein translation becomes deregulated, for example in many types of cancers. 
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However, recent evidence suggests that it is not the global reduction in protein 
translation that mediates overall lifespan extension, rather the promotion of translation 
of specific mRNAs. For example, it was recently shown in yeast that genetic or 
pharmacological reduction of the 60S ribosomal subunit extends lifespan33. In this 
study, the authors found that 60S reduction lead to an increase in the activation of 
general control protein 4 (Gcn4), a transcription factor that is regulated by nutrient 
availability. Interestingly, they showed that this factor alone appeared to be essential for 
lifespan extension. In fact, in a number of long-lived mutant strains, this effect was 
abolished when Gcn4 was deleted. Gcn4 regulates the expression of many genes 
relating to both lifespan extension and autophagy and appears to be preferentially 
translated when mTORC1 is inhibited, due to structural features in its 5’ region34. The 
idea that a subset of mRNAs is preferentially translated upon mTOR inhibition and that 
this may influence lifespan extension is further supported by evidence that 
downregulation of the eukaryotic translational initiation factor 4G (eIF4G) in C. elegans 
lead to an increase in lifespan, which is mediated by an increase in translation of genes 
relating to the stress response33. 
 
The activation of autophagy has also been suggested as a potential mechanism that 
affects lifespan after mTOR inhibition, since mTOR is a negative regulator of this 
process35.  When nutrient availability is limited, cells initiate autophagy, a lysosomal-
dependent process of self-digestion, as mentioned previously. In this process, damaged 
organelles are hydrolysed, so that energy can be produced and used for other processes. 
ATG1 is an important kinase that forms a complex with ATG13 and ATG17 to initiate 
autophagy35. Autophagy declines with age and this has been implicated in a number of 
age-related illnesses, as previously discussed in the context of inflamm-ageing36. In a 
study in fruit flies, rapamycin caused an increase in lifespan that was accompanied by 
an increase in the number of lysosomes and autolysosomes, which indicated activation 
of autophagy. The authors used RNA interference to downregulate the autophagy gene 
ATG5 in rapamycin-treated flies and found that this completely abrogated lifespan 
extension, suggesting that, at least in Drosophila, the induction of autophagy was 
essential for mediating an increase in lifespan37. This report was further supported by a 
similar study in C. elegans in which TOR inhibition was also associated with an 
induction of autophagy and the autophagy genes bec-1 and vps-34 were shown to be 
required for longevity28. 
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Other mechanisms that have been linked to extension of lifespan via mTOR inhibition 
include enhanced stress resistance and improved mitochondrial function, as well as 
possible links to inflammation30.  The potential role of mTOR in the regulation of the 
inflammatory response will be further discussed in a later section.  
 
 
Table 1.1 Summary of studies on TOR signalling pathway and lifespan extension. 
The table provides a comparison of studies in which the mTOR pathway was either genetically 
or pharmacologically inhibited and then lifespan extension was assessed. The table includes 
studies carried out in four different model organisms; yeast, worms, flies and mice.  Table 1 is 
adapted from a review by Johnson et al.30.  
 
1.5 Microglia  
1.5.1 Microglia origin and discovery 
Microglia are immune cells that derive from myeloid progenitors residing in the brain 
during development38,39. They play an important role in the development, repair, 
response to injury and maintenance of the neural environment40. Pio del Rio Hortega 
first introduced microglia as morphologically distinct from astrocytes and neurons in a 
breakthrough publication in 1932, in which he made several observations that are still 
relevant today41 (Fig. 1.5).  
S. cerevisiae C. elegans D. melanogaster M. musculus
Rapamycin YES YES YES YES
mTOR gene mutation or knockdown YES YES YES YES
Raptor gene mutation or knockdown Not reported YES Not reported Not reported 
Tsc1 and Tsc2 activation Not applicable Not applicable YES Not reported 
S6K gene mutation or knockdown YES YES YES YES
4E-BP activation Not applicable Not applicable YES Not reported 
Translation initiation factor knockdown YES YES Not reported Not reported 
Ribosmal protein knockdown YES YES Not reported Not reported 
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Figure 1.5 Microglia cells as described by Rio Hortega in 1932. Photomicrographs 
showing the evolution of microglia during phagocytic activity. A) A cell with thick, rough 
prolongations; B) a cell with short prolongations and enlarged cell body; C) an hypertrophic cell 
with pseudopodia; D) and E), amoeboid and pseudopodic forms; F) a cell with phagocytosed 
leukocyte; G) a cell with numerous phagocytosed erythrocytes; H) a fat-granule cell; I) a cell in 
mitotic division41. 
1.5.2 Microglia function 
Microglia share both phenotypic and functional characteristics with other mononuclear 
phagocytes. Phenotypically, they express major histocompatibility complex (MHC) 
molecules I and II, as well as several cluster of differentiation (CD) proteins42-44. 
Functionally they are able to carry out myeloid-specific functions including antigen 
presentation and phagocytosis as well as contribute to inflammation45.  However, 
microglia are also quite distinct from other tissue-resident macrophages due to their 
neural environment46. While there have been many studies focusing on the role of 
microglia in CNS pathology, it is only becoming apparent that these cells play a vital 
role in CNS homeostasis47, participating in functions such as phagocytosis of apoptotic 
neurons, synaptic pruning48, reorganisation of neuronal circuitry, as well as regulation 
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of neurons and their numbers in the developing and adult CNS. They carry out this 
function by phagocytosing neurons with an “eat me” signature and also by triggering 
programmed cell death in neurons by the release of neurotoxic substances49. One 
possible “eat me” signal detected by microglia is phosphatidylserine (PS), expressed on 
the plasma membrane of dying cells. One study showed that primary rat cultures of 
neurons co-cultured with microglia and stimulated with lipopolysaccaride (LPS) lead to 
neurons exposing PS, resulting in phagocytosis of dying neurons by microglia. In fact 
the authors showed that up to 90% of neurons in this system could be rescued by 
blocking the microglia receptor for PS, the vibronectin receptor50. Another possible “eat 
me” signal is the cellular ligand for TREM2 (triggering receptor expressed by myeloid 
cells-2) that is upregulated on dying neurons. It has been suggested that this interaction 
promotes microglia-mediated phagocytosis51. 
There are also important neuronal “don’t eat me” signals that can inhibit phagocytosis 
in microglia, for example, CD47 is expressed on cells and myelin in the brain and binds 
to SIRPα expressed on microglia. It has been shown that binding of CD47 to this 
receptor inhibits phagocytosis in microglia52. Another example of a “don’t eat me” 
signal is polysialylated proteins that are expressed on the surface of neurons. These 
proteins have been shown to bind to sialic acid-binding immunoglobulin-like lectins 
known as SIGLECs. The binding of these proteins can active SIGLEC-E expressed on 
mouse neurons and can also inhibit phagocytosis53. It has also been shown that neurons 
can secrete the chemokine CX3CL1, known as fractalkine. This chemokine can 
suppress the microglia-mediated inflammatory response by binding to it’s receptor 
CX3CR1 expressed on the surface of microglia and in this way can provide another 
signal preventing the phagocytosis of the neurons by microglia54. 
Microglia also play a role in adult neurogenesis by either phagocytosing neural 
progenitor cells55 or by stimulating the proliferation of progenitor cells through the 
secretion of soluble factors such as the protease inhibitor, TIMP-1, chemokines such as 
CXCL1 and RANTES and pro-inflammatory cytokines such as IL-656.  
Evidence is also emerging that microglia monitor and maintain synapses in the 
uninjured brain. Two-photon imaging has shown that microglia cells are highly active 
and motile even in their resting state. They are highly branched and continually survey 
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their microenvironment57,58, which results in frequent and persistent contact with 
synapses47. During early development, new neurons and synapses are made at a very 
high rate, resulting in more neurons and synapses than required. Synaptic pruning is a 
process by which these “excessive” synapses are removed. Overgrowing synapses 
followed by their pruning was first shown to be important for optimal memory 
performance59. Paolicelli et al.48 showed through the use of immunohistochemistry and 
electron microscopy that uninjured brain microglia engulfed synaptic material in the 
process described as synaptic pruning48. The authors suggested that microglia exerted a 
central role in the accurate maturation of synapses and that a deficit in this process 
could lead to neurodevelopmental disorders48.  
Recently a number of signals have been identified that may trigger the process of 
synaptic pruning by microglia. One of the best described is the complement proteins 
C1q and C3. These proteins have been shown to be expressed in a variety of regions in 
the healthy postnatal brain mainly localising to immature synapses in these regions60. 
Microglia are known to express the receptor for these complement proteins known as 
complement receptor 3 (CR3) and in fact the engulfment of synapses by these cells has 
been shown to be significantly reduced in both C3 and CR3 KO mice suggesting that 
microglia are targeted to immature synapses by the complement proteins61. The 
CX3CL1-CX3CR1 signalling axis between neurons and microglia has also been 
implicated in the process of synaptic pruning. Most of evidence for this comes from KO 
models where CX3CR1 was deleted. One study showed that CX3CR1 KO mice had an 
accumulation of immature dendritic spines in the developing hippocampus48. A similar 
study showed an increase in immature synapses in the cortex of CX3CR1 KO mice62. 
Both the complement system and the CX3CR1 signalling axis have both been 
implicated in the process of synaptic pruning during brain development; however, other 
molecules have been implicated in this process in the adult brain. One example is ATP, 
which has been shown to be important for purinergic signalling, as well as enhancing 
the outgrowth of microglia processes during times of high neuronal activity63. Other 
molecules implicated in the adult brain include cytokines such as TNF which has been 
shown to modify the strength of synapses64 as well as brain-derived neurotropic factor 
(BNDF)48,65. 
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1.5.3 Microglia activation 
One of the characteristic features of microglia is their rapid activation in response to 
minor changes in the CNS. Given the appropriate stimuli, microglia undergo a 
morphological shift from a highly branched and ramified morphology to an activated 
amoeboid morphology with retracted processes and enlarged cell bodies66. This 
phenotypic shift is different to other antigen presenting cells (APCs) such as dendritic 
cells and splenic macrophages, which extend their dendrites upon antigen stimulation67. 
Microglia activation proceeds through a series of steps (Fig. 1.5)68. Their activation 
involves two mechanisms: the loss of inhibitory signals received from neurons or the 
triggering of receptors by a range of stimuli69 (Fig. 1.6).  
 
Figure 1.6 Illustration depicting the fine balance between inhibitory and activating 
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1.6 Microglia and ageing 
To date, the majority of studies on microglia have focused on the adult brain, yet it 
appears that the function and phenotype of these cells changes over the entire lifespan. 
For example, during development, microglia clear unnecessary debris, aberrant 
proteins42 and apoptotic cells72. They exert an important function in pruning excess 
neurons in the developing brain73, eliminating synapses74 and possibly influencing the 
formation of neural circuits and the correct development of the brain75,76, as previously 
mentioned. In the adult brain, resting microglia are continuingly surveying the brain58 
and play an important part in maintaining CNS homeostasis47.  
1.6.1 Morphology and distribution 
While it is known that microglia activation becomes deregulated in the course of 
diseases such as Alzheimer’s, during which they become reactive and inflammatory13, 
less is known about microglia function during the process of  “healthy” brain ageing. A 
study by Tremblay et al.77 showed that microglia increase in numbers and become 
unevenly distributed throughout the cortices in two inbred strains of mice as they 
aged77. This agreed with an earlier study that examined the cortex region of the brain in 
rats, reporting a similar increase in numbers and shape alterations in aged microglia78. 
Aged microglia in the human brain demonstrated a change in morphology including de-
ramification, loss of protrusions and branches, spheroid formation and fragmentation of 
processes40. These findings were confirmed using time-lapse live-cell confocal imaging 
of resting retinal microglia in the mouse eye, where aged microglia appeared 
significantly smaller and less branched than their younger counterparts79. This 
dystrophic change in morphology has been suggested as an indication of microglial cell 
senescence80, whereas other studies suggest that the changes are a reflection of a more 
active phenotype81. 
1.6.2 Microglia activation markers  
Other studies that have investigated changes in microglia in the ageing brain have 
looked at the expression of activation markers. Ogura et al. showed that the number of 
MHC II-positive microglia increased in older (12 month) rats compared to their younger 
counterparts (3 months)82. This observation was further supported by a later study that 
isolated microglia from the hippocampus of 3- and 24-month old rats. Here, the authors 
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showed, by quantitative real-time PCR (qPCR), an increase in expression of MHC II 
and also of another microglia activation marker, CD8683. Letiembre et al. also used 
qPCR but this time using RNA from the whole brain to show an increase in the 
expression of the microglia activation marker CD1484. 
1.6.3 Microglia regulation of inflammation 
Several studies have focused on microglia in the ageing brain and whether they 
contribute to “inflamm-ageing”10. One study used immunohistochemical analysis and 
qPCR to show that, in human brain samples, there was an increase in the number of IL-
1α positive microglia in the ageing brain85. Another study showed an increase in the 
levels of the pro-inflammatory cytokine IL-6 in protein extracts from different regions 
of the brain, such as the cortex and cerebellum, in 24-month old mice compared to 
young counterparts. The authors also reported a spontaneous increase in the expression 
of IL-6 in microglia cultures prepared from aged mice, as well as an increase in the 
number of IL-6+ microglia cells. Therefore, they suggested that microglia might be 
responsible for the increase in IL-6 in the ageing brain86. While these two studies 
suggest an increase in basal levels of pro-inflammatory cytokines in the ageing brain, 
other studies have also shown a more profound activation of the inflammatory response 
in aged rodents upon peripheral LPS challenge, which appeared to be attributed to more 
active microglia87. Henry et al.88 further supported this hypothesis by showing that 
peripheral LPS caused an overactive response in microglia from aged mice. A specific 
increase in IL-1β production was observed in the microglia from aged mice compared 
to younger mice upon LPS administration88. 
It has been suggested that, with ageing, microglia become “primed” and more sensitive 
to a second “triggering” stimulus. In the above study, this is demonstrated by the 
administration of LPS, which then lead to an increase in pro-inflammatory cytokine 
production in the aged mice, as explained in the schematic in Fig 1.789. Other studies 
also support the age-related inflammatory response in microglia, for example a recent 
publication in the journal Nature suggested a critical signalling axis whereby soluble 
TNFα, a major pro-inflammatory cytokine, mediated microglia-neuron crosstalk via 
IkappaB kinase-alpha (IKK-β) and NF-κB90. In this study, Zhang et al. showed that 
TNFα produced by microglia had an impact not only on cognitive function but also 
seemed to exhibit some control over systemic ageing, given its action on neurons in the 
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hypothalamus and regulation of their Gonadotropin Releasing Hormone (GnRH) 
production, highlighting the importance of both microglia and the key regulator of 
inflammation, NF-κB90. 
 
Figure 1.7 Schematic showing how microglia in the ageing brain may contribute to 
neurodegeneration. Microglia become primed by endogenous proteins in the brain that 
accumulate with age. This priming causes the microglia to become over-responsive to a 
peripheral infection. This increase in neurotoxic factors may then contribute to the overall 
degeneration of the ageing brain, leading to cognitive decline91. TNFα, tumour necrosis factor-
α; Il-1β, Interleukin 1β; NO, nitric oxide; PGE2, prostaglandin E2.  This figure is based on 
reports from the literature42,92,93. 
1.6.4 Loss of regulatory signals in microglia with ageing 
It has been suggested that the priming of microglia depends on the loss of regulatory 
signals in the ageing brain (as previously described in Fig. 1.7). This is supported by 
studies that have shown that the receptors CX3CR194 and CD200R83 are decreased on 
microglia with age, suggesting a loss of regulation from neurons to keep microglia in a 
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1.7 The transcriptome of ageing microglia  
Four independent papers have investigated age-related changes in gene expression in 
microglia. They have all demonstrated that the gene expression profile of microglia 
from the ageing brain changes considerably when compared to microglia isolated from 
young brains.  
Ma et al.91 isolated microglia from the retina of wild type C57BL/6J mice of 3, 12, 18 
and 24-months of age. Affymetrix gene chip technology was used to profile changes in 
gene expression as the age of the mice progressed. The authors identified 719 genes 
with a fold change of 1.5 or greater that were differentially expressed between at least 
two of the three age groups compared. Among the top genes, they identified the 
chemokine and neuroinflammatory biomarker Cxcl13, with a 15-fold change in old 
versus young microglia. They also observed changes in expression in the complement 
protein C3 and the positive regulator of complement Cfb, which were validated at 
protein level with immunohistochemical staining. Using pathway analysis, they 
identified a number of deregulated inflammatory pathways, including IL-1 and MAPK 
signalling pathway, as well as pathways involved in lipid biosynthesis, angiogenesis 
and neurotrophin signalling. The authors suggested that deregulation of these pathways 
may indicate a more active phenotype91.   
Orre et al.95 isolated microglia and astrocytes from the cortices of C57BL/6 mice of 2.5 
months and 15-18 months of age and used microarrays to profile changes in gene 
expression. In this study, they identified 482 genes with a fold change of 2 or greater 
differentially expressed in old versus young microglia. Among the most differentially 
expressed genes were Ccl3, Pik3cd, Lyzl and genes within the TNF (Tumour necrosis 
factor) ligand family. They also found an enrichment of genes related to cytoskeletal 
protein binding and phagocytosis95.  
Hickman et al.96 isolated microglia from the whole brain from 5-month and 24-month 
old C57BL/6J mice and they carried out transcriptome profiling by direct RNA 
sequencing, which is done without prior cDNA amplification. The authors identified a 
set of genes which they define as the microglia “sensome”, determined by using gene 
ontology analysis and comparing adult microglia with the whole adult brain. In doing 
so, they identified 1,299 genes that may be involved in sensing the neural environment 
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and selected the top 100 differentially expressed to describe the microglia sensome, 
which included many purinergic receptors, chemokine receptors, members of the Siglec 
family and Toll-like receptor 2 (Tlr2). They then assessed changes that occurred in the 
microglia sensome between young and aged mice. They found that 31% (31 of 100) of 
the sensome genes were significantly downregulated, including genes involved in 
sensing endogenous ligands. On the other hand, 13% (13 of 100) of the sensome genes 
were upregulated; many were involved in sensing microbial agents such as bacteria or 
fungi and included genes such as Tlr2, CD74, Clec7a, Cxcl16 and Ifitm6. Looking at the 
entire transcriptome between old and young microglia, they identified 1,832 transcripts 
to be upregulated in aged microglia and 1,672 to be downregulated. Gene set 
enrichment analysis (GSEA) was then used to identify pathways that were also affected 
by age. They found oxidative phosphorylation, which they describe as potentially 
neurotoxic, to be downregulated and several pathways that have been linked to 
neuroprotection to be upregulated, such as the Stat3 and Neuroegulin-1 pathway96. 
Grabert et al.97 carried out transcriptional profiling of microglia from discrete brain 
regions including the cerebellum, cerebral cortex, hippocampus and striatum. This paper 
addressed two questions. Firstly the consistency of the microglia transcriptome across 
different brain regions in 4-month old mice and secondly how microglia change with 
age, using 12-month and 22-month old mice. They found that the microglia 
transcriptome was in fact regionally heterogeneous. Their analysis suggested that the 
majority of genes expressed by microglia are fairly consistent between the cerebral 
cortex and striatum but the expression profiles from the cerebellum and hippocampus 
were more distinct. In young mice, the major differences appeared to fall into two major 
categories; bioenergetics/metabolic processes and those related to immune function. 
Microglia from young mice had higher expression of genes relating to immune function 
such as antigen presentation, chemotaxis and cell adhesion in the cerebellum, whereas 
genes relating to energy metabolism were enriched in both the cerebellum and 
hippocampus. One such example was the transcription factor and mTOR target, PPAR-
γ, which is known to be involved in lipid biosynthesis and mitochondrial function. 
Overall it appeared that microglia from the cerebellum and hippocampus have 
transcriptome profiles that indicate they are in a more immune vigilant state and 
possibly, as a consequence, they express higher levels of bioenergetics genes compared 
to microglia from the cortex and striatum97. 
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To understand if the impact of ageing on microglia was consistent among the identified 
brain regions, the authors also looked at the microglia transcriptome from aged mice 
and found that 50% of the region-defining transcripts from young mice were 
deregulated with age. However, these differences appeared to be due to changes in 
expression of genes relating to immune regulation, rather than the bioenergetics cluster 
of genes previously described. Interestingly, it seemed there was a region-dependent 
influence on microglia with age, most notably a reduction in the distinction of 
hippocampus microglia and an increase in the immunophenotype associated with the 
cerebellum microglia. Microglia in the cerebellum appeared to be more immune alert 
with age. The authors speculate that this heightened alertness is important and could be 
detrimental if poorly controlled. However, it could also confer protective functions by 
increasing vigilance and potentially clearing harmful agents more efficiently97.  
1.8 mTOR signalling structure, organisation and activation 
mTOR is a 298-kDa serine/threonine kinase of the phosphoinositide 3-kinase (PI3K) 
related family, a master regulator of cellular growth and metabolism, which is 
deregulated in a number of human diseases, including type 2 diabetes and cancer98. 
mTOR forms the catalytic subunit of two distinct complexes known as mTORC1 and 
mTORC2 that differ in their composition, substrates, activation and functions. 
mTORC1 is composed of three core components: Raptor, mLST8 and mTOR itself, 
plus two distinct negative regulatory components known as Deptor and PRAS40. The 
roles of both Raptor and mLST8 are relatively unknown, although it has been suggested 
that Raptor acts as a scaffolding protein essential for mTORC1 assembly99. mTORC2 
comprises six components; Rictor, mSIN1, Protor-1, mLST8 and Deptor100. Deptor is a 
negative regulatory subunit of both mTORC1 and mTORC2, whereas mSIN1 and 
Rictor are necessary for the assembly of mTORC2101. 
mTOR acts as a rheostat, sensing both extracellular and intracellular changes and  
regulating how the cell responds. mTORC1 plays an important role in sensing 
alterations in growth factors, energy status, amino acids and oxygen. The tuberous 
sclerosis complex (TSC), which is constituted of two components, TSC1 and TSC2, is 
an important sensor of these signals and can regulate mTORC1 activity accordingly. 
The TSC complex negatively regulates mTOR through the small GTPase known as the 
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ras homolog in brain (Rheb). It has recently been identified that the TSC complex 
regulates Rheb by acting as a GTPase-activating protein (GAP) towards Rheb. When 
the TSC complex is active, it causes hydrolysis of guanosine triphosphate (GTP) by 
Rheb, which leads to the conversion of active GTP to inactive guanosine diphosphate 
(GDP). This renders Rheb inactive and therefore it can no longer interact and activate 
mTORC1. However, when PI3K is activated, this will lead to phosphorylation of its 
downstream target AKT by PDK1. Activated AKT can then phosphorylate TSC2 at 
S939, S1130 and T462, which leads to a complete inhibition of the TSC complex, 
allowing Rheb to remain in its active GTP state and fully activate mTORC1 (Fig 
1.8)102. 
 
Figure 1.8 Structure and function of mTOR.  Growth factors, cytokines and hormones 
can bind to the IGF/Insulin receptor and drive the activation of PI3K leading to activation of 
PDK1 and subsequent phosphorylation of AKT at threonine 308. When AKT is active, it can 
phosphorylate TSC2 rendering the TSC1/TSC2 complex inactive. This results in the GTPase 
Rheb to remain in its GTP-bound active state, therefore positively regulating mTORC1. 
mTORC1 can then phosphorylate a number of downstream substrates and regulate different 
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1.8.1 mTOR regulation by growth factors  
The mechanism by which AKT inactivates the TSC complex has been demonstrated to 
occur in response to growth factor activation103. However, other mechanisms have also 
been described that are independent of the TSC complex. Vander Haar et al. described a 
mechanism by which the mTOR binding partner PRAS40 was phosphorylated by AKT, 
reducing its binding and therefore inhibitory capacity towards mTORC1. This was 
shown in cells lacking TSC2, emphasising that PRAS40 is an important regulator of 
insulin sensitivity independent of the TSC complex104. Activation of mTORC1 by 
growth factors leads to a negative feedback mechanism by which PI3K activation is 
inhibited. This is probably a mechanism evoked by the cell to prevent chronic activation 
of mTORC1. This inhibitory loop occurs through phosphorylation of Insulin Receptor 
Substrate 1 (IRS-1) by S6K1, a downstream target of mTORC1. IRS-1 becomes 
phosphorylated at multiple tyrosine residues when the IGF/Insulin receptor is 
appropriately engaged and its phosphorylation leads to the recruitment and activation of 
PI3K. However, when IRS-1 is phosphorylated at certain serine residues, like Ser-
270105, its stability is reduced and this leads to a downregulation of PI3K signalling106. 
1.8.2 Regulation of mTOR by energy status  
 
AMP-dependent kinase (AMPK) is important for maintaining a homeostatic level of 
adenosine triphosphate (ATP) within the cell. When energy demands increase, cells 
activate processes that drive energy production, such as autophagy and inhibit energy 
consuming processes, such as the synthesis of new proteins107. AMPK is a critical 
regulator in the maintenance of ATP levels and it regulates these functions at least in 
part through inhibition of mTOR108. When intracellular ATP is low, AMPK is activated 
and phosphorylates TSC2, in a manner that enhances its suppression of mTOR. It has 
also been shown that AMPK can directly phosphorylate Raptor on two well-conserved 
serine residues that lead to inhibition of mTORC1. Therefore, during times of energy 
stress, AMPK act as a metabolic checkpoint through inhibition of mTORC1107.  
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1.8.3 Regulation of mTOR by amino acids  
 
Availability of amino acids also affects mTORC1 activation. This phenomenon appears 
independent of insulin and TSC and is therefore mechanistically different from the 
insulin/PI3K pathway that is normally activated by growth factors109. A small group of 
GTPases, known as the Rag proteins, are key mediators of amino acid-mTORC1 
signalling. mTOR is normally localised to the endomembrane, which consists of the 
endoplasmic reticulum, golgi apparatus and endosomes. However, one group showed 
that under amino acid deprivation, mTOR was found in tiny punta throughout the 
cytoplasm but relocated to the perinuclear region of the cell, following just three 
minutes of amino acid stimulation. The authors showed that this re-localisation required 
the expression of the Rag proteins and Raptor.  They also showed that amino acids 
appear to regulate the nucleotide loading and subsequent activation of the Rag proteins 
and further suggested that the re-localisation of the mTORC1 complex to the 
perinuclear region takes place in order to direct mTOR to the same intracellular 
compartment as its activator Rheb110.  
1.8.4 Regulation of mTOR by oxygen levels  
 
Oxygen levels have also been shown to activate and regulate mTORC1. Oxygen is 
essential for regulating metabolism and in hypoxia, when oxygen levels are low, cells 
activate a number of mechanisms that reduce energy expenditure and protein synthesis. 
For example, hypoxia has been shown to inhibit mTORC1 through TSC1/2 and 
REDD1. REDD1 activity allows the TSC complex to be released from its association 
with the inhibitory 14-3-3 proteins, therefore it can resume its negative regulation of 
mTOR during hypoxic conditions111.  
1.9 mTORC1 function 
 
Much of our knowledge about the functions of mTORC1 comes from the use of its 
inhibitor rapamycin. Rapamycin is a lipophilic macrolide, originally isolated from 
Streptomyces hygrocropicus by Suren Sehgal and given the name of rapamycin (from 
Rapa Nui, the Polynesian name of Easter island)112. Rapamycin functions by binding to 
a small protein known as FKBP12. When rapamycin is bound, FKBP12 cannot interact 
with mTORC1 and therefore mTORC1 activation is prevented. It was originally thought 
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that rapamycin was specific to mTORC1 as this FKBP12-rapamycin complex cannot 
interact with mTORC2, however in recent years it has been shown that the duration and 
concentration of rapamycin can result in inhibition of mTORC2, as well as mTORC1. 
This is due to the fact that rapamycin can bind newly synthesised molecules of mTOR, 
preventing its recruitment in the mTORC2 complex113. It is important to note that some 
functions of mTORC1 are rapamycin-resistant, for example translation of certain 
transcripts114,115, this must be taken into account when assessing mTORC1 function 
based on the use of this drug.  
1.9.1 mTOR regulation of protein synthesis  
 
One of the main functions of mTOR is to drive cell growth and proliferation. It does so 
by regulating different aspects of protein synthesis through a number of mechanisms. 
Active mTORC1 phosphorylates the translational repressor 4E-BP1. Upon 
phosphorylation, 4E-BP1 releases the eukaryotic translation initiation factor eIF4E, 
allowing it to interact with other eIF proteins and drive the initiation of cap-dependent 
translation114. mTOR can also phosphorylate p70 S6 kinase (p70S6K), also involved in 
protein synthesis, particularly in regulating the elongation phase of protein translation as 
described in Fig. 1.8. Recently, it has been shown that the subset of mRNAs that appear 
to be specifically regulated by mTORC1 are transcripts that have a 5’-terminal 
oligopyrimidine (TOP) motif114,115. 
1.9.2 mTOR regulation of lipid synthesis 
 
Lipid biosynthesis is extremely important for the maintenance of homeostasis in the 
cell. Lipids such as fatty acids, cholesterol and phospholipids are essential for a number 
of functions, for example, to act as an energy source, signalling molecules or for the 
assembly of new organelles and plasma membrane upon cell division116. There is 
growing evidence that mTORC1 may play a very important role in lipid synthesis. It 
has been shown that the PI3K/AKT/mTOR pathway positively regulates the 
transcription factor PPARγ (Fig. 1.8), therefore regulating the expression of genes 
involved in adipogenesis117. There is also evidence that mTORC1 positively regulates 
the activity of the transcription factor sterol regulatory element-binding protein-1 
(SREBP-1). SREBP-1 controls the expression of genes involved in lipid homeostasis 
such as those relating to cholesterol, fatty acid and phospholipid synthesis118.  
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1.9.3 mTOR and autophagy  
 
Autophagy, as previously discussed in the paragraph on inflamm-ageing, is an 
important process by which dysfunctional organelles and cellular components are 
degraded by lysosomes. While this is important for maintaining homeostasis, it also 
provides biological material to sustain processes such as the synthesis of new lipids, 
carbohydrates and proteins as a source of energy35. It is well accepted that inhibition of 
mTORC1 leads to induction of autophagy, suggesting that mTOR negatively regulates 
this process. Recently, it was shown that the autophagy factor Atg13 forms a complex 
with unc-51-like kinase 1 (ULK1) and focal adhesion kinase family interacting protein 
(FIP200). mTOR phosphorylates ULK1 and Atg13 in a nutrient dependent manner, 
blocking the induction of autophagy119 (Fig. 1.8). 
1.9.4 mTOR and mitochondria metabolism  
 
It has been shown that mTORC1 plays a role in mitochondrial function and biogenesis. 
For example, Sieke et al. showed that mTORC1 regulates oxygen consumption as well 
as oxidative capacity, as inhibiting mTOR with rapamycin had a significant impact on 
ATP synthetic capacity and lowered both mitochondrial membrane potential and 
oxygen consumption. Interestingly, the authors also found that inhibiting mTORC1 had 
a dramatic effect on the mitochondrial phosphoproteome120.  Another study provided 
supporting evidence that mTORC1 is important for mitochondrial function121. The 
authors showed that inhibition of mTOR with rapamycin in skeletal muscle resulted in a 
decrease in the expression of the PPARγ coactivator 1, known as PGC1-α. This 
transcription factor is an important regulator that controls mitochondrial oxidative 
function and sustains energy levels in response to nutrients and hormones. mTORC1 
inhibition by rapamycin lead to a decrease in mitochondrial gene expression and oxygen 
consumption121. 
1.10 mTORC2 function and activation  
mTORC1 is the mTOR complex more intensely studied, on the other hand, relatively 
little is known about mTORC2 in comparison. This may be caused by a lack of specific 
inhibitors of mTORC2, therefore most of the research to date has been carried out with 
genetic models in which elements of the complex were deleted. The main downstream 
substrate of mTORC2 is AKT. AKT is phosphorylated by PDK1 on threonine 308 when 
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PI3K signalling is activated, however full activation of AKT requires an additional 
phosphorylation on serine 473, which is mediated by mTORC2 (Fig. 1.8)122. Through 
its regulation of AKT, mTORC2 regulates the phosphorylation of the transcription 
factors FOXO1 and FOXO3a, which causes their inhibition. These transcription factors 
are involved in multiple cellular processes including cell-cycle arrest, apoptosis, 
autophagy and inflammation123. Besides a potential role of mTORC2 in cell survival 
and metabolism, it has been shown to regulate the organisation of the cytoskeleton, 
since knock down of components of the mTORC2 complex appeared to affect actin 
polymerisation, possibly through phosphorylation of protein kinase C alpha (PKCα)124.  
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1.11 Regulation of inflammation in innate immune cells by 
mTOR 
The mTOR pathway plays an important role in regulating immune cell function. This is 
well established, especially in T cells, which has lead to the use of mTOR inhibitors to 
suppress T cell function in transplantation125. However, there is evidence that mTOR 
regulates inflammation and metabolic processes also in myeloid cells, which is the 
focus of my PhD project.  
The first evidence that PI3K was involved in the regulation of myeloid inflammatory 
responses came in 2002, when a group investigated the role of PI3K in regulating IL-12 
production in dendritic cells (DCs)126. In this Nature Immunology paper, Fakao et al.126 
studied DCs isolated from the spleens of PI3K -/- mice, characterised by deletion of the 
gene for the p85α regulatory subunit. They stimulated PI3K -/- and wild-type DCs with 
Staphylococcus Aureus Cowan 1 (SAC) and anti-CD40 to trigger the induction of IL-
12, in the presence or absence of factors that enhance IL-12 production, such as 
interferon-γ (IFN-γ) and IL-4. They found in all conditions tested that splenic DCs from 
PI3K -/- mice produced significantly larger amounts of IL-12 compared to wild-type 
counterparts.  They confirmed these findings in DCs generated from bone-marrow cells, 
known as bone marrow derived dendritic cells (BMDCs) and also by using the PI3K 
inhibitor wortmannin. These results suggested that PI3K negatively regulated IL-12 
production in mouse splenic DCs and BMDCs. The increased IL-12 production 
correlated with an increase at transcriptional level of the two subunits for IL-12, known 
as p35 and p40. They found that the kinetics of cytokine production was not altered but 
that gene expression for both p35 and p40 was significantly increased in PI3K-/- 
BMDCs, suggesting that the increase in IL-12 production is due to enhanced 
transcription rather than post-transcriptional modifications. Mechanistically, the authors 
showed that activation of the MAPK p38 was higher in wortmannin-treated BMDCs 
following LPS stimulation and a selective inhibitor of p38 caused a reduction in IL-12. 
Finally, the study assessed if mice infected with Leishmania major which requires an 
effective Th1 response to clear the infection, were protected when PI3K was inhibited. 
It has previously been established that Balb/c mice are susceptible to L. major infection, 
since they cannot mount an effective Th1 response; this is normally rescued by the 
administration of IL-12. Indeed, infected Balb/c PI3K -/- mice were resistant to the 
	   45	  
infection, as indicated by a significant reduction in the number of parasites in the 
popliteal lymph nodes 6-weeks post infection. This resistance was accompanied by an 
increase in Th1 cytokines IFN-γ and TNF126. These experiments highlighted the 
biological relevance of IL-12 regulation by PI3K.  
These findings were further supported by Martin et al.127 that found IL-12 production 
was enhanced in human monocytes following PI3K inhibition and that IL-10 production 
was suppressed127.  This is consistent with a report by Aksoy et al.128 who showed that 
DCs from mice with a knock-in mutation in the p110δ isoform (rendering it inactive) of 
PI3K had augmented cytokine production128. The authors went on to explain that this is 
due to differences in TLR4 internalisation and downstream consequences on alternative 
TLR signalling. 
Weichhart et al.129 went on to investigate the role of mTOR in these processes. This 
paper demonstrated that inhibition of mTOR by rapamycin lead to the production of 
pro-inflammatory cytokines (IL-12p40, IL-12p70, IL-6 and TNF) and a decrease in IL-
10 in human peripheral blood mononuclear cells (PBMCs) and monocytes upon 
stimulation by LPS or SAC. Upon LPS stimulation, TSC2 was phosphorylated in an 
AKT dependent manner and phosphorylation of mTOR and its downstream targets was 
observed. These events could be prevented by treatment with wortmannin, suggesting 
that PI3K signalling is upstream of mTOR in LPS signalling in human monocytes. 
These findings were confirmed in TSC2 -/- murine embryonic fibroblasts (MEFs) 
transfected with an IL-12p40 plasmid. TSC2 is important for negatively regulating 
mTOR activation; therefore the mTOR pathway is constitutively active in cells lacking 
TSC2. IL-12p40 could not be induced in TSC -/- MEFs upon LPS stimulation compared 
to wild-type MEFs, which supported the idea that mTOR negatively regulates IL-12 
production. To understand how mTOR regulates the expression of inflammatory 
cytokines, the authors examined the effect of mTOR inhibition on the activity of the 
transcription factor NF-κB. NF-κB is a master regulator of inflammatory responses and 
controls the expression of many pro-inflammatory cytokines130. Indeed, mTOR 
inhibition with rapamycin lead to enhanced activation of NF-κB upon LPS stimulation, 
as demonstrated by the electromobility shift assay. Consistent with this, TSC2 -/- 
showed a decreased ability to activate NF-κB. These findings, and the relevant 
molecular interactions, are exemplified in the schematic in Fig. 1.9. Furthermore, the 
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authors found that mTOR inhibition lead also to a decrease in IL-10 production. Since 
STAT3 regulates IL-10 expression, STAT3 phosphorylation was assessed and found to 
be reduced when mTOR was inhibited.  
 
Finally, similarly to Fakao et al.126 the authors wanted to assess the biological relevance 
of these findings and used a Listeria monocytogenes infection in Balb/c mice, which 
usually are unable to produce sufficient amounts of IL-12, IFN-γ and IL-6. Strikingly, a 
3-day pre-treatment with rapamycin, given by intraperitoneal injection, was enough to 
improve survival, an effect abolished by macrophages and DCs depletion with 
clodronate. Mice treated with rapamycin had a reduced bacterial burden in the liver and 
an increase in nitric oxide production, which is critical for clearing L. monocytogenes. 
Furthermore, there was an increase in IL-12p70, IL-6 and IFN-γ in the blood of 
rapamycin-treated mice. Overall, mTOR inhibition by rapamycin caused an increased 
production of key factors needed to clear the infection129. This paper was important in 
highlighting both the molecular mechanisms that underlie the increased cytokine 
production but also the biological relevance of these findings. The authors concluded 
that the mTOR signalling pathway plays a major role in limiting excessive 
inflammation during infection.  
 
 
Figure 1.9 Schematic of how mTORC1 inhibition by the drug rapamycin can lead 
to an increase in NF-κb signaling and subsequent increase in inflammation. 
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rapamycin leads to an increase in NF-κb activation, measured by translocation of the p65/p50 
complex into the nucleus of myeloid cells, This results in an increase in the transcription of 
inflammatory genes and an overall augmentation of the inflammatory response, However, the 
molecular link has not been elucidated. Figure based on findings from Weichhart et al.129.  
 
 
Other studies have also provided evidence that mTOR inhibition leads to an increase in 
inflammatory responses, for example, mice lacking the mTORC1 scaffolding protein 
Raptor specifically in DCs showed increased susceptibility to colitis induced by dextran 
sodium sulphate. The study suggested that this severe inflammatory response is due to a 
DC-mediated suppression of IL-10131.  
Studies have indicated that inflammation associated with transplantation may be mTOR 
mediated.  Gallon et al.132 profiled biopsies taken from transplanted kidneys. In patients 
taking rapamycin as an immunosuppressant, they found increased IL-12 signalling as 
well as an increase in inflammatory and immune responses132. This observation was 
further supported by another study in which the blood from kidney transplant patients 
was examined. Similarly, expression profiles obtained from the blood of rapamycin-
treated patients appeared to be dominated by innate immune cell transcripts, as well as 
NF-κB-related inflammatory genes133.   
Another study in 2011 by Weichhart et al. showed that renal transplant patients 
receiving rapamycin presented with a phenotype of activated immune cells, despite 
having combination therapy with anti-inflammatory glucocorticoids. PBMCs from these 
patients produced elevated levels of IL-12, IL-6, TNFα and IL-1β ex vivo compared to 
patients on other regimens. In fact, rapamycin and Torin 1 (an inhibitor of mTORC1 
and mTORC2) blocked the anti-inflammatory effect of glucocorticoids in both human 
monocytes and myeloid DC in vitro134. 
The reports described so far all indicate that mTOR inhibition leads to an increase in 
pro-inflammatory cytokines such as IL-12 and TNF and a suppression of IL-10 in 
monocytes, BMDMs and DC both in vitro and in vivo. The proposed mechanism of 
action is through NF-κB activation. However, there are other reports that conflict with 
these observations. For example, an article published in 2011 demonstrated that TSC1 
deficiency in BMDMs resulted in increased production of the pro-inflammatory 
cytokines TNFα, IL-12p40, IL-6 and increased nitric oxide production when stimulated 
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with LPS. This appears to be contrary to what has been previously described: as TSC1 
is known to negatively regulate mTORC1, its deficiency should result in an increase in 
mTOR activation. However, TSC1 KO BMDMs did not have an increase in NF-κB 
activation but rather an increase in JNK1/2 phosphorylation that accompanied mTORC1 
activation. The authors showed that either a JNK1/2 inhibitor or rapamycin could partly 
rescue the inflammatory phenotype, whereas the combination almost restored normal 
responses. The authors suggested that mTORC1 acts as an upstream regulator of 
JNK1/2 activation during TLR signalling in BMDMs135.  
This study was supported by Byles et al. who found that TSC1f/f LysM-Cre BMDMs 
also displayed an increase in pro-inflammatory cytokines IL-6 and TNFα upon LPS 
stimulation compared with controls. Furthermore, TSC1 KO BMDMs failed to polarise 
to an M2 phenotype when stimulated with IL-4/IL-13.  This study indicated that the 
defect was caused by a reduction in AKT phosphorylation as a consequence of chronic 
activation of mTORC1, which lead to a decrease in mTORC2 activation and 
subsequently reduced phosphorylation of the transcription factor FOXO1, which 
regulates some of the M2 genes such as Fizz1 and Arg1136. Phosphorylation of FOXO1 
causes its inhibition as it results in its sequestration into the cytoplasm, where FOXO1 
can no longer drive the transcription of target genes137. 
A more recent study by Zhu et al.138 sheds light on these apparent discrepancies. The 
authors also used the TSC1f/f; LysM-Cre mice and showed that both peritoneal 
macrophages and BMDMs produced significantly more pro-inflammatory cytokines IL-
12 and TNFα compared to controls. However, treatment with high or low doses of 
rapamycin failed to inhibit this enhanced cytokine production. Furthermore, they 
showed that genetic deletion of mTOR promoted rather than reversed the increase in 
TNF and IL-12 in TSC1 KO BMDMs. These results suggested that the increase in pro-
inflammatory responses associated with TSC1 deletion are either mTOR-independent or 
might depend on downstream signalling pathways that are regulated in a similar fashion 
upon mTOR inhibition or loss of TSC1, like increased PI3K or AKT activation. In 
addition, the authors showed that TSC1 can inhibit Ras GTPase activity, similarly to 
Rheb, and this leads to a reduction in activation of the RAF-MEK-ERK signalling 
pathway and subsequent cytokine production. Therefore, this process was 
hyperactivated in TSC1 KO BMDMs and resulted in an increase in cytokine 
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production. Interestingly, germline TSC1 KO mice spontaneously develop 
inflammatory disorders and have reduced survival, indicating the importance of this 
potential signalling axis in maintaining homeostasis. This paper was important in 
highlighting that TSC1 may have additional targets other than mTOR and that, at least 
in this instance, the increase in inflammatory responses governed by TSC1 deletion was 
not mTOR-mediated138. 
The idea that inactivation of TSC1 and TSC2 could lead to an increase in the 
inflammatory response, through inhibition of mTORC2, has also been suggested by a 
study in 2011 published in the Journal of Biological Chemistry. In this study mTORC2 
was inhibited through the deletion of a key component of the complex, Rictor, in MEFs. 
Rictor KO MEFs showed a hyperinflammatory phenotype upon LPS stimulation, 
accompanied by a reduction in AKT phosphorylation, as well as reduced 
phosphorylation of the transcription factor FOXO1. Therefore, in RICTOR KO MEFS, 
a reduction in AKT and consequently FOXO1 phosphorylation results in elevated 
nuclear FOXO1 levels and increased cytokine production of IL-6 and IL-8139. The 
notion that mTORC2 negatively regulates the inflammatory response was further 
supported by in vivo evidence that Rictor deletion in the myeloid compartment caused 
an increased response to LPS injection. As expected, these mice displayed a higher 
sensitivity to septic shock, accompanied by an increase in TNFα levels in the plasma140. 
Therefore, it is possible to conclude that mTORC1 and mTORC2 inhibition both lead to 
an increase in inflammatory responses, however, they seem to be mediated by different 
mechanisms. While mTORC1 inhibition leads to NF-κB activation, mTORC2 inhibition 
does not.  
One interesting study emphasised the importance of mTOR on the production of 
inflammatory cytokines in response to pathogenic and non-pathogenic microbes. This 
study suggested that infection with certain pathogens can result in a translational bias 
toward pro-inflammatory cytokines, through the regulation of translation by mTORC1. 
The authors compared the effects on macrophages with an infection with either a fully 
virulent strain of Legionella pneumophilia or a non-pathogenic strain, in which the 
effector system that delivers proteins to the host cell, the Dot/ICM system, is 
inactivated. Only the infection with the virulent strain, and not the Dot/ICM defective 
strain, resulted in the suppression of mTOR function, which was accompanied by a 
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robust pro-inflammatory response at an RNA and protein level. mTOR regulates the 
initiation of translation through negative regulation of 4E-BP1. In its unphosphorylated 
state, 4E-BP1 binds to eIF4E. When 4E-BP1 becomes phosphorylated by mTORC1, it 
releases eIF4E, which then forms a complex with other eIF proteins to initiate 
translation. The bias in cytokine production observed in macrophages infected with the 
virulent strain appeared to be inhibited upon blocking this interaction. The authors went 
on to show that this bias in cytokine production could be mimicked in the Dot/ICM 
strain using rapamycin, further proving that suppression of the mTOR pathway was 
responsible for this effect. The authors speculated that this abundance in pro-
inflammatory cytokine transcripts upon infection with a pathogen such as legionella 
could have evolved as a mechanism that allows the cells of the innate immune system to 
mount an inflammatory response even under conditions in which mTOR function is 
suppressed141. 
Another study that also highlights the importance of translation when considering 
mTOR inhibition and cytokine production was carried out examining the effects of 
rapamycin on the SASP. The group, led by Jesus Gil, showed that mTOR inhibition 
prevents the induction of the SASP in a model of oncogene-induced senescence (IMR90 
ER:RAS). mTOR appears to suppresses the SASP through the translation of 
MAPKAPK2 kinase, which is dependent on 4E-BP1. When mTOR is inhibited, 4E-BP1 
phosphorylation is lost and 4E-BP1 remains in a complex with eIF4E, preventing the 
initiation of translation. Therefore, mTOR inhibition in senescent cells leads to a 
reduction in the translation and overall activity of MAPKAPK2 kinase. ZFP36L1, a 
zinc finger protein that destabilizes mRNAs, is a known substrate of MAPKAPK2 and 
becomes phosphorylated during oncogene-induced senescence, which prevents it from 
degrading transcripts of numerous SASP components. Therefore, inhibition of mTOR 
leads to phosphorylation and consequently activation of ZFP36L1 by MAPKAPK2, 
which leads to degradation of SASP transcripts and overall reduction in the SASP. This 
study may offer some explanations as to how rapamycin appears to exert anti-ageing 
properties, by reducing the production of inflammatory genes associated with ageing, at 
least in certain cell types142. 
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1.11 Regulation of microglia function by mTOR  
The first evidence that mTOR might regulate microglia function was published in 
2005143. In this article, the authors investigated the effect of the cellular antioxidant 
enzyme catalase on the induction of cyclooxygenase-2 (COX-2) and iNOS in the 
microglia cell line, BV-2, by treating the cells for four hours with this antioxidant. They 
found that catalase induced activation of the mTOR pathway, as demonstrated by the 
increase in phosphorylation of p70S6K as well as upregulation of COX-2 and iNOS at 
protein level, which appeared to be associated with NF-κB activation. Treatment with 
either rapamycin, a PI3K inhibitor or an NF-κB inhibitor reversed the induction of 
COX2 and iNOS in the BV-2 cell line upon catalase treatment. This report appears 
contradictory to earlier reports that associated mTOR inhibition with an increase in NF-
κB activation, however it must be considered that it is not known which receptors are 
activated by catalase. Therefore, the mechanism of action in this setting could be very 
different to TLR-mediated mTOR activation previously described143.  
Another study that appears to complement this report investigated the effect of hypoxia 
on microglia activation. The hypoxia-inducible factor-1α (Hif1α), which is involved in 
sensing the level of oxygen within the cell, plays a central role in the adaptation the cell 
makes to survive in hypoxia. In this study, the authors investigated the induction of 
iNOS in both primary rat microglia and the BV-2 microglia cell line under hypoxic 
conditions. As previously reported, it appeared that hypoxia caused an upregulation of 
Hif1α in a time-dependent manner that was dependent on the PI3K/AKT/mTOR 
pathway.  Interestingly, inhibitors of PI3K and mTOR abolished the induction of Hif1α 
as well as the associated iNOS expression under hypoxic conditions, suggesting, for the 
first time, that the PI3K/mTOR/HIF1α signalling is in involved in regulating iNOS 
production in microglia under hypoxic conditions144.  
Chong et al. also showed that the activation of the PI3K/mTOR pathway in primary 
microglia and the EOC2 microglia cell line was protective during oxygen and/or 
glucose deprivation. This was evident as inhibition of mTOR in these conditions lead to 
significantly more microglia apoptosis, DNA fragmentation and membrane 
phosphatidylserine exposure145.  
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These articles suggest that the mTOR pathway plays a role in different aspects of 
microglia function, such as survival and NOS2 expression. Another study investigated 
the activation of mTOR in response to either LPS or a mixture of cytokines that were 
biologically relevant to the pathogenesis of MS referred to as TII (TNFα, IL1β and IFN-
γ) in primary cultures of rat cortical microglia. They found that mTOR was activated by 
both stimuli, as measured by the phosphorylation of mTOR at S2448. NOS2 expression 
was also induced by both stimuli but with very different kinetics. Interestingly, pre-
treatment with rapamycin blocked the production of NO in the TII treated cells but not 
in the LPS-treated microglia cells. mTOR inhibition lead to an increase in NOS2 
mRNA levels in LPS-treated cells at 24 hours after stimulation, although there was no 
difference in the protein levels in LPS-treated cells with and without rapamycin. mTOR 
inhibition in TII treated cells resulted also in diminished production of COX1, COX2 
and prostaglandin E2. All three of these factors are increased under inflammatory 
conditions and are generally associated with a pro-inflammatory phenotype. Lastly, the 
authors showed that mTOR inhibitors also affected microglia proliferation and viability. 
This paper highlighted how mTOR inhibition can have differential effects, depending 
on the type of stimulation and downstream signalling pathways146.  
One interesting study that suggested a possible role for mTOR in the chronic activation 
state of microglia was carried out in a mouse model of chronic neuroinflammation, the 
germline multifunctional protein 2 (MFP2) knock out mouse. MFP2 is an important 
enzyme in peroxisomal β-oxidation and its deletion results in inflammation and a 
neurological phenotype characterized by motor and cognitive impairments, leading to 
eventual death by 6-months of age. The study sought to understand the role microglia 
may play in the pathogenesis of this disease. To this end, the authors carried out 
microarray analysis to characterise the microglia transcriptome in this disease.  
Interestingly, they found that the most upregulated pathways were related to protein 
translation, cellular growth and proliferation such as eIF2, mTOR, p70S6K and eIF4E 
signalling. The activation of mTOR as well as the upregulation of one of its 
downstream targets, HIF1α, was validated by IHC. Microglia appeared to be in a 
primed state, as they produced more pro-inflammatory cytokines upon in vivo LPS 
stimulation compared to WT microglia, However, they also lacked signs of phagocytic 
or neurotoxic activity. The authors hypothesise that the activation of the transcription 
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factor HIF1α might be important in the primed state of MFP2 -/- brain and the chronic 
neuroinflammatory phenotype observed with the disease147.  
In conclusion, it seems that mTOR plays an important role in regulating the 
inflammatory response in myeloid cells and is also a key pathway implicated in the 
ageing brain. Given how microglia changes with age remain understudied and the 
importance of mTOR in regulating inflammatory processes, I set out to investigate 
microglia in ageing, with a particular focus on the mTOR pathway.  
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Aim      
Based on the evidence provided so far, the aim of my PhD thesis was to profile 
transcriptome changes occurring in microglia with age and to elucidate the molecular 
mechanisms underlying these changes. 
 
  




For the microglia transcriptome experiment, cells were isolated from three different age 
groups of mice: young (6 months), middle aged (15 months) and old (23 months). Mice 
were C57BL/6J, female and ex-breeders. They were obtained from Charles River and 
were housed according to Home Office guidelines.  Mice with a transgenic construct 
containing a Cre recombinase coding sequence under the control of the promoter for the 
murine colony stimulating factor 1 receptor (Csf1r-Cre) were obtained from Jackson 
laboratories. LoxP-flanked Rheb alleles were generated in the laboratory of P.F. 
Worley148. In this model, exon 3 of Rheb is floxed. This exon encodes the critical GTP 
binding domain. This is an out-of-frame deletion and therefore the protein is not 
produced148. All experiments carried out with mice were in accordance with the Home 
Office licence PPL 70/7411.  
2.2 Organ processing  
 
Cells were obtained from the blood, bone marrow and spleen. The processing of each 
organ is briefly described below. 
2.2.1 Blood 
 
Blood was obtained by cardiac puncture using a 27G needle and 1 mL syringe coated in 
0.5 M Ethylenediaminetetraacetic acid (EDTA). It was then transferred into a 1.5 mL 
eppendorf tube and placed on ice. To obtain plasma for cytokine analysis, blood was 
spun three times with increasing speed in a microfuge, with the supernatant being 
removed each time. The first speed used was 200 x g for 10 minutes, followed by 2,300 
x g for 5 minutes and finally 16,100 x g for 3 minutes. Plasma was then aliquoted and 
snap frozen before being stored at -80°C until cytokine assessment was carried out. 
Following the first spin, the pellet of blood cells was kept for flow cytometry analysis. 
They were placed in a 50 mL falcon with 20 mL of PBS and centrifuged at 300 x g for 
10 minutes at 4°C. Red blood cell lysis was carried out by using 10X red blood cell 
lysis buffer (eBioscience, Cat. No. 00-4300-54), diluted 1:10 in distilled water. Cell 
pellet was resuspended in 10 mL of 1X lysis buffer and placed in the dark for 10 
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minutes at room temperature. Following this incubation, cells were washed twice with 
incubation buffer and a cell count was performed. Cells were resuspended at 2 x 107 
cells/ mL in incubation buffer [phosphate buffered saline (PBS) + 0.5% bovine serum 
albumin (BSA) + 2 mM EDTA].  
2.2.2 Spleen 
 
Spleens were harvested, placed in 10 mL of PBS and kept on ice until further 
processing. Afterwards, they were placed on a 70 µm cell strainer from Fisher Scientific 
(Cat. No. 11597522). They were gently mashed through the strainer using a 5 mL 
syringe plunger. 10 mL of PBS was added to the cell suspension before centrifugation 
at 300 x g for 10 minutes at 4°C. To remove red cells, 10 mL of 1X red blood cell lysis 
buffer was added to the pellet and incubated for 10 minutes at room temperature in the 
dark. Cells were then washed twice with PBS and resuspended at 2 x 107 cells/ mL in 
incubation buffer. 
2.2.3 Bone Marrow 
 
Cells were obtained from the bone marrow by flushing the femurs and tibia with 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma, D5768) supplemented with 10% 
Foetal Bovine Serum (FBS, Life Technology, Cat. No. 10500-064) and 1% 
penicillin/streptomycin (Sigma, Cat. No. P4333). This is referred to as complete media. 
1 mL of complete media was flushed through the bone marrow using a 27G needle, 
several times. Cells were then strained through a 70 µm cell strainer before 20 mL of 
PBS was added to the cell suspension and cells were spun at 300 x g for 10 minutes 
4°C. Red cell lysis was carried out as described for spleen and blood and cells were 
resuspended at 2 x 107 cells/ mL. 
2.3 Flow cytometry Staining  
 
Flow cytometry staining was carried out in 96-well V-bottom plates from Thermo 
Fisher (Cat. No.  2605). For each stain performed, 2 x 106 cells were used, therefore 100 
µl of a 20 X 106 cells/ mL cell suspension was added to appropriate wells and then the 
plate was spun at 320 x g for 5 minutes at 4°C. The cells were then resuspended in 30 µl 
of CD16/CD32 FcR block (eBioscience, Cat. No. 14-0161-86) for 15 minutes at 4°C.  
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CD16 and CD32 are FcRIII and FcRII receptors, respectively, which are expressed by a 
range of immune cells including monocytes/macrophages and B cells. It is important to 
block these receptors as antibodies used for flow cytometry can non-specifically bind to 
these receptors and affect the results. Following FcR block, a 2X antibody mix was 
prepared using Incubation buffer and 30 µl was added to each well. All relevant 
information regarding the panel of antibodies used (manufacturer, clone and dilutions) 
is summarised in Tab. 2.1. Cells were incubated with antibodies used for flow 
cytometry for 20-30 minutes at 4°C in the dark. Following this incubation, cells were 
washed twice with 150 µl of incubation buffer before being resuspended in 150 µl of 
incubation buffer, which was transferred to 1.2 mL tubes (Star lab, Cat. No. I1412-
7400). Data acquisition was carried out with a 4-laser LSR-Fortessa (BD Biosciences) 




Table 2.1 List of antibodies used for flow cytometry including clone, manufacturer, 
dilution and catalogue number.  
2.4 Isolation of microglia 
 
Microglia for RNA sequencing were isolated as follows: brain and spinal cord were 
dissected following perfusion with 35 mL of ice-cold Hank’s balanced salt solution 
(HBSS) for 5 minutes. The perfusion step was carried out in order to remove any blood 
cells, particularly monocytes, which express the same markers as microglia. Tissues 
were then digested using a neuronal dissociation kit (Miltenyi Biotec, Cat. No. 130-092-
628), which is based on the enzyme papain, in order to obtain a single cell suspension. 
Next, cells were washed twice in HBSS and myelin was removed by negative selection 
Antibody) Manufacturer Cat)Number) Clone) Dilution
CD4 eBioscience 17-0041-83 GK1.5 1 in 100
CD8 eBiosceince 46-0081-80 53-6.7 1 in 100
CD45 eBiosceince 9047-9459-120 2D1 1 in 100
CD62L eBiosceince 12-0621-85 MEL-14 1 in 100
CD11b eBiosceince 25-0112-82 M1/70 1 in 200
Ly6C eBiosceince 48-5932-82 HK1.4 1 in 100
Ly6G eBiosceince 17-5931-81 RB6-8C5 1 in 100
F4/80 eBiosceince 11-4801-85 BM8 1 in 100
CLEC7A eBiosceince 17-5859-80 bg1fpj 1 in 100
TLR2 eBiosceince 12-9021-80 6C2 1 in 200
Dapi Cambridge Bioscience 40043-BT NA 2.5 µg/ml
Fixable viability dye (FVD) eBiosceince 65-0863-18 NA 1 in 200
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using myelin removal beads (Miltenyi Biotec, 130-094-060) in MACS LS columns 
(Miltenyi Biotec, Cat. No. 140-096-433). Briefly, 1.8 mL of incubation buffer and 200 
µl of myelin removal beads were added to each brain cell suspension and incubated at 
4°C in the dark for 15 minutes. Following this incubation, 18 mL of incubation buffer 
was added to each sample in order to wash the cells, which were centrifuged for 10 
minutes at 300 x g. Using three LS columns per brain, 1 of 3 mL of beads/cell 
suspension were loaded onto each column placed in a MidiMACS separator magnet 
(Miltenyi Biotec, Cat No. 130-042-302). This step was required to separate bead-bound 
myelin from the cell suspension. Each LS column was washed twice with incubation 
buffer and each time the flow-through was collected. Cells were then incubated with the 
microglia marker antibodies CD11b and CD45 for 20 minutes at 4°C in the dark, prior 
to being washed twice in incubation buffer and then sorted on a LSR-Fortessa (BD 
Biosciences). A DAPI suspension (2.5 µg/ml, Cambridge Bioscience, Cat. No. 40443) 
was used to exclude dead cells and was added just prior to flow sorting. 
 
For experiments using Csf1r-Cre; Rheb f/f mice and rapamycin-treated mice, in which 
microglia were used for quantitative PCR analysis, microglia cells were isolated in a 
similar manner as described above. However, CD11b microbeads instead of FACS 
sorting were used to enrich microglia following myelin removal. Briefly, 500 µl of 
incubation buffer and 40 µl of CD11b microbeads (Miltenyi Biotec, Cat. No. 130-093-
636) were added to each cell suspension and incubated at 4°C in the dark for 15 
minutes. Following this incubation, 3 mL of incubation buffer was added to each 
sample in order to wash the cells, which were centrifuged for 10 minutes at 300 x g at 
4°C. Using one MS column (Miltenyi Biotec, Cat. No. 130-042-201) per sample, 500 µl 
of bead/cells were loaded onto each column placed in an OctoMACS separator magnet 
(Miltenyi Biotec, Cat. No. 130-042-108). This is a positive selection whereby CD11b 
microglia bind to the column via the CD11b microbeads. Each MS column was washed 
twice with incubation buffer and then 1 mL of incubation buffer was used to flush the 
contents of the column using the plunger provided. This positive fraction contained 
CD11b positive microglia. The purity of the microglia obtained was assessed by flow 
cytometry analysis by staining an aliquot of cells with the microglia-specific markers 
CD11b and CD45.  
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2.5 RNA extraction 
 
For RNA sequencing experiments, microglia were lysed in 120 µl RLT lysis buffer 
(Qiagen, Cat. No. 74004) and stored at -80°C.  Three lysates per replicate were then 
pooled and RNA was extracted according to the manufacturers guidelines using the 
RNeasy microkit from Qiagen (Cat. No. 74004). Samples were not randomised for 
RNA sequencing experiments, however samples that were FACS sorted on the same 
day were not used for pooling of RNA. Therefore each of the three samples used per 
RNA extraction were all sorted on different days to eliminate a same day bias. For 
qPCR experiments, cells were lysed in 350 µl of RLT buffer and were not pooled. RNA 
was extracted in the same way.  
2.6 RNA assessment 
 
The quality and quantity of RNA was measured by Agilent Bioanalyzer 2100 RNA pico 
chip. Briefly, pico dye (1:65) was added to an aliquot of filtered gel. The gel/dye mix 
was spun for 10 minutes at room temperature at 13,000 x g and then allowed to 
equilibrate at room temperature for a further 30 minutes. The gel was then dispensed 
into a RNA pico chip. Pico conditioning solution, pico marker and pico ladder were 
dispensed into the appropriate wells.  
From each sample, 1 µl was dispensed into appropriate wells and after 60 seconds the 
chip was inserted into the Agilent 2100 Bioanalyzer. RNA quality was assessed by the 
presence of the two ribosomal peaks (18S and 28S). The 2100 expert software was then 
used to calculate RNA concentrations and RNA integrity numbers (RIN) for each 
sample. Only samples with a RIN>7 were subjected to RNA sequencing. 
2.7 RNA Sequencing  
 
Samples were prepared in house up to the point of RNA extraction and assessment. 
They were then sent to Oxford Gene Technology (OGT) where they were prepared for 
RNA sequencing using the SMARTer Ultra Low RNA kit for Illumina sequencing 
(Clontech Laboratories, Inc, Cat. No. 634936). OGT also performed initial analysis on 
the samples, where they used Boxtie2 and Tophat2 to align reads to the reference 
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sequences. Transcripts were assembled and quantified using Cufflinks. Cufflinks 
measures transcript abundances in Fragments Per Kilobase of exon per Million 
fragments mapped (FPKM) values. These values were received from OGT and then 
subjected to further statistical analysis.  
2.8 Protocol used by OGT to prepare samples for sequencing 
 
SMARTer cDNA synthesis allows the amplification of cDNA with as little as 10 pg of 
total starting RNA. An oligo (dT) primer is used to prime the first strand reaction. The 
SMARTer reverse transcriptase used in this protocol reverse transcribes the RNA from 
the 3’ -5’ primed end of the mRNA. It also has terminal transferase activity, which 
means it can add additional nucleotides when it reaches the end of the mRNA. The 
smarter oligonucleotide is then designed to base-pair with this nucleotide stretch, which 
allows the creation of an extended template. This results in a full-length cDNA being 
transcribed containing the complete mRNA as well as anchor sequences, that then 
serves as a priming site for second-strand synthesis. Following first-strand DNA 
synthesis, SPRI beads were used to purify the cDNA, as the cDNA will bind to the 
beads leaving any impurities in the remaining solution. cDNA amplification was 
achieved using the Advantage 2 PCR kit (part of the Clontech Ultra Low kit) . The 
amplified cDNA was validated using the Agilent 2100 BioAnalyzer and the high 
sensitivity DNA chip from Agilent (Cat. No. 5067-4626). Before a library can be 
generated for Illumina sequencing, the full-length cDNA must be sheared into smaller 
fragments of roughly 200-500 bp in size. This was done using the Covaris System, an 
acoustic shearing instrument. Following fragmentation of double-stranded cDNA, the 
Low Input Library Prep kit from Clontech (Cat. No. 634947) was used to generate a 
sequencing library. Sequencing was then done on the Illumina Hiseq 200, with each 
sample being sequenced with 100 bp paired ends at a depth of 33 million reads. 
 
2.9 cDNA synthesis and Quantitative Real-Time Polymerase 
Chain Reaction (qPCR) 
 
Following RNA extraction, RNA was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription kit from Applied Biosystems (Cat. No. 436-
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8814). Briefly, a master mix was prepared that contained (per reaction): 1X RT buffer, 
1X random hexamers, 4 mM dNTP, 1 µl of reverse transcriptase (50 U/ml) and 2.2 µl of 
nuclease-free water. This master mix was added to the extracted RNA, contained in 12 
µl, therefore the final volume per reaction was 20 µl. All samples were then incubated 
in a thermocycler using the following programme; 25°C for 10 minutes, 37°C for 120 
minutes, 85°C for 5 minutes and held at 4°C. 
 
Following cDNA synthesis, 130 µl of nuclease-free water was added to each sample to 
dilute the enzymes used in the cDNA synthesis. A master mix was then prepared for the 
qPCR for each gene of interest, which included per reaction: 10 µl of Biorad iTaq 
master mix (Biorad, Cat. No. 436-814) and 1 µl of each FAM labelled gene of interest. 
This master mix was added to wells on a qPCR plate and 9 µl of diluted cDNA was 
added to each corresponding well. The Step One Plus Real Time PCR machine from 
Applied Biosystems was used to carry out the qPCR. The PCR programme included an 
initial denaturation cycle that lasted for 10 minutes at 95°C, followed by 40 cycles of 
amplification that included 15 seconds at 95°C and one minute at 60°C; the last part of 
the programme included one more cycle at 25°C for 15 seconds. All primers used are 
summarised in Tab. 2.2. 
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Table 2.2 List of qPCR primers used including manufacturer and catalogue number.  
2.10 Differentiation of bone marrow derived macrophages 
(BMDMs) 
 
Bone marrow cells were obtained as previously described for the processing of the bone 
marrow for flow cytometry analysis. Cells were obtained by flushing the tibia and 
femur from both legs of a mouse. These cells were then pelleted and resuspended in 20 
mL of complete media containing 20 ng/mL of M-CSF (eBioscience, Cat. No. 34-8983-
85). M-CSF is a growth factor essential for the differentiation of bone marrow 
progenitors into macrophages. Approximately 6 x 107 cells were obtained from one 
mouse and they were then split equally into two 15 mm Petri dishes (Falcon, Cat. No. 
351058) and allowed to differentiate for 8 days. Following this differentiation step, the 
BMDMs were re-plated for subsequent experiments. Briefly, the media was removed 
from each Petri dish and cells were washed once with 10 mL of PBS. Cell Dissociation 
buffer (Gibco Life Technologies, Cat. No. 13151014) was used to detach the 
macrophages from the petri dishes by incubating each plate in 10 mL of buffer for 10 
minutes at 37°C. Following this incubation, cells were gently scraped off using a 1.8 cm 
Primer Manufacturer Cat Number 
P2ry12 Applied Biosystems Mm01950543_s1
P2ry13 Applied Biosystems Mm01951265_s1
Tlr2 Applied Biosystems Mm00442346_m1
Clec7a Applied Biosystems Mm01183349_m1
Cox6a2 Applied Biosystems Mm00438295_g1
Atp6v1b2 Applied Biosystems Mm00431987_m1
Hprt1 Applied Biosystems Mm01545399_m1 
Mmp12 Applied Biosystems Mm00500554_m1
Spp1 Applied Biosystems Mm00436767_m1
Cst7 Applied Biosystems Mm00438349_m1
Cxcl13 Applied Biosystems Mm00444534_m1
Gpnmb Applied Biosystems Mm01328587_m1
Apoe4 Applied Biosystems Mm00545713_m
Mir-155 Applied Biosystems Mm03306395_pri
Tnf Applied Biosystems Mm00443258_m1 
Il1b Applied Biosystems Mm00434228_m1
Il12a Applied Biosystems Mm00434169_m1
Il12b Applied Biosystems Mm01288989_m1
Il10 Applied Biosystems Mm00439614_m1
Il6 Applied Biosystems Mm00446190_m1
Rela Applied Biosystems Mm00501346_m1
	   63	  
blade cell scraper from Falcon (Cat. No. 353085). Cells were then placed in complete 
media before being centrifuged at 300 x g for 10 minutes at 4°C. After this step, they 
were resuspended in complete media at a concentration of 1 x 106 cells per mL. For 
signalling experiments, 1 mL of cell suspension was used per time-point in a 6-well 
plate. For qPCR or ELISA experiments, 500 µl of cell suspension was used in a 12-well 
plate. BMDMs were stimulated with 200 ng/mL of LPS from Escherichia coli 0111:B4 
(Sigma, Cat. No.  297-473-0) diluted in complete medium.  
 
2.11 Preparation of protein lysates and protein quantification  
 
Cells were stimulated with LPS for a variety of time points (0,5,15,30 or 60 minutes) in 
6-well plates and then placed on ice immediately; media was removed and each well 
was washed with ice-cold PBS. PBS was aspirated and 80 µl of ice-cold protein lysis 
buffer was added to each well and left to incubate on ice for 60 minutes. Lysis buffer 
was made using 10 mL of Ripa buffer (Sigma, Cat. No. R0278) supplemented with 1 
tablet of Complete Mini, EDTA-Free Protease Inhibitor (Roche, Cat. No. 12371700), 
Phosphatase Inhibitor Cocktail 2 (1:100, Sigma, Cat. No. P5726) and Phosphatase 
Inhibitor Cocktail 3 (1:100, Cat. No. Sigma, P0044). Following incubation with lysis 
buffer, macrophages were scraped vigorously before cellular material was transferred to 
1.5 mL eppendorf tubes. Lysed cells were centrifuged at 16,100 x g for 30 minutes at 
4°C. The supernatant was then removed and snap-frozen on dry ice and stored at -80°C. 
Five µl were kept for protein quantification using the Bicinchoninic Acid assay (BCA). 
This assay includes the generation of a protein standard curve using bovine serum 
albumin to determine the protein concentration in the samples. Standards and samples  
(10 µl) were prepared in PBS and added to a 96-well plate. A solution containing 50 
parts Bicinchoninic Acid solution (Sigma, Cat. No. B9643-L) and 1 part of Copper (II) 
solution (Sigma, Cat. No. C2284) was made and added to each sample and standard 
(final volume of 200 µl). The plate was then incubated at 37°C for 30 minutes. The 
colorimetric change caused by the presence of proteins was quantified using a plate 
reader to read the optical density at 595 nm.  
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2.12 Western blot  
 
Western blot was used to detect specific proteins based on their size. Proteins were first 
denatured and then separated by the length of their polypeptide by gel electrophoresis. 
Proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane, which 
was incubated with specific antibodies in order to identify proteins of interest.  
 
All samples were thawed on ice. Each sample containing 15 µg of proteins was 
resuspended to a final volume of 13 µl, prior to the addition of 5 µl 4x NuPAGE LDS 
Sample buffer (Invitrogen, Cat. No. NP007) and 2 µl 10x NuPAGE Sample Reducing 
Agent (Invitrogen, Cat. No. NP004). Samples were vortexed and then placed at 70°C 
for 10 minutes before being loaded on a 4-12% NuPAGE Bis-Tris (Invitrogen, Cat. No. 
NP0336BOX), 1.5 mm, 15-well pre-cast gel in a running chamber containing 500 mL 
of 1x MOPS SDS Running buffer (Invitrogen, Cat. No. NP001).  SeeBlue Plus2 1X 
ladder (Invitrogen, Cat. No. LC5925) was loaded with each gel as a molecular weight 
protein standard. Gels were allowed to run for approximately 90 minutes at 150 V until 
the blue bands reached the bottom of the gel. The Invitrogen Transfer System was used 
to transfer proteins from the gel onto PVDF membranes. 1X NuPAGE Transfer buffer 
(Invitrogen, Cat. No. NP0006), containing 20% methanol (50 mL of 20x NuPAGE 
Transfer buffer diluted in 750 mL of deionised water and 200 mL of methanol) and 
Invitrolon™ PVDF/Filter Paper Sandwich (Thermo Fisher Scientific, Cat. No. LC2005) 
were used. The PVDF membrane was activated in 100% methanol before being 
equilibrated in deionised water followed by transfer buffer. In a transfer cassette, the 
activated PVDF membrane was placed on the gel and sandwiched between mattresses 
and Whatman paper (pre-soaked in transfer buffer). The cassette was then placed in the 
running chamber, which was filled with running buffer. The entire chamber was placed 
in a box of ice and an ice pack was also placed in the running chamber to keep the 
apparatus cold. The transfer was carried out for 2 hours at 65 V. The following step was 
incubation with a blocking buffer to avoid non-specific binding. The blocking buffer 
consisted of 5% w/v skimmed milk (Marvel) made in TBST (50 mM Tris-HCl, 150 mM 
NaCl, 0.1% Tween-20) for 1 hour at room temperature. The membrane was then 
incubated in primary antibody overnight on a roller at 4°C. Primary antibodies were 
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diluted in blocking buffer and were all obtained from Cell Signalling. Phospho-S6 
Ribosomal Protein (Ser240/244) (1:1000, Cat. No. 5364), S6 Ribosomal Protein 
(1:1000, Cat. No. 2217) and Total Rheb (1:500, Cat. No. 4935). Following overnight 
incubation with primary antibodies, membranes were washed 3 times in TBST for 5 
minutes at room temperature and then placed in secondary antibody solution – 
horseradish peroxidase (HRP) conjugated antibodies diluted 1:3000 in blocking buffer – 
for 1 hour at room temperature. Membranes were then washed again 3 times with 
TBST. Specific proteins were visualised using the ECL Western Blot Detection System 
from Amersham (Cat. No. RPN2106) and Hyperfilm ECL (Amersham).  
 
2.13 In vitro LPS stimulation of primary adult microglia 
 
Microglia were isolated as described above from adult mice (3-6 months). Following 
CD11b enrichment, microglia cells were incubated with 100 ng of LPS or complete 
media for 2 hours. This stimulation was performed in 1.5 mL eppendorf tubes in a water 
bath at 37°C. Following stimulation, cells were spun at 300 x g for 10 minutes at 4°C to 
obtain a cell pellet. The supernatant was then discarded and the cells were lysed in 350 
µl of RLT buffer. The cells were vortexed for 1 minute to obtain complete lysis before 




ELISA kits were obtained from BD Biosciences: IL-12p40 (Cat. No. 555165), IL-6 
(Cat. No. 555240) and TNFα (Cat. No. 558534).  ELISA was performed according to 
the manufacturer’s guidelines; however, half-surface area 96-well plates were obtained 
from Costar (Cat. No. 3690) and used for the assay. The wells in these plates are half 
the volume of standard 96-well plates, allowing the use of a reduced amount of samples 
and reagents. This was particularly important for plasma cytokine levels, as the amount 
of plasma obtained from each mouse was potentially a limiting factor. Briefly, capture 
antibody was diluted in PBS and added to each well of a 96-well plate. The plate was 
then incubated overnight at 4°C, prior to being washed three times with wash buffer 
(PBS with 0.05% Tween-20). The plate was then incubated with assay diluent (PBS 
with 10% FBS) for 1 hour, in order to block non-specific binding and washed three 
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times with wash buffer. The highest concentration of standards (1000 pg/mL) were 
made using a stock solution of each cytokine and then a serial dilution was performed 
on a separate plate to obtain the remaining standards (500, 250, 125, 62.5, 31.3 and 15.6 
pg/mL). Samples and standards were then added to the ELISA plate and incubated for 2 
hours at room temperature. Samples that required dilution were diluted in assay diluent. 
Following incubation, the plate was washed 5 times with wash buffer and then the 
working detector solution (detection antibody and HRP) was added to the plate and it 
was incubated at room temperature for 1 hour. The plate was then washed 7 times 
before the substrate solution [Tetramethylbenzidine (TMB) and hydrogen peroxide from 
the TMB Substrate Reagent Set (BD Pharmingen, Cat. No.555214)] was added and 
incubated in the dark for a maximum of 30 minutes. Following the appropriate colour 
change, 25 ml of 1M H3PO4 was added to stop the reaction. Plates were analysed on a 
plate reader plate reader to read the optical density at 450 nm.  
2.15 Open field test protocol and analysis  
 
Wild-type mice were given an intraperitoneal injection of either LPS (0.33 mg/kg) or 
PBS before being assessed in an open-field test 6 hours post injection. Mice were 
brought into the testing room 30 minutes prior to the test, so that they could acclimatise 
to their new surroundings. The test was conducted in a 15-square gridded box. The box 
was cleaned with ethanol prior to the first mouse being tested and in between each 
mouse. Each mouse was placed in the left corner of the gridded box at the start of the 
test and was recorded for a total of 5 minutes. The test was performed so that the 
analyser was blind to the genotype and treatment group of each mouse. Analysis was 
conducted by counting the number of times the mouse passed through each square 
during the 5-minute test (distance travelled). All four paws of the mouse were required 
to pass within each square to be counted. The number of times the mouse reared (both 
paws) was counted as another measure of locomotion. Anxiety or stress-like behaviour 
was also assessed by measuring the number of times the mouse passed through any of 
the 3 central squares (time in centre) or the first time the mouse passed through one of 
these central squares (time to centre).  
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2.16 Rapamycin diet  
 
Rapamycin was first obtained from Rapamycin Holdings in San Antonio, Texas and 
then microencapsulated with an enteric coating called Eudragit S100. This material was 
used because it increases the amount of the drug that survives the food preparation and 
also prevents the drug from being prematurely digested in the stomach. 
Microencapsulated rapamycin and Eudragit (serving as a control) were then 
incorporated into separate LabDiets on a 5058 base by Purina labs. The base diet was 
the same used in our Biological Services Unit and therefore eliminated potential 
confounding factors. The amount of rapamycin used corresponded to 152 ppm, which 
resulted in 14 ppm active rapamycin. This diet was similar to the diet used in several of 
the ageing studies, including the 2012 Nature paper by Harrison et al. which showed 
that rapamyin extended lifespan in mice31. 
 
2.17 LPS injection in vivo  
For all in vivo experiments mice were injected using a 27G needle and 1 mL syringe 
intraperitoneally with either 200 µl of E. coli 0111:B4 (Sigma, Cat. No. 297-473-0) or 
PBS as control. For Rheb ageing experiments, all mice received 5 mg/kg of LPS. This is 
a high dose of LPS that induces a robust inflammatory response and mice were culled 
after 3.5 hours. For sickness behaviour experiments in Rheb KO mice, 0.33 mg/kg of 
LPS was used to induce transient sickness behaviour and mice were culled after 48 
hours. Finally for the rapamycin ageing study, 2 mg/kg of LPS was used and mice were 
culled after 5 hours.  
 
 
2.18 Experimental design and statistical analysis  
Number of animals were kept to the minimum required for experiments, calculated by 
power analysis where possible using the software available at www.biomath.info. For 
RNA sequencing experiments, n=3 was used for each of the three age groups (young, 
middle and old), where each replicate consisted of 3 pooled samples.  This number of 
replicates was chosen, as there was no prior data available to predict statistical 
variability at the time of experimental design. For Rheb in vivo experiments, this was 
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also true, so it was difficult to predict the number of mice needed to achieve 
significance. However we used the power analysis calculator to calculate how many 
mice to use for the rapamycin ageing study based on observations from the Rheb in vivo 
experiments.  
 
For RNA sequencing experiments data was analysed using an uncorrected one-way 
ANOVA or unpaired T-test where appropriate. For all other experiments a two-tailed 
unpaired student T-test was used to calculate significance between two groups or 
populations. All data was represented with error bars representing the standard error of 
the mean (of a group). All p values obtained>0.05 were considered significant with an 
an asterisk indicating the following: * p<0.05, ** p<0.01 and *** p<0.001.  
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Chapter 3: Characterisation of the Immune System in 
Ageing  
  
3.1 Naive T cells decline with age 
	  
The immune system is known to deteriorate with age in a process known as 
Immunosenescence and this deterioration is thought to contribute to the overall burden 
of chronic illness that accompanies ageing149. I therefore wanted to profile the changes 
in the immune system with age. I was particularly interested in changes in the myleoid 
compartment, as this is less studied than lymphocytes in ageing. Firstly, I assessed T 
lymphocytes, which form an essential part of the adaptive immune response and can be 
broadly divided into two main subclasses based on their surface expression of CD4 and 
CD8 glycoproteins. I used flow cytometry analysis to profile these lymphocyte 
populations in the bone marrow, blood and spleen from mice of different age groups. 
Positive populations were obtained for all data using floresence minus one (FMO) and 
unstained controls.  
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Figure 3.1 Gating strategy used to profile T lymphocytes in the spleen. A) Cells were 
first gated by their size (forward scatter) and granularity (sideward scatter), then duplets were 
excluded by gating on cells by their sideward area against their sideward width. Dead cells were 
excluded by using a viability dye that stains dead cells; therefore live cells are negative for this 
stain. Finally, immune cells are identified by gating on the B) CD45+ population, and C) T cell 
subpopulations, identified by CD4 and CD8 markers.   
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I stained spleen, bone marrow and blood cells with antibodies to CD45 to identify 
leukocytes and CD4 and CD8 to assess T cell subsets. It would have been advisable to 
include CD3 in this analysis, which is a pan marker that stains all T cells, as there are 
small subsets of other immune cells that express CD4 and CD8 besides T cells. 
However, to avoid over complicating the flow cytometry staining, CD3 was not 
included in this analysis. 
 
An example of the gating strategy used is depicted in (Fig. 3.1A); briefly, cells were 
first gated by their forward and sideward scatter. These parameters provide information 
about the size and overall granularity of the cells. It also allows the exclusion of debris. 
Next, clumped cells forming doublets were excluded by gating on the sideward width 
against the sideward area. Dead cells were excluded by gating on the population that is 
negative for a viability dye. Finally, leukocytes were identified as CD45+ cells  (Fig. 










Figure 3.2 Naïve T-lymphocyte populations decline with age.  The blood, spleen and 
bone marrow from 3, 6, 12, 16 and 20-month old mice was assessed by flow cytometry analysis, 
stained for CD4, CD8 and the naïve T-cell marker CD62L. A) Total CD4 T cells B) total CD8 T 
cells are shown as a % of CD45 cells for all three organs. The surface expression of CD62L on 
CD4 T cells (C) and CD8 T cells (D) is shown for all three organs as the MFI (median 
florescence intensity). The data shown are from one experiment, where n=3 for each group and 
* p<0.05, **p<0.01. Significance was calculated using the unpaired two tailed student T-test 
between individual groups. 
I carried out this staining on the blood, bone marrow and spleen from five different age 
groups of mice that ranged from young to old age. These included 3, 6, 12, 16 and 20-
months of age.  I found that the total number of CD4 T cells did not appear to change in 
the blood, spleen or bone marrow with age (Fig. 3.2A). However, I did observe a trend 
with regards to CD8 T cells, which appeared to decrease with age in the blood and 
spleen (Fig 3.2B). This decrease was significantly different between the youngest age 
group (3 months) and the oldest age group (20 months) and suggested an overall 
decrease in circulating CD8 T cells, as previously reported149. 	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I next looked at the expression of L-selectin also known as CD62L. CD62L is an 
adhesion molecule that is expressed on naïve T cells that have not yet encountered an 
antigen and is not expressed by effector memory cells150. In the bone marrow, the 
expression of L-selectin is associated with cells that are committed to lymphoid 
differentiation. I therefore used CD62L to measure loss of naïve T cells with age. I 
found that the expression of CD62L on both CD4 and CD8 T cells steadily declined in 
the spleen over the five age groups tested (Fig 3.2B and Fig. 3.2D). I found that the 
entire population of both CD4 or CD8 T cells showed a decrease in expression of 
CD62L with age, therefore I show changes as MFI rather than percentage of cells. Both 
CD4 and CD8 T cells from 20-month old mice expressed significantly less CD62L 
compared to CD4 and CD8 cells from 3-month old mice. On the other hand, T cells in 
the blood did not show differences in CD62L expression with age, in either CD4 or 
CD8 cells (Fig. 3.2C and 3.2D). In the bone marrow, CD4 T cells did not show 
differences in CD62L expression with age but there was a steady decrease in CD62L on 
CD8 T cells in the bone marrow, significantly different between 3 and 20 months of age 
(Fig. 3.2D). This finding might suggest that fewer cells in the bone marrow are 
committing to the lymphocyte lineage with age, which is also consistent with what has 
been reported in the literature151. 
	  
3.2 Monocyte populations appear to decline with age 
	  
Next I wanted to profile how the myeloid compartment of the immune system changed 
with age. Monocytes are circulating myeloid cells that differentiate into the two main 
types of antigen presenting cells, known as macrophages and dendritic cells. In order to 
profile these cells, I again used flow cytometry analysis. I stained the bone marrow, 
spleen and blood with an antibody for the myeloid marker CD11b, an integrin expressed 
on monocytes, macrophages, granulocytes and immature myeloid cells.  An example of 
the gating strategy used for cells from the spleen is shown in Fig. 3.3. I first excluded 
doublets and dead cells, as described previously, and then gated cells on CD11b 
expression (Fig. 3.3B). Within this gate, I used the two markers Ly6C and Ly6G to 
identify monocytes and granulocytes, respectively. Four populations could be identified 
with this staining. Ly6ChiLy6G– cells are known as inflammatory monocytes, Ly6C–
Ly6Ghi cells are granulocytes, Ly6CdimLy6Gdim cells are known as immature myeloid 
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cells and finally cells that are Ly6CdimLy6G–are known as patrolling monocytes (Fig. 
3.3C). Using this analysis, I assessed the number of these cell populations as well as 
total CD11b+ cells in the blood, spleen and bone marrow from young, middle-aged and 
old mice of 6, 15 and 23 months of age.  
	  
	  
Figure 3.3 Gating strategy used to profile myeloid cells in the spleen. A) Cells are 
first gated by their size (forward scatter) and granularity (sideward scatter), then doublets are 
excluded by gating on cells by their sideward area against their sideward width. Dead cells are 
excluded by using a viability dye that stains dead cells. B) Myeloid cells are identified based on 
their expression of the integrin CD11b. C) Different populations of myeloid cells are defined 
based on their expression levels of Ly6C and Ly6G. Four populations could be identified with 
this staining. Ly6ChiLy6G– cells are known as inflammatory monocytes, Ly6C–Ly6Ghi cells are 
granulocytes, Ly6CdimLy6Gdim cells are known as immature myeloid cells and finally cells that 
are Ly6CdimLy6G–are known as patrolling monocytes. D) Macrophages in the spleen identified 
based on their expression of the macrophage specific marker F4/80. 
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Unfortunately, I was not able to collect data from the blood of old mice due to problems 
with the staining.  Nonetheless, I found that the number of CD11b+ cells in the blood 
between the age of 6 and 15 months did not change; this was also true for the CD11b+ 
cells in the spleen (Fig. 3.4A). However, in the bone marrow the number of CD11b+ 
cells appeared to be maintained until middle age, before significantly decreasing 
between the ages of 15 and 23 months, from almost 70% of total live cells to 
approximately 40% (Fig. 3.4A). The difference between the 3-month and 23-month old 
mice was statistically significant with a p value<0.001 and between 15 and 23 months 
with a p value <0.01 (Fig. 3.4A).  
 
I also analysed the total number of granulocytic cells and found that these cells 
decreased with increasing age, particularly in the spleen. This trend, however, was not 
significant (Fig 3.4C).	  	  	  
	  
The total number of immature myeloid cells, expressing intermediate levels of both 
Ly6C and Ly6G, was also analysed. Immature myeloid cells are thought to have 
immunosuppressive properties and are sometimes described as myeloid derived 
suppressor cells. In a healthy mouse, these cells are not very abundant and constitute 
between 2-5% of CD11b+ cells in the spleen, blood and bone marrow.  In cancer, 
however, these cells can expand and suppress T cells and other immune functions152. In 
my cohort of mice, it appeared that the overall total number of immature myeloid cells 
decreased across all compartments measured. This difference though was only 
significant in the bone marrow with a p value<0.001 between the 6 and 23-month age 
group and p value<0.01 between 6 and 15 months of age (Fig 3.4B).  
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Figure 3.4 Myeloid populations appear to decline with age.  The blood, spleen and 
bone marrow from 6, 15 and 23-month old mice was taken for flow cytometry analysis and 
stained for the myeloid marker, CD11b, the monocyte marker, Ly6C, the granulocyte marker, 
Ly6G, and the macrophage marker, F480. A) Total CD11b cells in spleen, bone marrow and 
blood shown as a % of live cells. B) Total immature myeloid cells (intermediate Ly6C and 
Ly6G expression), shown as a % of CD11b+ C) Total granulocytic cells (Ly6G high) as a % of 
CD11b+ D) Total inflammatory monocytes (Ly6C high) as a % of CD11b+ E) Total F4/80 
positive macrophages in the spleen shown as a % of total live cells. F) Total patrolling 
monocytes in blood, spleen and bone marrow shown as a % of CD11b cells. The data shown are 
from one experiment, where n=5 for each group and * p<0.05, **p<0.01, *p<0.001. 
Significance was calculated using the unpaired two tailed student T-test between individual 
groups.  
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There are two main monocyte populations in the adult mouse that can be broadly 
divided by the expression of Ly6C. Monocytes in the blood that express very high 
levels of Ly6C are called inflammatory monocytes and the cells that express lower 
levels are called patrolling monocytes153. The two populations of Ly6C monocytes are 
easily distinguishable in both the spleen and blood by the gating strategy illustrated in 
Fig. 3.3C. In the bone marrow, there is only a Ly6Chi population.  
 
Both monocyte populations decreased in all organs with ageing (Fig. 3.4D and 3.4F). 
For the Ly6Chi population, the most striking differences were in the bone marrow with a 
dramatic drop by 15 months of age compared to 6 months of age with a p value<0.05, a 
decrease that was maintained at 23 months of age (Fig 3.4D).  No differences were 
observed in the blood but, in the spleen, the decrease was evident by 15 months with a p 
value <0.05 (Fig. 3.4D).  For Ly6Cdim patrolling monocytes, a decrease in cell number 
with age was more evident in the blood and was statistically significant between the 6 
and 15-month age group. A similar reduction in Ly6Cdim patrolling monocytes was 
observed in the spleen between 6 and 15 months of age (p<0.01), with an even more 
pronounced change between 6 and 23 months of age (p<0.001, Fig. 3.4F).  
 
Not many studies have addressed changes in macrophages with age. Therefore, I 
analysed the total number of macrophages in the spleen using the macrophage specific 
marker F4/80, as shown by the gating strategy in Fig. 3.3D.  No differences were 
detected, however, in splenic macrophages (Fig. 3.4E). This finding does not rule out 
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3 Discussion  
	  
	  
Understanding how the immune system changes with age is an important aspect of 
ageing research. This is because the immune system is essential for maintaining health 
throughout lifespan. Many age-related illnesses have a strong immune component, most 
notably cancer, where the immune system influences both the initiation and progression 
of the disease154. In the course of my PhD, I wanted to firstly reproduce some of the 
findings that have already been described in the field of Immunosenescence, most 
notably regarding T cells. T cells mature in the thymus, however, this organ undergoes a 
significant involution over time, a phenomenon associated with a dramatic decrease in 
the output of naïve T cells155, especially cytotoxic CD8 T cells156. My results agreed 
with the literature, with a significant decline in the number of CD8 T cells with age but 
unaltered numbers of CD4 T cells. I have also shown that the expression of the naïve T-
cell marker CD62L decreases with age in both CD4 and CD8 T cells, most notably in 
the spleen. This would indicate that the T cells residing in this organ are predominantly 
of an effector or effector memory phenotype, but I should have included additional 
markers of memory T cells such as CD44 to confirm this finding. This overall change in 
the naïve/memory T-cell ratio has important implications for the immune response, as it 
could potentially compromise overall ability to clear new infections156. In conclusion, 
my findings on T lymphocytes are consistent with the literature and indicate a decline 
with age.  
 
Given the interest in inflamm-ageing and the low-grade pro-inflammatory phenotype 
that accompanies the ageing process, I was particularly interested in assessing the 
myeloid compartment for possible changes. Myeloid cells were profiled in the blood, 
spleen, and bone marrow from young, middle-aged and old mice. The most striking 
observation was the significant decline in monocytes. This was true for both 
inflammatory monocytes and patrolling monocytes but also for immature myeloid cells. 
These results are in contrast to what has been previously reported in the literature, 
indicating that haematopoiesis is skewed towards the myeloid lineage with age157. It has 
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been shown previously that the number of myeloid-derived suppressor cells increases in 
the spleen, blood and bone marrow in aged mice158. The mice used in these studies were 
Balb/c, whereas the mice I analysed here were C57BL/6, furthermore the markers used 
to define myeloid-derived suppressor cells were different. These differences may 
account for the contrasting results obtained.  
 
Despite the observed decrease in monocytes, particularly in the spleen, the number of 
splenic macrophages appeared unaffected by age. There is a paucity of reports on 
tissue-resident macrophages in ageing. It has been published that there is an overall 
reduction in the response to TLR stimulation in macrophages with age, which results in 
a reduced inflammatory response159. Additional studies have addressed the impact of 
ageing on macrophage phagocytosis, showing that aged macrophages have impaired 
phagocytic abilities. Also, it has been shown that microglia internalised less amyloid 
beta when isolated from old mice compared to young ones160, however other studies in 
humans have shown that this response is unchanged with age161. One interesting study 
isolated peritoneal macrophages form young and aged mice and showed that 
phagocytosis of fluorescent particles was impaired162.  Given their impaired ability to 
clear debris, maybe it is not surprising that the wound healing ability of macrophages 
also appears defective with increasing age: one study showed that VEGF, an essential 
angiogenic factor in wound healing, was produced significantly less by macrophages 
from old mice163.  
  
There are limitations to representing the data as a percentage of CD45 immune cells or 
CD11b myeloid cells, as you only obtain a change in proportion of a particular cell type. 
In the data presented here, for example, the proportion of inflammatory myeloid cells 
appears to decrease with age. It would be important to establish if the inflammatory 
monocytes are in fact decreasing. This could be done by showing the data as absolute 
cell counts to understand if there are less inflammatory monocytes in the blood and 
spleen with age. The limitations of using proportions rather than absolute cell counts is 
if another population is increasing within the CD11b population, the changes observed 
for the monocyte populations may just be a reflection of this. Therefore if these 
experiments were repeated, it would be important to use absolute cell counts and show 
plots as percentage live rather than percentage CD45 or CD11b.  
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3 Conclusion 
The profiling carried out in the course of this project was limited and only gives an 
indication of what happens to myeloid cells with age. It would be very interesting to 
assess the characteristics of these cells in more detail. For example, I could stain for 
markers of macrophage polarisation, such as MHC II (M1 marker), or the mannose 
receptor (M2 marker) as well as markers of activation such as CD40, CD80 and CD86. 
It would also be important to isolate macrophages from the spleen or monocytes from 
the blood and look at how their function changes with age, similar to some of the 
studies described above (phagocytosis, wound healing). In terms of TLR signalling and 
overall inflammatory capacity, the literature is limited to the use of the TLR4 agonist 
LPS. It would be important to test a range of TLR ligands that would mimic both 
bacterial and viral infections and to analyse a range of cytokines that characterise 
inflammatory responses.  
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Chapter 4: RNA sequencing of the microglia 
transcriptome from the ageing brain 
Following on from phenotyping of the ageing myeloid populations in the blood, spleen 
and bone marrow, we decided to focus on the myeloid cells of the brain known as 
microglia. We wanted to gain as much information as possible on how microglia change 
with age so we decided to use RNA sequencing, a method that would allow us to look at 
the entire transcriptome. This would enable us to identify key pathways or genes that 
were deregulated with age and provide important information about how the brain ages. 
Although there have been studies that have described how the microglia transcriptome 
changes with age91,95-97,164,165, the novelty of our study is defined by the fact that we 
used microglia cells from the whole brain, rather than the retina or cortices, we used a 
new system for RNA sequencing, using low amounts of starting RNA, and finally we 
used three age groups of mice that would allow us to gain insight into the progressive 
changes that occur in microglia as the whole brain ages.  
4.1 Microglia Isolation  
 
4.1.1 Florescence Activated cell sorting was essential for 
obtaining microglia purity over 95% in aged mice  
	  
In order to isolate microglia with a high degree of purity and sufficient yield from both 
the adult and aged brain, a purification protocol was optimised. The standard protocol 
for isolating microglia from the mouse brain involves two steps; firstly, the brain is 
digested with a cocktail of enzymes (dispase and collagenase) and secondly the cells are 
suspended in different Percoll gradients (30%, 37% and 70%), as depicted in Fig. 4.1, 
Protocol 1. This is a well-described method that results in approximately 70-80% purity 
of microglia54. This purity was, however, too low for an RNA sequencing experiment 
and I aimed to achieve values above 95%, as even a 10% contamination of another cell 
type could dramatically bias the results.  
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Therefore, I tested a number of other methods for isolating microglia.  I began using a 
dissociation technique for digesting the brain tissue developed by Miltenyi Biotec. 
Using a cocktail of enzymes that included papain, the mouse brains were placed in C-
tubes and processed through a dissociator with intermittent pulses for 30 minutes. 
Following the digestion/dissociation, I enriched for microglia using CD11b magnetic 
microbeads. The use of microbeads for the isolation of immune cells is a well-
established protocol. This technique, though, depicted in Fig. 4.1, Protocol 2 resulted in 
even worse purity (less than 30%) than using percoll gradients in Protocol 1.  
 
Figure 4.1 Schematic of the four protocols used to isolate microglia from the aged 
brain. Each protocol included dissection of the brain and enzyme digestions. In Protocol 1, 
percoll gradients were used to separate microglia from other brain cells. In Protocol 2, CD11b 
enrichment was used after the brain was digested and dissociated. In Protocol 3 an extra step 
was used before CD11b enrichment to remove myelin. Protocol 4 is highlighted, as it is the 
technique finally used for the RNA sequencing experiments, this protocol differs from Protocol 
3, only in the final microglia isolation step, which was carried out using FACS sorting based on 
CD11b staining rather than using CD11b microbeads.	  
The reason for such poor purity using Protocol 1 was found to be the large amount of 
myelin, a mixture of proteins and phospholipids that insulate nerve fibres and is 
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Protocol 3 had drastic affects on the overall purity of cells (greater than 90%). An 
example of the purity of microglia, obtained from an adult brain, using Protocol 3, is 
shown in Fig. 4.2A, in which cells are first gated by their forward and side scatter, 
parameters that represent the size and granularity of the cells, respectively. Cells can 
often form clumps and stick together which can lead to misinterpreting their fluorescent 
labelling, therefore duplet cells were excluded by gating on the width against the area of 
the cells. Dead cells can stick non-specifically to antibodies and also auto-fluoresce, so 
it was also important to exclude them. Here I used a viability dye that stains dead cells 
and can be used before fixation; therefore dead cells were excluded by gating on the 
negative population.  Finally, the number of cells that are CD11b+ and therefore 
microglia were obtained by gating on this marker compared to an unstained control. In 
this example, 96.5% of cells obtained were positive for CD11b (Fig. 4.2A). 
I now had an established protocol (Fig. 4.1, Protocol 3) to obtain high purity and 
sufficient yield of microglia from the adult brain (2-8 x 106). However, I found that 
purity could be variable, between 85 and 95%, so I decided to use flow sorting, based 
on the microglia markers CD11b and CD45. The gating strategy used for FACS sorting 
is depicted in Fig. 4.2B, sample purity was checked after every sort (Fig. 4.2C), 
ensuring that every sample used for RNA sequencing had purity above 95%.  
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Figure 4.2 Microglia isolated using CD11b and FACS sorting yielded cells with a 
high degree of purity (>95%). The gating strategy is shown for microglia cells isolated 
using myelin removal and CD11b microbeads. A) Cells were first gated by forward and side 
scatter and then duplets and dead cells were excluded, finally cells were gated based on their 
expression of CD11b relative to an unstained control. B) Gating strategy for microglia cells 
isolated by FACS sorting, based on their expression of CD11b and CD45 C) An example of a 
purity check run after the sort to assess purity.	  
Microglia were isolated using FACS sorting, as described above, from three different 
age groups of mice. The age groups chosen were 6 months, 15 months and 23 months, 
reflecting young, middle and old age, respectively. All mice were female, ex-breeders 
and on a C57BL/6J background to try to minimise other variables besides their different 
age. For each of the nine biological replicates, microglia cells were pooled from three 
different mice. On average I obtained 100,000 microglia cells by FACS sorting from 
one whole brain. Each sample was lysed in RLT buffer and then the three lysed samples 
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were pooled together just before RNA extraction, to represent one biological replicate 
as described in Tab 4.1.  
Table 4.1. Summary of the experimental design used to obtain RNA from the 
microglia of different age groups of mice to be used for RNA sequencing. The age, 
gender, background and breeding status are all given for each of the three age groups 
corresponding to young, middle and old age. The number of samples that were pooled for each 
replicate is also given. 
The profile of the microglia cells before sorting between age groups was similar. It was 
found that the MFI of the marker CD11b was increased with age but this has also been 
observed in the literature82. 
4.1.2 RNA isolated from microglia of aged mice was of high 
quality  
	  
The integrity of RNA is an important consideration for any large-scale expression data. 
Using degraded RNA can introduce biases into experiments; meaning RNA of a high 
integrity must be used. The integrity of the RNA can be measured using the Agilent 
2100 Bioanalyzer. The system is based on electrophoretic separation, where each RNA 
sample is placed on a microchip and is then detected by a laser. The software will 
generate an electropherogram, which is based on the ratio between the 18S and 28S 
ribosomal subunits. If the RNA is degraded, there will be a decrease in the 18S to 28S 
ratio. The software generates a RNA integrity number (RIN) based on this ratio with 1 
being the most degraded and 10 having the best integrity. When carrying out the RNA 
extraction and testing the quality of the RNA using the Agilent system, peripheral blood 
mononuclear cells (PBMCs) were used as a control. It was found that both the control 
PBMC sample and the sorted microglia samples contained RNA with a high integrity. 
Examples of RIN numbers obtained for microglia RNA are given for each age group in 
Fig. 4.3, whereby samples obtained from microglia isolated from young mice is shown 
in Fig. 4.3A, middle aged in Fig. 4.3B and old in Fig. 4.3C.  All samples (except for 
one-Y2) were of high quality, indicated by a RIN number of >8. The quantity of RNA 
obtained ranged from 13-126 ng. All RIN numbers and amounts of RNA obtained are 
given for every replicate in the table in Fig. 4.3. All nine samples were sent to the 
Group Age (M) Gender Background Breeding status Pooled Reps Total mice
Young 6 Female C57BL/6J Ex-Breeder 3 3 9
Middle 15 Female C57BL/6J Ex-Breeder 3 3 9
Old 23 Female C57BL/6J Ex-Breeder 3 3 9
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company Oxford Gene Technology (OGT), where they performed the RNA integrity 
analysis again. They found that all samples including sample Y2 had a RIN value >8 so 
this sample was included in the RNA sequencing. 
 
Figure 4.3 Quality of RNA isolated from aged microglia.	  Examples of RNA profiles 
measured using an Agilent RNA 6000 Pico Chip.5.2 are given for A) PBMC control and 
microglia obtained from young mice B) middle aged and C) old aged mice. The RNA integrity 
number is shown for every sample and is a measure of the overall integrity of the RNA with 1 
being very degraded and 10 being fully intact RNA. The table summarises RIN numbers and 
quantities of RNA obtained for each replicate for RNA sequencing.	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4.2 Differential expression analysis and pathway 
analysis 
4.2.1 ANOVA analysis of aged microglia revealed eight 
distinct subsets of genes with similar behaviours. 
	  
After establishing a technique to isolate microglia with sufficient purity and yield and 
obtaining RNA of high quality, I sent my nine biological samples for RNA sequencing 
to the company called Oxford Gene Technology (OGT). On receiving the raw data, all 
subsequent bioinformatics analysis was carried out by a senior postdoctoral assistant in 
our lab, Dr. Raphael Zollinger. We named the three young samples mGLIA.Y1, 
mGLIA.Y2 and mGLIA.Y3; three middle aged samples mGLIA.M1, mGLIA.M2 and 
mGLIA.M3; finally the three old samples mGLIA.O1, mGLIA.O2 and mGLIA.O3. The 
expression of genes, based on RNA sequencing, is defined by the fragments per 
kilobase of transcript per million mapped reads also known as the FPKM expression 
values. We first looked at the expression of a number of genes that were microglia 
specific or specific to other cells of the brain. This would allow us to determine if our 
samples truly represented microglia cells.  We found that in all three age groups there 
was a high expression of the microglia specific marker known as purinergic receptor 12 
(P2ry12) and also of Itgam (CD11b, Fig. 4.4).  We also found that Padi4, a gene 
expressed in macrophages at a higher level than in microglia, was less expressed 
relative to Itgam and P2ry12. Finally, we found that markers of other brain cells, such 
as neurons (Eno2), oligodendrocytes (Mog) and astrocytes (Gfap) were not expressed in 
any of our samples (Fig. 4.4). This indicated that we did not have contaminations from 
these cells types in our microglia preparations. 
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Figure 4.4 The raw FPKM expression values are given for 6 cell-specific genes. 
Each age group is represented by a bar graph. The genes described are P2ry12 (microglia 
specific), Itgam (myeloid specific), Padi4 (macrophage specific), Eno (neuron specific), Mog 
(oligodendrocyte specific) and Gfap (astrocyte specific).  
 
The RNA sequencing of microglia from young, middle-aged and old mice identified 
367 transcripts that were regulated in at least one of the three age groups using the 
following three criteria: 1) uncorrected 1-way ANOVA p value<0.05, 2) Fold change 
between highest and lowest expression >2, 3) Group with highest average FPKM value 
>1.We chose these criteria as they are similar to what has been published in another 
study on the microglia transcriptome91. For example, Ma et al. also used an uncorrected 
1-way ANOVA and a p value<0.05, but they used a fold change cut off of >1.591. For 
this analysis we decided to be more stringent, in order to identify important genes with a 
more robust change in gene expression. We then used hierarchical clustering on these 
367 genes, using Spearman correlation and complete linkage to identify groups of genes 
with similar behaviours among the samples. 
 
We identified eight distinct subgroups of genes within our hierarchical clustering 
analysis as depicted by the heat-map in Fig. 4.5. A heat map is a graphical 
representation of the FPKM expression values for each of the 367 transcripts, identified 
to differ in at least one of the three age groups. Expression values are represented by 
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gene. Purple lines separate the eight subgroups and the number of transcripts belonging 
to each group is indicated.	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Figure 4.5 There were eight distinct sets of genes with different behaviours in 
young, middle-aged and old microglia. Hierarchical clustering heat map of the 367 
transcripts differentially expressed in one of the two age group comparisons (fold change >2, 
uncorrected p values<0.05, groups are young vs. middle aged; young vs. old; middle aged vs. 
old.) obtained using an uncorrected 1-way ANOVA. Each column represents one replicate from 
each age group; each row represents a single gene. Red indicates an upregulation of the gene 
and green indicates a downregulation of the gene. 
 
Changes in each of these eight groups are shown in Fig. 4.6. The patterns of change of 
some of these groups of genes were similar, in some cases. For example for group 1, 3, 
and 4, genes were increasing in a monotonic pattern from young to middle aged and 
then from middle aged to old. These three groups alone made up 57% of the total genes 
(Fig. 4.6). There were also sets of genes that demonstrated a monotonic decrease in 
expression from young to old as shown in-group 7 (47). There were sets of genes that 
decreased in expression from young to middle aged but then increased from middle 
aged to old, this was the case for group 2 (23) and similarly group 8 (31). Another trend 
of interest was shown in groups 5 and 6, where sets of genes were increased in middle-
aged mice compared to both young and old, suggesting that their peak of expression 
was at middle age. These groups collectively demonstrate that there are significant 
progressive changes in microglia as the brain ages.  It must also be considered that some 
of these groups are quite similar to one another and may form separately because there 
may be an outlier. This could be true for example for group 8 and group 7 because the 
pattern of gene expression for mGLIA.01 and mGLIA.02 appear similar in both these 
groups but mGLIA.03 has a different expression for both groups and this variability 










Figure 4.6 There are eight distinct sets of genes with different behaviour in young, 
middle and old microglia. Visualisation of the profiles by group clustering subgroup, as 
defined by the hierarchical clustering. Each graph represents a set of genes with a distinct 
behaviour over the three age groups termed young, middle and old. The number of genes 
represented in each group is given.  
 
4.2.2 Glycoprotein Gpnmb and chemokine Cxcl13 are among 
the top genes differentially expressed in aged microglia.  
	  
While an ANOVA test is a powerful tool for identifying changes in gene expression 
among three or more groups, it does not give any information about where the 
significant change is occurring; is the gene significantly different between young vs. 
old, young vs. middle aged or middle aged vs. old? Therefore, to gain more specific 
information about what genes/transcripts were significantly different between specific 
groups, we carried out three pairwise comparison t-tests and used the same criteria as 
the 1-way ANOVA previously described i.e. 1) p value <0.05, 2) Fold change between 
highest and lowest expression > 2, 3) Group with highest average FPKM value >1.The 
top 50 genes upregulated in old mice vs. young are shown in Fig. 4.7.  Each gene 
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aged groups are shown relative to the young group. This allows an easy visual 
comparison between the middle-aged and old groups. 
 
Interestingly, and similarly to what was discussed in the previous paragraph, the 
majority (37 out of 50 genes) were already increased in the middle–aged group to some 
extent and then increased further in the old group. Among the top differentially 
expressed genes was the glycoprotein, Gpnmb, and the neuroinflammatory chemokine 
Cxcl13. Gpnmb was dramatically upregulated in middle-aged microglia by 16-fold and 
this was further increased to a 32-fold change in old microglia. Cxcl13 was only 
moderately upregulated by 2-fold and then dramatically upregulated by another 30-fold 
in old microglia.  
 
Another gene of interest was Spp1, known as secreted phosphoprotein 1 or osteopontin. 
Spp1 is a cytokine whose upregulation has been described as characteristic of central 
nervous system pathologies166.  This gene has also been shown to be highly induced by 
macrophages upon inflammatory activation and is associated with the inflammatory 
response167. This gene was also significantly upregulated in both the middle- and old-
age groups, with a 32-fold increase in old vs. young microglia. 	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Figure 4.7. Profiles of age-associated gene expression changes in isolated microglia. 
Top 50 genes that were upregulated in old vs. young microglia (black bar) and middle-aged vs. 
young microglia (grey bar). Values shown as Log2 fold changes and calculated using pairwise 
comparison analysis where p<0.05 and fold change >2.  
50 top genes up-regulated in Old -vs- Young

























































50 top genes up regulated in Old/Middle – versus young  
Middle versus young 
Old versus young 
	   96	  
	  
This gene was closely followed by cystatin F, Cst7, a papain-like lysosomal cysteine 
protease inhibitor. This is an interesting gene, as its expression in microglia has recently 
been associated with acute demyelination168, and is also dramatically upregulated with 
age (Fig. 4.7). Furthermore, the metallopeptidase 12, known as Mmp12, was the most 
upregulated Mmp with age, 8-fold increase in old vs. young microglia. Mmp12 has 
recently been associated with the ageing brain and neuroinflammation, with one study 
showing that Mmp12 is upregulated in microglia with age, consistent with our RNA 
sequencing study. This study also showed that Mmp12 -/- mice had considerably less 
inflammation in the brain with age169.  
 
Using the same criteria, we identified the top 50 genes downregulated in microglia from 
the young brain vs. the middle-aged and old brain. Similarly to upregulated genes, 35 
out of the 50 most downregulated genes are decreased in a monotonic fashion i.e. we 
observed a steady decrease in gene expression in the middle-aged group and this 
decrease was even more apparent in the old group. Among the most downregulated 
genes were the chemokine Ccl25 and the proteoglycan Prg2, as illustrated in Fig. 4.8.	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Figure 4.8 Profiles of age-associated gene expression changes in isolated microglia. 
Top 50 genes that were downregulated in old vs. young (black bar) and middle-aged vs. young 
microglia (grey bar). Values shown as Log2 fold changes and calculated using pairwise 
comparison analysis where p< 0.05 and fold change >2.  
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4.2.3 Regulated genes are enriched in age-related pathways 
	  
We identified 367 genes that were differentially expressed in at least one of the two age 
group comparisons using >2 fold change at p value<0.05 and uncorrected 1-way 
ANOVA, as described in Fig. 4.6. Using this data set, we performed gene ontology 
analysis, which is based on the classification of genes by their functional characteristics. 
Using this bioinformatics tool we identified several pathways that were deregulated 
with age. The top five pathways and the genes involved are shown in Tab. 4.2. They 
included the immune response, defence response, response to wounding, inflammatory 
response and cell adhesion. The p value for each pathway is given, as well as the 
percentage of genes that are represented by each pathway. For example, the immune 
response had a very significant p value of 2.123 E09 and includes 9.1% of all genes 
differentially expressed, suggesting that this pathway is significantly deregulated with 
age in microglia.  
 
 
Table 4.2 Pathways that are enriched in microglia from old vs. young mice. Gene 
ontology enrichment analysis (GSEA) of 367 genes that were differentially expressed in one of 
the two age group comparisons (fold change >2, p value<0.05, calculated by 1-way ANOVA).  
 
We wanted to specifically look at the affected pathways between young and old 
microglia, rather than among the three groups. To this end, we decided to use a pairwise 
comparison t-test between the young and old groups. For this analysis, we lowered the 
fold change threshold to >1.5 with a p<0.05. We reasoned that a lower fold change 
could identify pathways in which many genes are subtly changed, which functionally 
might be more important than a few genes being highly differentially expressed. The 
analysis with the fold change >1.5 identified 888 differentially expressed genes. 
Ingenuity pathway analysis (IPA) was carried out on this dataset, in order to identify 
Term Pvalue % of genes Genes
Immune response 2.123E-09 9.1
IL1R1, TNF, ENPP1, H2-D1, TLR2, TNFSF13, CCL5, PRDX1, 
FTH1, B2M, CXCL10, GM15753, H2-Q5, CD8B1, OLR1, H2-
M2, CFB, IL1RN, CD300E, COLEC12, H2-Q6, TNFSF9, H2-Q7, 
CLEC4N, TNFSF8, CCL12, CXCL13, LILRB4, OAS1A, 
CLEC7A
Defense response 3.173E-06 7.2
IL1R1, TNF, OLR1, CEBPE, FGR, CFB, H2-D1, TLR2, CHST2, 
SAA3, CCL5, H2-Q6, PRDX1, H2-Q7, CD163, B2M, CXCL10, 
CCL12, P2RX1, CXCL13, GM15753, DEFB11, CLEC7A, FN1
Response to wounding 4.501E-05 5.7
TNF, F10, OLR1, CFB, TLR2, CHST2, SAA3, ANXA5, CCL5, 
CD163, CXCL10, CCL12, F5, P2RX1, CXCL13, PECAM1, 
CLEC7A, FN1
Inflammatory response 7.009E-05 4.4 TNF, OLR1, CFB, CHST2, SAA3, TLR2, CCL5, CD163, CXCL10, CCL12, P2RX1, CXCL13, CLEC7A, FN1
Cell adhesion 0.0001016 7.2
OLR1, CDHR4, GM13213, POSTN, LY9, ALCAM, LGALS3BP, 
F5, ITGAX, SIGLEC5, ITGA5, ITGB7, PECAM1, CD2, CD22, 
MADCAM1, CLEC7A, SSX2IP, GPNMB, MLLT4, CYR61, 
SPP1, FN1
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pathways and biological functions differentially regulated between young and old 
microglia. The top 15 enriched pathways are shown in Tab. 4.3, with individual genes 
annotated.  Interestingly, the top three pathways 1) EIf2 signalling 2) mTOR signalling 
and 3) regulation of eIf4 and p70S6K signalling are all related to the serine/threonine 
kinase mTOR, a key modulator of ageing and age-related disease30.  The genes 
differentially expressed in these three pathways are mainly the ribosomal proteins that 
make up the ribosomal subunits. All of these genes were slightly upregulated in old vs. 
young microglia with an average fold change between 1.5-2.5. These subtle, yet 
consistent, changes in gene expression of genes relating to mTOR signalling may 
indicate that this pathway is more active in microglia with age. 
 
 
Table 4.3 Pathways that are enriched in microglia from old vs. young mice. 
Ingenuity pathway analysis showing pathways differentially regulated between young and old 
microglia, using 888 genes identified by pairwise comparison. 
 
Finally using this list of 888 genes we looked at the potential upstream regulators using 
the Ingenuity software. This database gives an indication of the stimuli that may be 
responsible for regulating subsets of genes among the 888 differentially expressed. The 
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Antioxidant Action of Vitamin C 5.00E+00 SLC2A5,PLCB2,PLD3,SLC2A1,PLCG1,PLCL2,GSTO1,IKBKG,NFKBIA,PLA2G2D,PLA2G4B,TXN,CHUK,TNF
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses 4.38E+00
OAS1,C3,PIK3R5,C1QC,C1QA,CCL5,TLR2,CLEC7A,IRF7,TLR5,IL1B,T
NF,PRKCA




Atherosclerosis Signaling 3.87E+00 APOE,CXCR4,APOC4,APOC2,APOC1,PLA2G2D,CCL2,CSF1,IL1RN,LPL,PLA2G4B,IL1B,TNF,ITGA4
Differential Regulation of Cytokine 
Production in Macrophages and T 
Helper Cells by IL-17A and IL-17F
3.45E+00 CCL4,CCL2,IL1B,CCL5,TNF
TREM1 Signaling 3.45E+00 TLR2,CCL2,TLR5,TYROBP,PLCG1,ITGA5,IL1B,CD83,TNF,ITGAX
Virus Entry via Endocytic Pathways 3.44E+00 B2M,HLA-B,PIK3R5,PLCG1,ITGA5,ITGAL,ITGB7,AP2S1,ITGA4,PRKCA,ITGB3
TNFR2 Signaling 3.38E+00 TANK,IKBKG,NFKBIA,TNFAIP3,CHUK,TNF
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top regulators are shown in Tab. 4.4, together with their function. Interestingly, many 
of the upstream regulators relate to the inflammatory response including cytokines such 
as Tnf and the bacterial cell wall component LPS. 
 
 
Table 4.4 Pathways enriched in microglia from old vs. young mice. Ingenuity 
pathway analysis showing potential regulators upstream of genes that were differentially 
expressed in old compared to young microglia calculated by pairwise comparison.  
 
4.2.4 Transcription factors relating to differentially expressed 
genes appear to be mTOR related 
	  
Given that the top upregulated pathways in old microglia were related to the mTOR 
pathway, we interrogated our dataset to assess if the differentially expressed genes were 
under the control of mTOR-related transcription factors. A number of transcription 
factors are known targets of mTOR, either directly or indirectly. As a result, we used 
the EnrichR database to determine what transcription factors were associated with the 
gene changes observed with ageing. The top hits are shown in Tab 4.5.  
 
Molecule Type Predicted Activation State p-value
transcription regulator Activated 7.06E-26
chemical drug Activated 7.98E-25
chemical drug Inhibited 7.49E-24
transcription regulator Activated 2.41E-22
chemical - endogenous mammalian Activated 1.37E-21
cytokine Activated 2.09E-21
cytokine  4.03E-21




chemical toxicant Activated 8.06E-18
cytokine Activated 3.56E-16
transmembrane receptor Activated 1.26E-15
chemical reagent Activated 1.37E-15
growth factor Activated 3.04E-15
chemical - endogenous mammalian  3.87E-15
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Table 4.5 Transcription factors that are enriched in microglia from old vs. young 
mice based on the differentially expressed genes. EnrichR analysis showing the 
transcription factors that are potentially deregulated based on the 888 genes identified by 
pairwise comparison.  
The top transcription factors that appeared to be responsible for the 888 genes that were 
differentially expressed between young and old microglia identified by ErichR analysis 
were Tfap2a, Pparg, Nr5a2 and Nfkb1. Pparg (peroxisome proliferator-activated 
receptor gamma) and Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in 
B cells 1) are both targets of the mTOR pathway98,170. This could indicate that mTOR 
activation in microglia from the ageing brain may be responsible for some of the 
transcriptome changes we observe through activation/inhibition of various transcription 
factors.  
4.3 Microglia function 
4.3.1 Age – related changes in key inflammatory genes 
	  
In order to assess whether immune functions changed in microglia with ageing, we 
designed specific gene lists based on reviews/reports from the literature. More general 
gene lists such as phagocytosis or antigen presentation were obtained from the pathway 
focused, PCR array profiler lists generated by Qiagen. We first looked at the key 
mediators of inflammation including cytokines, chemokines and their receptors. 
 
We made four gene lists and used the software R, which is a programming language 
used for statistical and graphical analysis, to generate graphs showing changes in gene 
expression in microglia from the aged brain relative to microglia from the young brain. 










	   102	  
Using this programme, we were able to generate graphs that indicated when a gene 
reached the significance threshold (p value<0.05) by an asterisk. Fold changes were 
represented as Log2 fold changes and a grey line represented where a gene had a 
reached a fold change of 2.  
 
 
Figure 4.9 Cytokines related to inflammation differentially expressed in old vs. 
young microglia. A) Cytokines; B) Cytokine receptors; grey line represents genes over a fold 
change of 2 (log of fold change >1 or <-1) and * represent genes with t-test p value <0.05.   
 
We examined a variety of cytokines, including members of the interferon, interleukin, 
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relating to inflammation were significantly upregulated in old vs. young microglia and 
included the pro-inflammatory cytokines Tnf, Il-1b and Csf1 (Fig. 4.9A). Il-2 cytokine 
was also significantly up regulated but was just below a 2-fold change (Fig. 4.9A). 
Lastly, the insulin like growth factor 1 (Ilgf1) was significantly upregulated. Igf1 is of 
interest as its production by microglia has recently been suggested to be 
neuroprotective171. It is worth noting that the Il-1β receptor, Il1r was also significantly 
upregulated (Fig. 4.9B). Other cytokine receptors upregulated with age included Il-2 
receptor alpha (Il2ra), beta (Il2rb) and gamma chain (Il2rg). Together these genes 
constitute the high-affinity Il-2 receptor. Both Il2ra and Il2rg were significantly 
increased, while Il2rb did not reach significance. Nevertheless, all three genes were 
increased by more than 2-fold (Fig. 4.9B).  
  
Chemokines play a pivotal role in inflammation by directing the movement of 
leukocytes to sites of injury172. In the brain, chemokines and their receptors also play an 
important role in cell-cell communication, particularly between neurons and 
microglia173.  Here we looked at the two main groups of chemokines, the CC and CXC 
families.  We found that many of them were differentially expressed with age, mostly 
upregulated. Three members of the CX family of chemokines were particularly over 
expressed in old compared to young microglia: Cxl13 (16-fold), Cxcl14 and Cxcl16 (4-
fold, Fig. 4.10A). Other chemokines that were statistically different included many CC 
chemokines, such as Ccl12, Ccl5, Ccl3 and Ccl4 (Fig. 4.10A). Interestingly, Cxcl16 is 
the chemokine ligand for Cxcr6, which was also up regulated in old microglia by 
approximately 4-fold (Fig. 4.10A). This is a particularly interesting observation, as a 
recent study showed that Cxcl16 could drive neuron-microglia crosstalk to promote 
neuroprotective mechanisms, similarly to Cx3cr1174. 
 
Ccl25 was the only significantly downregulated chemokine in old vs. young microglia 
by almost 4-fold (Fig. 4.10A). Its receptor, Ccr9, was also the only chemokine receptor 
that was significantly downregulated by a 2-fold change (Fig. 4.10B). Interestingly, the 
chemokine Cx3cr1, which has been reported to be downregulated with age96, also 
appeared to be downregulated in our study, however, not significantly (Fig. 4.10B).  
 
Overall, old microglia showed an upregulation of different inflammatory mediators, 
which may indicate they are more inflammatory than young counterparts. 




Figure 4.10 Chemokines related to inflammation that were differentially expressed 
in old vs. young microglia. A) Chemokines; B) Chemokines receptors, grey line represents 
genes over a fold change of 2 (log of fold change >1 or <-1) and * represent genes with t-test p 
value <0.05.   
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4.3.2 Age-related changes in key genes involved in 
phagocytosis and antigen presentation 
 
The processes of phagocytosis and antigen presentation are both important functions 
carried out by innate immune cells.   
 
Macrophage phagocytosis is essential for the uptake and the degradation of dead cells 
and microbes. Phagocytosis can play an important role in regulating the immune 
response, often resulting in the activation of the adaptive response. In order to 
understand if this process was more or less activated in microglia with age, we designed 
a list of genes known to be involved in phagocytosis. Genes included in this list could 
broadly be divided into; a) receptors involved in phagocytosis, b) genes involved in 
recognition and engulfment and c) genes involved in signal transduction. We used the R 
programme to interrogate our dataset and found a number of genes relating to 
phagocytosis to be differentially expressed in microglia from the aged brain. Among 
these genes were receptors associated with phagocytosis, for example, the pattern 
recognition receptor Clec7a that recognises a variety of β-1,3-linked and β-1,6 linked 
glucans175 (Fig. 4.11). This gene was four times more expressed in microglia from old 
mice than from young ones.  Another receptor that was differentially expressed was the 
death receptor Fas. Additional genes involved in antigen recognition and phagocytosis 
were differentially expressed. These included the glycoprotein CD44 and Sirpb1a, a 
gene shown to positively regulate phagocytosis in macrophages176, which was 
upregulated, albeit not significantly (Fig. 4.11).   
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Figure 4.11 Genes related to phagocytosis that were differentially expressed in old 
vs. young microglia identified by pairwise comparison t-test. Grey line represents 
genes over a fold change of 2 and * represent genes that were statistically significant and have a 
p value <0.05.   
	  
Microglia and macrophages are also antigen-presenting cells (APCs), together with 
dendritic cells. APCs capture antigens, process them and then present them on MHC 
molecules in order to prime T cells. Similarly to phagocytosis, understanding if 
microglia upregulate antigen presentation may be an indication of the activation state of 
the cells with age. We therefore designed a gene list for antigen presentation that 
included genes relating to a) antigen uptake; b), antigen presentation; c) cell 
differentiation and d) chemotaxis. Compared to the phagocytic genes, fewer genes were 
differentially expressed (Fig. 4.12). Most of the significantly upregulated genes were 
chemokines or chemokine receptors that are involved in chemotaxis associated with 
antigen presentation such as Ccl5, Ccr2, Ccl19 and Ccr1. Most genes associated with 
antigen presentation, specifically the co-stimulatory molecules Cd80, Cd86, Cd40 and 
Cd209a, were either unchanged or downregulated. The only genes significantly 
upregulated were Cd8a, and Tapbp, a transmembrane glycoprotein (Fig. 4.12).	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Figure 4.12 Genes related to antigen presentation that were differentially 
expressed in old vs. young microglia identified by pairwise comparison t-test. Grey 
line represents genes over a fold change of 2 and * represent genes that were statistically 
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4.4 Microglia and environmental sensing 
4.4.1 Age-related changes in receptor genes involved in 
sensing the neural environment 
	  
In 2013 Hickman et al. showed that microglia have a unique transcriptome compared to 
tissue macrophages that included the expression of genes relating to sensing the neural 
environment. They also showed that with age, microglia appear to downregulate 
transcripts relating to the sensing of endogenous ligands and upregulate transcripts 
relating to host defence96. In order to understand if our data indicate similar changes in 
the sensome genes, we assessed levels of expression of a number of receptors used by 
microglia to sense changes in their environment. These include purinergic receptors, 
adenosine receptors, neurotransmitter receptors, innate immune receptors, 
neuromodulator receptors and pattern recognition receptors.  
 
We compiled gene lists for each of these categories to generate graphs containing 
information regarding fold change and significance, similarly to those relating to 
antigen presentation and phagocytosis. In order to obtain a comprehensive picture of all 
the different changes taking place in microglia from aged mice, we combined the gene 
lists for innate immune receptors, pattern recognition receptors, purinergic and 
adenosine receptors, neurotransmitter receptors and neurohormone receptors in a heat-
map (Fig. 4.13A). Genes which expression was either significantly different or above a 
2-fold change were used to generate a categorised heat map. This heat map indicated 
that there are many receptors in the ageing brain that were differentially expressed from 
all categories. The two most striking observations that can be deducted from the heat-
map were that many neurotransmitter receptors, particularly the gabaergic receptors, 
were downregulated in old and middle aged, compared to young, and secondly that 
many innate immune receptors, which will be showed in more detail below, were 
upregulated in middle-aged mice and to a greater extent in old mice (Fig. 4.13A).  
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The pattern recognition receptors included a broad list of innate immune receptors that 
included intracellular Tlrs, extracellular Tlrs, Nucleotide-binding oligomerization 
domain receptors (Nod receptors), Nod-like receptors (Nlr), Nlr-related apoptosis 
inhibitory protein receptors (Naip).  All these receptors are involved in the recognition 
of pathogen associated molecular patterns (PAMPs), expressed by invading 
pathogens177and danger associated molecular patterns (DAMPs). Results are shown in 
Fig. 4.13B. The only gene significantly upregulated with age was Tlr2, an important 
receptor in microglia function that will be discussed in the next section. Interestingly, 
the only receptor significantly downregulated was Tlr5, the receptor for flagellin.  
 
The innate immune receptors included a) Fc receptors which bind immunoglobulins and 
are important for regulating immune responses178 b) interferon-induced transmembrane 
proteins, i.e. IFITMs, which are involved in inhibition of pathogenic viruses179 and c) 
sialic acid binding Ig-like lectins (Siglecs), which bind sialic acid and play an important 
role in cell-cell interactions180. The genes that were differentially expressed from this 
list are shown in Fig. 4.13C. The most striking observation is that many of the Ifitm 
genes are upregulated in microglia with age and that many of the Siglec genes were 
downregulated. These two observations are similar to the findings of Hickman et al. 
which may confirm their view that microglia with age, upregulate receptors that are 
important for sensing pathogens96.  
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Figure 4.13 Genes involved in sensing changes in the neural environment that were 
differentially expressed in old vs. young microglia identified by pairwise 
comparison t-test. A) Categorised heat map of pattern recognition receptors, innate immune 
receptors, purinergic receptors, adenosine receptors, neurotransmitter receptors and 
neurohormone receptors. Each column represents one replicate from each age group; each row 
represents a single gene. Red indicates upregulated genes and green downregulated ones. B) 
Pattern recognition receptors; including intracellular and extracellular Tlrs, Nod, Nlr and Naip 
receptors; C) Innate immune receptors including Fc receptors, Ifitms and Siglecs; grey line 
represents genes over a fold change of 2 and * represent genes that were statistically significant 
(p<0.05). 
 
4.4.2 Tlr2 and Tlr2-pathway genes are differentially expressed 
in aged microglia 
	  
The upregulation of Tlr2 in aged microglia seemed to us particularly interesting, since 
this toll-like receptor has been implicated in neurodegenerative disorders such as 
Alzheimer’s disease and Parkinson’s disease181.  
 
To investigate this pathway further, we generated a list for Tlr2-related genes, based on 
a study in Nature Communications, which investigated the role of neuron-released α-
synuclein as an agonist of Tlr2182. We compared genes from our dataset to genes 
described by the authors in a hypothetical network of microglia activated by α-
synuclein. We found that many of the genes they predicted as being affected by a Tlr2 
agonist were also differentially expressed in microglia from the aged brain. These genes 
fell into several categories regulated by Tlr pathways including: cell migration and 
motility, inflammation, Jak-Stat signalling and genes relating to integrin signalling. We 
found that the integrin Itgax, encoding CD11c, was the most upregulated gene, which 
was 8-times more expressed in microglia isolated from the aged brain (Fig. 4.14A). 
Two additional integrins were also upregulated; Itga5 and Itga1, and no members of 
this family appeared to be downregulated with age. Several signalling molecules 
implicated in Tlr2 signalling were differentially expressed, as were other genes relating 
to inflammation (Fig. 4.14A).  The gene for Tlr2 itself was significantly upregulated by 
at least 2-fold in old vs. young microglia and interestingly Clec7a, a receptor that  
cooperates with Tlr2 in macrophage phagocytosis175, was also significantly upregulated 
by 4-fold. 
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Figure 4.14 Genes related to the Tlr2 pathway identified by pairwise comparison t-
test between old and young microglia. Grey line represents genes over a fold change of 2 
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Based on these profiles, and our interest in this pathway, we wanted to validate both 
Tlr2 and Clec7a by quantitative real time PCR. To this end, we used the same protocol 
as the RNA sequencing experiments to obtain microglia RNA but used a new cohort of 
young, middle-aged and old mice.  We also prepared lysates from a number of controls, 
which included: whole brain from young mice, the microglia cell line BV-2, un-
stimulated BMDMs, macrophages stimulated with LPS and finally we used the negative 
fraction from our sorting, called here ‘other brain cells’. These experiments confirmed 
the results from the RNA seq. data showing a steady increase in both receptors from 
young to middle aged and a further increase in old aged mice (Fig. 4.15A and 4.15B). 	  
 
We went on to validate Tlr2 and Clec7a on a protein level, using flow cytometry in 
young and old mice. We found a striking upregulation in both receptors in old vs. young 
microglia, similar to what we had observed by qPCR and in the RNA sequencing 
analysis (Fig. 4.15E and 4.15F). 
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Figure 4.15 Age-related changes in gene expression quantified by qPCR. A) Clec7a 
and B) Tlr2 expression are shown relative to Hprt1 expression. Overlay of flow cytometry 
analysis gated on CD11b+ microglia between one young (6 months – red line) and one old (24 
months- blue line) for Clec7a (C) and Tlr2 (D). Quantification defined by a change in mean 
fluorescence intensity (MFI) for Clec7a (E) and Tlr2 (F). Data shown are from one experiment 
where n=3 for each group (qPCR) and n=4 for each group (flow cytometry),  * p<0.05, ** 
p<0.01. Significance was calculated using the unpaired two tailed student t-test between 
individual groups.	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4.4.3 Changes in adenosine and purinergic receptor expression may 
indicate microglia activation during ageing  
	  
As reported in Fig. 4.13C, several purinergic and adenosine receptors were 
differentially expressed in aged microglia. Microglia express a variety of purinergic 
receptors that can be categorised into two families, P2x and P2y, which primarily 
recognise ATP/ADP. These receptors have been proposed to have many important roles 
in microglia including activation, migration and response to injury183.  
 
Extracellular adenosine can be produced by cells following injury or damage and can 
bind to a number of G-protein-coupled receptors known collectively as adenosine 
receptors184. Recently, it has been shown that these receptors can play an important role 
in the control of the inflammatory response185.  
 
We combined a gene list that included all known purinergic receptors divided into these 
two subtypes and that also included the adenosine receptors. We found that several were 
differentially expressed in old vs. young microglia. P2ry12, which has recently been 
described as a microglia specific marker in the adult brain186, was significantly 
downregulated with age (Fig. 4.16A). This downregulation has been proposed as a 
marker of microglia activation in response to injury or damage187. P2ry13 was also 
significantly downregulated, as were two P2x receptors, P2rx6 and P2rx1. Several 
receptors were upregulated, including the two adenosine receptors Adora2b and 
Adora2a, albeit not significantly (Fig. 4.16A). Recently, the upregulation of Adora2a, 
concomitantly to the downregulation of P2ry12, has been implicated in the retraction of 
cellular processes during inflammation, further indicating that it constitutes a marker of 
microglia activation. We proceeded to validate P2ry12 and P2ry13 by qPCR using the 
same controls and conditions as described for Tlr2 and Clec7a validation (Fig. 4.16A 
and Fig. 4.16B). Interestingly, none of our selected controls expressed either purinergic 
receptors, further confirming that these genes are specific to primary microglia and are 
not expressed by macrophages or the WT brain186.  We observed a similar 
downregulation of P2ry12 and P2ry13 in microglia isolated from the new cohort of 
aged mice when compared to microglia isolated from young mice. These changes were 
significant for both receptors (Fig. 4.16B and 4.16C). 
	  
	  







Figure 4.16 Changes in purinergic and adenosine receptors and validation of 
purinergic receptor genes. A) Purinergic and adenosine receptors identified by pairwise 
comparison t-test between old and young microglia. Grey line represents genes over a fold 
change of 2 and * represent genes that were statistically significant and have a p value of <0.05. 
Age-related changes in gene expression quantified by qPCR for B) P2ry12 and C) P2ry13 
relative to Hprt1 expression. Data shown are from one experiment where n=3 for each group, * 
p<0.05, ** p<0.01. Significance was calculated using the unpaired two tailed student t-test 
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4.5 Age-related changes in genes associated with 
metabolism  
 
Energy metabolism can change significantly with age and in macrophages, changes in 
glucose metabolism and upregulation of glycolysis are known to be important to 
maintain an inflammatory phenotype188. Therefore, we assessed whether there were any 
metabolic changes in microglia from aged mice. We compiled lists of genes that are 
involved in the main metabolic pathways, including the pentose phosphate pathway, the 
tricarboxylic acid cycle (TCA), glycolysis, gluconeogenesis and oxidative 
phosphorylation (OXPHOS).  
 
We found that very few genes were differentially expressed in all the key metabolic 
pathways except for the OXPHOS pathway (Fig. 4.17A), in which we found 23 genes 
differentially expressed. Strikingly, all these genes were upregulated and were all 
members of complex IV and V of the electron transport chain.  We picked the two most 
differentially expressed genes from the 23 OXPHOS gene for validation by qPCR, 
Atp6v1b2 and Cox6a2, which were upregulated by 16-fold and 8-fold, respectively. In 
the qPCR assays, from a new cohort of young, middle-aged and old mice, we found that 
both Cox6a2 and Atp6v1b steadily increased from young to middle aged and from 
middle aged to old, as previously observed in the RNA sequencing data (Fig. 4.17B).  
These data suggest that although some metabolic pathways may be increased in 
microglia with age, overall, little change was observed between young and old 

















Figure 4.17 Age-related changes in genes associated with key metabolic pathways. 
A) Pie chart showing the number of genes that were differentially expressed in each of the 
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sequencing experiments are shown for two of the genes relating to OXPHOS; Atp6v1b2 and 
Cox6a2, as well as age-related changes in gene expression quantified by qPCR relative to Hprt1 
expression. Data are from one experiment where n=3 for each group,* p<0.05, ** p<0.01. 




4.1 Why the transcriptome of microglia in ageing is 
important 
 
Given that microglia have been implicated in several pathologies that affect the central 
nervous system, including many types of cancer, neurodegenerative diseases and mental 
illnesses, it has been suggested that they also play a key role in the ageing of the brain. 
The literature indicates that microglia in the ageing brain are morphologically distinct 
from their younger counterparts, becoming more amoeboid in shape. However, it is still 
relatively unclear whether these cells reflect a senescent or activated phenotype or 
perhaps both.  In my project I addressed the following question - do microglia in the 
ageing brain have an age-associated change in gene expression? This is an important 
question in trying to understand the role that microglia play in the ageing brain, 
including whether they become neurotoxic or neuroprotective. Considering that so 
many diseases of the CNS are age-associated, understanding what happens during this 
process may give insight into the pathogenesis of neurodegenerative diseases. 	  
4.2 The isolation technique and the clontech ultralow 
RNA sequencing system 
	  
To study microglia in ageing, I first had to optimise a technique to isolate microglia 
from the ageing brain. It was extremely difficult to establish a technique that allowed 
the isolation of microglia with sufficient purity, particularly from brains over 18- 
months of age.  This proved problematic but an important challenge to address, as even 
a 5-10% contamination with another cell type can severely distort gene expression 
results. Therefore, when considering doing large-scale gene expression, such as RNA 
sequencing, we needed a reliable method that allowed the isolation of microglia with 
purity of  >95%. I found that in order to accomplish this, I had to first remove the 
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myelin with myelin removal microbeads and then flow sort the cells based on their 
expression of CD11b and CD45. While this technique proved to be reliable and robust, 
it had one major disadvantage; it reduced the yield in cell numbers dramatically. As a 
result, even by pooling three mice per replicate in each group, we still did not obtain 
sufficient quantities of RNA for standard RNA sequencing protocols. Therefore, a 
relatively novel system was used in which the quantity of the starting RNA can be as 
low as 10 pg. However, it needs to be considered that starting with such low amounts of 
RNA may introduce some bias into the experiment, particularly when considering genes 
or transcripts that are differentially expressed at low levels. This could potentially 
explain why so many genes that were differentially expressed were upregulated rather 
than downregulated in my data set. If some genes were subtly downregulated, it may 
have been difficult to measure this if the starting amount of RNA was already low this 
could possibly be introducing a bias. One was of overcoming this potential bias would 
be to increase the starting amounts of RNA or the depth of sequencing.  
 
4.3 ANOVA analysis of aged microglia revealed eight 
distinct subsets of genes with similar behaviours 
	  
Our first analysis of the RNA seq. data was aimed at categorising the changes observed 
and whether there were any patterns. We first showed that there are distinct sets of 
genes, with expression profiles that change with age in a similar fashion. This is a major 
advantage to having a middle-aged group.  Many studies, that have investigated 
microglia in the ageing brain, have only used a young and an old group 95,96. In our 
study, having this additional age group, has allowed us to draw some interesting 
observations.  Many of the changes we see in gene expression in the old group are also 
changed in the middle-aged group. This reflects the ageing process as it is generally 
defined as a gradual decline and functional deterioration of the body4, the monotonic 
changes we observe from young to middle aged and from middle aged to old may 
mirror this gradual decline. It would have been interesting to look at an even earlier age 
group, for example 9 or 12 months, to try and understand when these changes in the 
microglia transcriptome start to appear in the brain.  
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We also observed that the majority of differentially expressed genes were upregulated, 
rather than downregulated, in the aged brain and that many of these genes were related 
to inflammation.  There were also sets of genes where the peak of expression was 
observed in the middle-aged group. On deeper inspection of this set of genes, they do 
not appear to belong specifically to any pathway or functional group, making it difficult 
to interpret what this upregulation in middle age might mean.  
4.4 Differential expression analysis 
	  
Our differential expression analysis revealed some interesting results. Many of the 
genes that appeared in our top 50 lists were genes related to inflammation. This is not 
surprising, given that ageing is associated with a low grade pro-inflammatory phenotype 
and senescent cells have been reported to secret inflammatory cytokines, known as the 
SASP17. We also saw changes in genes related to translation, metabolism, pathogen 
recognition and cell adhesion. The most differentially expressed gene in our dataset was 
the type 1 transmembrane glycoprotein Gpmnb, which has been implicated in a number 
of biological roles including inflammation. While the majority of research on Gpmnb 
has been in relation to its role in glioblastoma as a potential therapeutic target189, there 
are two studies that have investigated its potential role in mediating inflammatory 
responses in microglia. Huang et al. showed that under basal conditions, Gpnmb was 
widely expressed in several regions of the brain and the majority of this expression co-
localised with the microglia marker CD11b. They also found that the intensity and 
number of Gpnmb positive microglia increased upon intra-peritoneal injection of LPS, 
which is an accepted model of neuroinflammation. They suggested that Gpnmb was up 
regulated in microglia, following treatment with LPS190. This was further supported by 
an additional study by Shi et al. which showed that both the expression of Gpnmb and 
the production of pro-inflammatory cytokines Tnf-α and Il-1β increased in the BV-2 
microglia cell line upon LPS treatment, however, Gpnmb knock down by siRNA 
dramatically reduced this pro-inflammatory response. They suggested that Gpnmb 
might stimulate excessive inflammatory responses in microglia, at least in vitro191. With 
regard to our study, it is interesting that a proven mediator of the inflammatory response 
in microglia is so upregulated in both middle-aged and old microglia. It would also be 
interesting to further explore the possible role of this glycoprotein in microglia in the 
ageing brain.  
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Another gene that was upregulated with age was the chemokine Cxcl13. Interestingly, 
Cxcl13 was only moderately upregulated (2-fold) in middle-aged mice and this 
dramatically increased in old age (16-fold). Cxcl13 has been implicated in 
neuroinflammation particularly in multiple sclerosis192 and recently it has been linked to 
microglia activation in a study that investigated the activation status of microglia in 
different age groups of mice. In this article, the authors assessed the brain response to 
inflammation by injecting a cocktail of cytokines, which included Il-12, Tnf-α and Il-
1β, into the hippocampus of mice aged 6-24 months. They then performed gene 
expression profiling and found that, across all age groups, Cxcl13 was significantly 
upregulated193. This study may have implications for our data presented here, especially 
given that Tnf and Il1b were upregulated in aged mice and that this upregulation was 
more pronounced in old mice compared to middle-aged ones. So, it would be interesting 
to determine if these cytokines induce the upregulation of Cxcl13 in the ageing brain, or 
if additional factors are involved. It would also be important to understand the effect of 
high levels of this chemokine (if any) in the ageing brain. Cxcl13 in MS has been 
described as an attractant of B cells into the CNS194 but given that the blood-brain-
barrier should be intact in the ageing brain195, it might have additional roles in this 
scenario. 
4.5 Functions that may be affected by age 
	  
The analysis of chemokine, cytokine genes and their receptors provided some 
interesting observations. As expected, many of these genes were differentially 
expressed. What was interesting is that in some cases, for example Il-1β, both the 
cytokine and its receptor, Il1r, were upregulated. Cytokines and chemokines are also 
known to act in an autocrine fashion, where the cell both produces and responds to the 
cytokine/chemokine, or in a paracrine fashion, where one cell type produces the 
chemokine/cytokine that acts on another cell in its vicinity196. In our study, we observe 
a number of differentially expressed cytokine-receptor pairs, indicating that potentially 
these cytokines, such as Il-1β-Il1r, are acting in an autocrine fashion on microglia. An 
example of a potential chemokine autocrine loop could be Cxcl16 and its receptor 
Cxcr16, both upregulated in aged mice. In the case of Tnf, for example, the cytokine is 
upregulated, unlike the receptor. This may indicate that Tnf is acting in a paracrine 
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fashion on neighbouring neurons or glia cells.  In general, the differential expression of 
so many mediators of inflammation is a clear indication that the pathway is deregulated 
in the ageing brain. 
 
4.6 Microglia sensing of the neural environment  
	  
4.6.1 The Tlr pathway 	  
	  
Overall, our data indicate that microglia from the ageing brain have a more activated 
inflammatory phenotype and may reflect a more primed status. It has been suggested 
that extrinsic factors in the ageing brain may be responsible for inducing changes in 
morphology and function in microglia. These may include stimuli such as 
neurotransmitters, ATP released from dying cells or astrocytes, cell debris, hormones, 
oxidative stress, or the build up of abnormal aggregates such as amyloid beta80. Our 
data supports this idea to a degree, given the differential expression of so many 
receptors that are responsible for sensing changes in the neural environment. These 
include Tlr2 and Clec7a. Given the clear up-regulation of Tlr2 and that signalling 
downstream of toll-like receptors such as Tlr2 can trigger the production of 
inflammatory cytokines and also increase phagocytic activity, we performed an 
additional analysis of possible Tlr2 target genes. To this end, we used a hypothetical 
pathway list of genes, generated from a previous study in which authors used α-
synuclein as Tlr2 agonist182. We found that many of the genes shown to be regulated by 
Tlr2 activation in this paper, were also upregulated in our aged microglia. We also 
found that Clec7a, which has been shown in many studies to co-localise with Tlr2, was 
also significantly upregulated in our data. Yadav et al. showed that Clec7a was required 
for Tlr2 mediated production of Tnf-α in macrophages infected with Mycobacterium 
avium or M smegmatis175. 
 
Tlr2 is of particular interest because several studies have shown that the amyloid 
plaques that are associated with Alzheimer’s disease and that build up as the illness 
progresses can trigger Tlr2197. Given that amyloid plaques are also present in the aged 
brain, albeit to a lesser extent, they may be partly responsible for the inflammatory 
phenotype we observe in the aged microglia. Depending on the potential stimuli, it is 
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possible that Clec7a is upregulated simultaneously, as it may be required for Tlr2 
mediated responses.  Our data on Tlr2 fits with the current literature on the ageing brain. 
Hickman et al. carried out a similar study using young and old mice and direct RNA 
sequencing and they also showed that the only significantly upregulated toll-like 
receptor in aged microglia was Tlr296. This was further supported by an earlier study in 
2006, in which in situ hybridisation was used to show that Tlr2 is upregulated in 
microglia form aged rats compared to young counterparts 84. 
4.6.2 The purinergic receptors 
	  
It is interesting that we see so many genes involved in sensing the neural environment 
being differentially expressed, for example many endogenous sensing genes, such as 
neurotransmitter receptors, were downregulated in aged microglia, perhaps to dampen 
microglia response to these stimuli. It is known that inflammation can be associated 
with the release of nucleotides, particularly ATP, which is recognised by purinergic 
receptors183. P2ry12 has been shown to be downregulated after microglia activation187. 
During inflammation microglia retract their cellular processes and downregulate this 
receptor, its downregulation coincides with the upregulation of the A2 (A) adenosine 
receptor. This switch in receptor expression is proposed as a “hallmark of CNS 
inflammation” by the authors198. Therefore, it is very interesting that in our study we see 
the same pattern of receptor expression in old vs. young microglia, which may be 
another indication of CNS inflammation and microglia activation in the ageing brain. It 
is also worth to note that P2ry13 (in the same family as P2ry12) is also downregulated 
and that the other adenosine receptor Adora2b is upregulated, suggesting a potential role 
also for these receptors in CNS inflammation. The downregulation of the purinergic 
receptors is further supported by our validation data, obtained from a separate cohort of 
mice and supported by the Hickman et al. ageing study96.  It would be important to 
validate some of these receptors on a protein level. Given the unavailability of 
antibodies that can be used for imaging, this is technically very difficult at present.  
4.7 Interpretation of our data  
	  
When interpreting and analysing our data, we need to consider the use of the Clontech 
system and the input of such low amounts of starting RNA. The fact that we were able 
to validate many of our candidate genes by qPCR, in which the RNA was not amplified 
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using the Clontech system, indicates that this technique does not seem to have 
introduced any major biases into our experiment. However, many genes of interest are 
upregulated, in some cases with a substantial fold change, but are not statistically 
significant. This may be due to the fact that one of the three replicates from the old mice 
had very small amount of total RNA, with the smallest being just 13 ng. This may have 
introduced some differences among our replicates, which may increase the standard 
deviation and reduce the statistical significance. Therefore, for some genes with a high 
fold change but a p value over 0.05, it may still be worthwhile, if they are of interest, to 
validate them in a new cohort of mice to see if the differences were significant.  This 
may be true for example for the Sirpbl1 gene, which has been shown to be a positive 
regulator of phagocytosis in macrophages176 and for which we observe a 2-fold increase 
between young and old microglia but the p value is 0.06.  
 
This is also an indication of the possible disadvantage of having only three replicates 
per group, as four or five replicates may have reduced the standard deviation. We did, 
though, have to limit our replicates to three given the difficulty in obtaining RNA from 
aged microglia.  
	  
4.8 How does our data compare to the field of 
microglia and ageing? 
	  
Since additional studies on the transcriptome of microglia in ageing have been 
published, it is important to compare our data to others in the microglia field. As 
discussed, our data show similarities with the Hickman et al. ageing study; this is true 
for many of our differentially expressed genes. Overall they report that many 
endogenous sensing genes are downregulated, whereas many pattern recognition 
transcripts are upregulated, which is similar to our data set. They do also observe an 
overall downregulation of the oxidative phosphorylation pathway, which has been 
suggested to promote neurotoxicity, whereas in our study we see an upregulation of 
many genes involved in the electron transport chain of oxidative phosphorylation, 
suggesting an overall upregulation of this pathway96.  
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We also see a clear upregulation of complement related genes C3 and Cfb, which was 
the main finding of the retina ageing study91. Finally, with regard to the Orre et al. 
ageing study, which isolated microglia from the cortices of aged mice, we observe very 
few similarities95.  
Another study by Grabert et al. showed that changes in the microglia transcriptome with 
age were non-uniform across different brain regions. In this study microglia were 
isolated from different regions of the brain from young and aged mice.  They identified 
major transcriptional networks relating to both immune function and bioenergetics that 
defined the microglia transcriptome from different regions of the brain.  Perhaps most 
relevant to our study was the finding that genes relating to the immune response were 
induced with age in the cerebellar microglia, whereas other genes more involved in 
limiting excessive inflammation were mainly stable across all brain regions.  Could the 
transcriptome changes we observe, particularly those relating to inflammation, be due to 
changes to cerebellar microglia rather than a general phenotype of aged microglia from 
the whole brain?  
When comparing these studies to our data or to each other, it is important to be aware 
that they differ in terms of how microglia were isolated from the ageing brain, the age 
groups of mice that were used, the regions of the brain used, the type of gene-expression 
profiling carried out and how the data were analysed. Potentially, the differences in 
overall experiment design and procedure may reflect the variations observed among 
data sets. 
 
4.9 The possible role of mTOR in microglia from the 
ageing brain 
	  
The two main themes emerging from our data set were the concomitant deregulation of 
inflammatory pathways and the mTOR pathway. This was further corroborated by the 
observation that transcription factors putatively upstream of the genes differentially 
expressed in age were related to mTOR, such as Pparg and Nfkb1. Maybe, it is not 
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surprising that the mTOR pathway is more active in microglia with age, given that its 
activation has been associated with ageing in a number of tissues199. In fact, inhibiting 
the pathway has also been shown to extend lifespan in a number of genetic models30 . 
What is not known however, is what role this activation may possibly have in microglia 
with age. Could it possibly be regulating some of the transcription changes we observe 
with ageing? It has been shown to negatively regulate NF-kB in primary monocytes and 
that mTOR inhibition in this setting actually leads to a more pronounced inflammatory 
response129.  Could mTOR activation in the ageing brain be preventing excessive 
inflammation or, on the contrary, be modulating microglia priming?  
 
4 Conclusion 
In conclusion, our results show that overall microglia from mice as young as 15 months 
of age display a global change in gene expression and that this change is often further 
increased, as the mice get older. These changes appear to relate to genes involved in 
microglia function, such as phagocytosis or inflammation, and may be a reflection of a 
more primed activated cell that seems to have an increased ability to sense changes in 
its environment. Nevertheless, the upregulation of the mTOR pathway with age may be 
an attempt to counterbalance excessive inflammation with age. The role of mTOR in 
ageing microglia clearly warrants further investigation.  
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Chapter 5: mTOR inhibition regulates inflammatory 
responses in microglia from the ageing brain 
 
As explained in the introduction, mTOR is a serine/threonine kinase of the PI3K related 
family and a master regulator of cellular growth and metabolism, which is deregulated 
in a number of human diseases, including type 2 diabetes and cancer98. Unsurprisingly, 
there is a strong interest around mTOR in the ageing field, since its inhibition, either 
genetically or with rapamycin, has been shown to extend lifespan in a number of model 
organisms30.  
 
I was particularly interested in the mTOR pathway, given that it appeared upregulated 
in microglia from the ageing brain. Weichhart et al. had previously described how 
mTOR inhibition in primary monocytes could lead to an increase in inflammatory 
responses through the activation of NF-κB129, therefore I hypothesised that, in the 
ageing brain, mTOR might be activated in microglia to prevent excessive inflammation 
in the brain. 
The Csf1r-Cre; Rheb f/f mouse model  
 
Rheb is a small GTPase upstream of mTORC1 signalling and activates it when bound to 
GTP102. This activation leads to phosphorylation of the downstream targets S6K1 and 
4E-BP1. Therefore, when Rheb is knocked out, the mTOR pathway is inhibited and 
phosphorylation of mTORC1 downstream targets are blocked. To investigate the 
potential link between mTOR and inflammation in microglia, I used a mouse model in 
which Rheb was deleted under the control of the Csf1r promoter. In this model, LoxP 
sites flank both Rheb alleles and the gene is deleted by the Cre recombinase. This 
occurs in cells that express Csf1r, which are primarily monocytes, macrophages and 
microglia, since Csf1 signalling is important for their differentiation and 
development200. This model made it possible to study the effect of mTOR inhibition in 
microglia and macrophages both in vivo and in vitro. The Rheb f/f model has been used 
previously, crossed with a T-cell Cre recombinase mouse model, which showed that 
Rheb was important for the differentiation of T cells into Th1201.  
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5.1 In vitro stimulation of BMDMs with LPS reveals the 
mTOR pathway is inhibited in Csf1r-Cre; Rheb f/f cells  
 
I first wanted to assess if the mouse model was working correctly. To this end, I 
differentiated macrophages from the bone marrow of both control and Csf1r-Cre; Rheb 
f/f mice (called Rheb KO for simplicity). Control mice were Rheb f/f and negative for 
Csf1r-Cre (called WT for simplicity). I decided to use this strategy in order to use 
littermates as controls. Given that the mouse line is on a mixed background, partly 129, 
partly FVB/N and partly C57BL/6J – backcrossed three times to C57BL/6J – it was 
important that controls had a similar background. Once macrophages were generated, 
they were stimulated with LPS at different time points to induce phosphorylation of S6, 
which is mediated by the kinase S6K1; therefore, it is directly downstream of 
mTORC1. I observed a complete deletion of the Rheb protein in Rheb KO BMDMs, as 
shown in Fig. 5.1A. 
 
Figure 5.1 Immunoblots showing that the mTOR pathway is inhibited in Csf1r-
Cre; Rheb f/f – Rheb KO – BMDMs. BMDMs were differentiated for 6 days and then re-
plated overnight in complete media.  A) Immunoblot for the GTPase Rheb from the whole cell 
lysate of three WT and three Rheb KO mice. B) BMDMs were stimulated with 200 ng/ml of 
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Upon LPS stimulation, there was a clear induction of p-S6 in WT cells, suggesting that 
LPS strongly activates the mTOR pathway, as previously published in the literature129. 
However, p-S6 levels were significantly reduced in Rheb KO BMDMs (Fig. 5.1B). 
5.2 The number of myeloid cells is not affected by Rheb 
deletion in vivo 
 
It was important to understand if Rheb KO mice had similar numbers of myeloid cells 
compared to littermate controls, as this would be important for in vivo experiments to 
measure their inflammatory responses. To this end, I assessed CD11b+ cells in the bone 
marrow and the spleen from both young and old WT and Rheb KO mice using flow 
cytometry analysis. As described in chapter 3, CD11b is an integrin that is expressed on 
all myeloid cells.  I found that there was no difference in the number of myeloid cells 
between WT and Rheb KO mice. This was the case for both young and old mice in the 
bone marrow (Fig. 5.2A) and similarly in the spleen (Fig. 5.2B).  
 
I also found that there were no differences in the total number of cells obtained from the 
bone marrow (Fig. 5.2C), spleen (Fig. 5.2D) or blood (Fig. 5.2E). Finally, a similar 
number of microglia cells were purified from WT and Rheb KO brains (Fig 5.2F). It 
would be important to confirm that there weren’t any changes in the number of 
microglia or the distribution of these cells in the brain in Rheb KO mice by using a 
microglia marker such as IBA-1 to stain brain sections form both Rheb KO and WT 
brains. 
 
Nevertheless, it would appear that the deletion of Rheb in myeloid cells does not have 
an effect on myeloid cell numbers in vivo. Both WT and Rheb KO mice were kept to a 
maximum age of 22 months and Rheb KO mice did not display any obvious phenotype 
compared to WT mice.  It must also be mentioned that I did notice, however, 
impairment in the growth of Rheb KO BMDMs in vitro. I found, in general, that I 
obtained fewer BMDMs from Rheb KO cultures compared to WTs.  
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Figure 5.2 Myeloid cell numbers are not affected by Rheb deletion in vivo.  The 
spleen and bone marrow from young (3 months) and old (22 months), Rheb KO and WT mice 
were assessed by flow cytometry analysis for CD11b expression. A) Percentage of CD11b+ 
cells in the bone marrow B) Percentage of CD11b+ cells in the spleen. C) Total number of cells 
in the bone marrow, D) total number of cells in the spleen E) total number of cells in the blood. 
F) The number of microglia obtained by purification is also shown. The data shown is from one 
experiment where n=3 for each group. 
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5.3 mTOR inhibition in BMDMs leads to an upregulation of 
inflammatory cytokine genes upon LPS stimulation in vitro  
 
It has been described in the literature that inhibition of the mTOR pathway by 
rapamycin leads to an increase in cytokine production, in response to bacterial 
infection129. Therefore, after establishing that the mTOR pathway was inhibited in 
BMDMs upon Rheb deletion, I wanted to establish if this inhibition would affect the 
inflammatory response, as previously described in chapter 4.  
 
To test this hypothesis, BMDMs were stimulated with 200 ng/ml of LPS for six hours to 
determine the effect of mTOR inhibition on the expression of pro-inflammatory 
cytokine genes, known to be regulated by NF-κB. It appeared that key inflammatory 
genes were upregulated in Rheb KO BMDMs upon LPS stimulation. These changes 
were consistent among inflammatory cytokines Tnf (Fig. 5.3A), Il1b (Fig. 5.3B) Il6 
(Fig. 5.3C) and Il12a (Fig. 5.3D) when mTOR was inhibited. Finally, I also looked at 
the expression of Tlr2 (Fig. 5.3E), one of the genes significantly upregulated with age 
in microglia, as described in chapter 4. Tlr2 expression also appeared increased in Rheb 
KO BMDMs upon LPS stimulation.  Statistical analysis was not carried out on this 
dataset, as the number of replicates was equal to two and therefore more replicates 
would be needed for this analysis.  
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Figure 5.3 Inhibition of mTORC1 signalling increases transcription of 
inflammatory genes in BMDMs in vitro. BMDMs were differentiated for 6 days before 
being re-plated overnight in complete media. They were then treated with 200 ng/ml of LPS for 
six hours, or media only as control, shown here as un-stimulated. Expression of inflammatory 
genes was determined using qPCR with fold changes being shown relative to the housekeeping 
gene Hprt1 for A) Tnf, B) Il1b, C) Il6, D) Il12a and for E) Tlr2. The data shown is from one 
experiment, where n=2 for each group. 
5.4 mTOR inhibition in primary adult microglia leads to an 
upregulation of inflammatory cytokine genes upon LPS 
stimulation in vitro  
 
Following the observation that mTOR inhibition by Rheb deletion resulted in an 
increase in inflammatory cytokine genes in BMDMs upon LPS stimulation, I wanted to 
test if this would also be the case in primary microglia.  To this end, I isolated microglia 
from the adult brain of both WT and Rheb KO mice and incubated them for two hours 
with LPS. A shorter time point was chosen because adult microglia are more sensitive 
to stress and apoptosis. Nevertheless, even at a shorter time point, the Rheb KO 
microglia showed an upregulation of inflammatory genes such as Tnf (Fig. 5.4A) and 
Il1b (Fig. 5.4B) although this was only significant for Il1b. Other inflammatory 
cytokines such as Il6 appeared only slightly upregulated (Fig. 5.4C), however, this 
could be due to the shorter time point used. It must be noted that, particularly for Tnf, 
the un-stimulated cells were expressing high levels already, which is probably due to 
their overall stress levels at the time of stimulation. Finally, the gene for Tlr2 was also 
upregulated upon LPS stimulation in Rheb KO microglia cells (Fig. 5.4D). 
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Figure 5.4 Inhibition of mTORC1 signalling affects inflammatory responses in 
vitro in primary adult microglia. Primary microglia were isolated from the adult brain and 
stimulated directly with 200 ng/ml of LPS for two hours. Expression of inflammatory genes was 
determined by qPCR for A) Tnf, B) Il1b, C) Il6 and D) Tlr2. The data shown are representative 
of two independent experiments, where n=3 for each group and * p<0.05. Significance was 
calculated using the unpaired two tailed student t-test between individual groups. 
5.5 Optimisation of LPS stimulation conditions to be used for 
in vivo ageing studies  
 
Following my in vitro observations that inhibiting the mTOR pathway by Rheb deletion 
lead to an increase in inflammatory cytokines upon LPS stimulation, I wanted to test if 
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this would also be the case in vivo. Furthermore, given my transcriptome data showing 
an upregulation of mTOR signalling in microglia with age, I wanted to understand what 
would be the effect of inhibiting mTORC1 in ageing in response to an LPS challenge. 
This is an important question, since mTOR inhibitors are being tested as anti-ageing 
interventions. If a more profound inflammatory response is a consequence of mTOR 
inhibition, when an infection is encountered, for example, this could have major 
implications for neuroinflammation and neurotoxicity.  
 
Lipopolysaccharide–induced neuroinflammation is a well-studied and accepted model 
of neuroinflammation, both in vivo and in vitro202.  The route of administration, 
however, dose and age of animals all need to be considered in the study design.  
 
In order to optimise a dose and duration of LPS treatment in vivo, I carried out a small 
pilot study in which I administered young WT mice either 1 mg/kg or 5 mg/kg of LPS 
for 4 or 24 hours. In addition, I used one aged mouse (24 months) to assess the 
tolerability of the higher dose. All mice received LPS by intraperitoneal injection, in 
order to model the scenario of an elderly individual contracting a peripheral infection. 
 
  
Figure 5.5 Optimisation of LPS dose and time-point for in vivo challenge. WT mice 
received LPS by intra-peritoneal injection for either 4 hours or 24 hours. The doses of LPS used 
were either 5mg/kg or 1 mg/kg at the time points indicated. Microglia were isolated from the 
brain using CD11b microbeads and the induction of inflammatory genes was measured by 
qPCR. Fold changes shown as relative to the housekeeping gene Hprt1 for A) Tnf and B) Tlr2. 
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Microglia were isolated following LPS challenge, and qPCR was carried out on the key 
inflammatory gene Tnf (Fig. 5.5A) and the age-related gene Tlr2 (Fig. 5.5B). Both 
genes should be strongly induced in microglia following an LPS challenge. I found that 
the strongest induction of Tnf in microglia, for both young and old mice, was observed 
with 5 mg/kg LPS after 24 hours (Fig 5.5A). A weaker induction of Tnf was observed at 
4 hours with this dose and an even lower one with 1 mg/kg of LPS for 4 and 24 hours.  
 
At the higher dose of LPS, after 24 hours, both the young and particularly the old mouse 
were extremely ill, therefore I deemed it inhumane to use this dose and time point for 
future experiments. The higher dose of LPS but the shorter time point of four hours was 
therefore used for future experiments.  
5.6 mTORC1 inhibition in the ageing brain  
 
In order to assess if mTORC1 inhibition leads to an increased inflammatory response in 
microglia from the ageing brain, I aged Rheb KO mice and WT littermate controls. 
Once mice were 18-months old (old group) and 4-months old (young group), they were 
divided into groups and given the sub lethal dose of LPS of 5 mg/kg intraperitoneally 
for 4 hours or PBS, as described in the schematic in Fig. 5.6. Following the in vivo 
stimulation, microglia were isolated, RNA extracted, and qPCR was conducted for a 
number of inflammatory and age-related genes. 
 
 
Figure 5.6 Experimental design for in vivo LPS challenge. Young and aged mice were 
used in this experiment and given a peripheral injection of PBS as control or LPS (5mg/kg) for 
four hours.  Microglia were isolated using magnetic beads and used for phospho-flow 
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5.7 Phosphorylation of p-S6 is reduced in microglia from aged 
Rheb KO mice compared to WT mice upon LPS stimulation 
in vivo  
 
In order to test that our in vivo model was working correctly, i.e. that there was a 
deletion of Rheb in microglia under the Csf1r-Cre, I assessed levels of p-S6 using a 
phospho-specific flow cytometry antibody (phospho-S6-Alexa 488). The use of flow 
cytometry was necessary, given that a low number of microglia can be recovered from 
each brain and was not sufficient for a western blot analysis. Following the LPS 
injection (5 mg/kg i.p. for four hours), brains were digested and myelin removed as 
previously described in chapter 4. Following myelin removal, the remaining glia cells 
were stained for p-S6 and the microglia specific markers CD11b and CD45. An 
example of the p-S6 levels in microglia comparing WT and Rheb KO cells is shown in 
Fig. 5.7A. There was a clear shift of p-S6 in the WT cells (green line) upon LPS 
stimulation that was not as pronounced in Rheb KO microglia cells (red line). A 
quantification of p-S6 levels from different mice is reported in Fig. 5.7B, which shows 
p-S6 levels were significantly lower in Rheb KO microglia.  
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Figure 5.7 Phospho flow cytometry reveals that the mTOR pathway is inhibited in 
Rheb KO microglia. Aged WT and Rheb KO mice were given a peripheral injection of LPS 
(5 mg/kg) for four hours. The brains were digested and myelin was removed. The cell 
suspension was stained for p-S6 after paraformaldehyde (PFA) fixation and methanol 
permeabilisation. A) Representative flow cytometry plots comparing p-S6 levels in microglia 
from an aged Rheb KO (red) and WT mouse (green), the isotype control is in blue. B) 
Quantification of p-S6 in microglia, expressed as median fluorescence intensity (MFI) from 
different mice. The data shown is from one experiment, where n=4 for each group and 
**p<0.01. Significance was calculated using the unpaired two tailed student t-test between 
individual groups. 
 
5.8 mTOR inhibition leads to an upregulation of 
inflammatory genes in microglia upon LPS injection in vivo  
 
Microglia cells from LPS-challenged mice were isolated and expression levels of pro-
inflammatory and age-related genes were quantified by qPCR.  
Figure 5.8 depicts the qPCR results for the pro-inflammatory genes Tnf (Fig. 5.8A), 
Il1b (Fig. 5.8B), Il12a (Fig. 5.8C) and Il6 (Fig. 5.8D) in microglia from both young and 
aged WT and Rheb KO mice. Regarding the young mice, consistent with what I 
observed in BMDMs and adult microglia in vitro, there was an upregulation of all four 
inflammatory genes upon LPS stimulation in Rheb KO microglia (Fig 5.8A-D).  These 
results were statistically significant for all genes (p<0.05), except Il1b (Fig. 5.8B), 
which showed a similar trend. No differences were observed in the PBS controls.  
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I also detected an upregulation of all four genes in microglia from aged Rheb KO mice 
that was statistically significant for Il1b (Fig. 5.8B), Il12a (Fig. 5.8C) and Il6 (Fig. 
5.8D) with  p<0.05 and Tnf with p<0.01. The upregulation of pro-inflammatory genes in 
Rheb KO microglia was consistent between young and aged mice, however it was 
significantly stronger with age. Indeed, Tnf (Fig. 5.8A), Il1b (Fig. 5.8B) and Il6 (Fig. 
5.8D) showed a significant increased expression in aged Rheb KO microglia compared 
to young counterparts, whereas Il12a (Fig. 5.8C) showed a similar trend. This, though, 
did not reach statistical significance. Overall it appeared that, consistent with the 
literature and our in vitro data, inhibition of the mTOR pathway in microglia led to an 
increase in the expression of pro-inflammatory genes upon LPS injection in vivo and 
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5.8 mTOR inhibition leads to an upregulation of inflammatory genes in microglia 
upon LPS injection in vivo.  Young (4 months) and old (18 months) WT and Rheb KO mice 
were given a peripheral injection of LPS 5mg/kg or PBS for four hours. Mice were perfused and 
the brains were removed, digested and myelin was removed, before microglia were isolated 
using magnetic beads. The induction of inflammatory genes was determined using qPCR with 
fold changes shown relative to the housekeeping gene Hprt1 for A) Tnf, B) Il1b C) Il12a and D) 
Il6. Data shown is representative of 2 independent experiments, * p<0.05, **p<0.01. 
Significance was calculated using the unpaired two tailed student t-test between individual 
groups. 
5.9 mTOR inhibition leads to an upregulation of age-
associated and sensing genes Tlr2 and Clec7a  
 
In the RNA sequencing data described in the previous chapter, I found an upregulation 
of both inflammatory pathways and the mTOR pathway in microglia from the ageing 
brain under basal conditions. This led to the hypothesis that the mTOR pathway could 
be regulating some of the transcriptional changes observed with ageing, possibly 
through regulation of transcription factors such as NF-κB. To test this hypothesis, I 
assessed some of the genes found upregulated with age in Rheb KO microglia such as 
Tlr2 and Clec7a.   
 
Tlr2 has been implicated in Alzheimer’s disease, where it is thought to be a ligand for 
amyloid beta197 and in other neurodegenerative disorders182. Clec7a, or Dectin-1, is also 
a pattern recognition receptor thought to function together with Tlr2 to mediate the 
inflammatory response175. 
 
Figure 5.9 shows the RNA sequencing results for these two age-related genes, Tlr2 and 
Clec7a. Both these genes were found to steadily increase with age in microglia, as 
shown by the FPKM expression values in Fig. 5.9A and Fig. 5.9B. In the LPS in vivo 
experiments, it was found that especially Tlr2 (Fig. 5.9C) but also Clec7a (Fig. 5.9D) 
were upregulated in Rheb KO microglia from young mice. A further increase was 
observed in the aged group for Clec7a (p<0.001) between young Rheb KO microglia 
and old Rheb KO microglia (Fig. 5.9D). However, this was not the case for Tlr2, where 
the age of the KO did not seem to affect its pattern of expression (Fig 5.9C).  
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Fig. 5.9 In vivo mTOR inhibition leads to an upregulation of age-associated genes 
Tlr2 and Clec7a in microglia.  Microglia isolated from young and aged mice was used for 
RNA sequencing analysis. The expression values for A) Tlr2 and B) Clec7a are shown. C) and 
D) Young and old Rheb KO and WT mice were given a peripheral injection of LPS 5mg/kg or 
PBS and culled after four hours. Mice were perfused and the brains were removed, digested and 
myelin was removed before microglia were isolated using magnetic beads. The induction of C) 
Tlr2 and D) Clec7a was determined using qPCR, shown as fold change relative to the 
housekeeping gene Hprt1. Data shown are representative of 2 independent experiments, * 
p<0.05, ***p<0.001. Significance was calculated using the unpaired two tailed student t-test 
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5.10 The mTOR pathway regulates the expression of other 
age-associated genes upon LPS injection in vivo   
 
I examined a range of other genes that appeared to be deregulated with age, especially 
genes most differentially expressed with age or linked to inflammation. These included 
the glycoprotein, Gpnmb, previously discussed in chapter 4. This gene was one of the 
most upregulated genes with age in microglia.  I found an increase in the expression of 
this gene in Rheb KO microglia compared to WTs. This appeared to be at steady state, 
as it was observed in both the PBS controls and did not increase further upon LPS 
stimulation. These differences were only evident in young mice, with no differences 
being observed in any of the groups with age (Fig. 5.10A). Cxcl13 (Fig. 5.10B), the 
most upregulated chemokine with age, and Ccl25 (Fig. 5.10C), one of the most down-
regulated chemokines in microglia with age, were also examined. There was no 
difference in expression of these genes in any of the groups tested, suggesting that 
mTOR inhibition did not appear to regulate their expression in either young or aged 
mice. The same was true for the age-related gene Apoe4, also known as alpoliprotein C4 
(Fig. 5.10D).  
 
 
	   145	  
 
Figure 5.10 In vivo mTOR inhibition does not regulate the expression of all age-
related genes. Young and old Rheb KO and WT mice were given a peripheral injection of 
LPS 5mg/kg or PBS and culled after four hours. Mice were perfused and the brains were 
removed, digested and myelin removed, before microglia were isolated using magnetic beads. 
The induction of A) Gpnmb, B) Cxcl13, C) Ccl25 and D) Apoe4 was determined using qPCR, 
shown as fold change relative to the housekeeping gene Hprt1. Data shown are representative of 
2 independent experiments,  * p<0.05, ***p<0.001. Significance was calculated using the 
unpaired two tailed student t-test between individual groups. 
The age-related genes Spp1, Cst7 and Mmp12, however, were significantly affected by 
loss of Rheb in microglia (Fig. 5.12A-C). Spp1, secreted phosphoprotein 1 or 
osteopontin is a cytokine upregulated in a number of central nervous system 
pathologies166. Its expression appeared to be strongly mediated by mTOR, as its 
inhibition lead to an increase in Spp1 expression in microglia from both young and aged 
mice (Fig.  5.11D).  
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Figure 5.11 mTOR inhibition in vivo leads to an upregulation of age-associated 
genes Spp1, Cst7 and Mmp12 in microglia. Microglia isolated from young and aged mice 
were used for RNA sequencing analysis. The expression values for three genes that were 
upregulated with age are shown: A), Spp1, B) Cst7 and C) Mmp12. D) to F) Young and old WT 
and Rheb KO mice were given a peripheral injection of LPS 5mg/kg or PBS and culled after 
four hours. Mice were perfused and the brains were removed, digested and myelin removed 
before microglia were isolated using magnetic beads. The induction of D) Spp1 E) Cst7 and F) 
Mmp12 was determined using qPCR and shown as fold change relative to the housekeeping 
gene Hprt1. The data shown are representative of two independent experiments, *p<0.05, 
**p<0.01, *p<0.001. Significance was calculated using the unpaired two tailed student t-test 
between individual groups. 
Next I looked at Cystatin F, Cst7, a papain-like lysosomal cysteine protease inhibitor. 
This is an interesting gene, as its expression in microglia has recently been associated 
with acute demyelination168. Similarly to Spp1, its expression is significantly increased 
in microglia with mTOR inhibition (p<0.001; Fig. 5.11E). Unlike Spp1, its expression 
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Lastly I looked at the Metallopeptidase 12 known as Mmp12. Mmps play multiple roles 
in signalling, migration and extracellular matrix remodelling. Mmp12 has recently been 
associated with ageing of the brain and neuroinflammation169. It was also the most 
upregulated Mmp in the RNA sequencing data. Its pattern of expression upon mTOR 
inhibition is similar to Cst7, with an upregulation in Rheb KO microglia in both age 
groups and a more exaggerated effect with age (Fig.  5.11F). 
 
In conclusion, it appears that mTOR plays a role in regulating expression of some age-
related genes but not all. Overall, it seems to negatively regulate the expression of a 
number of age-related genes, since its loss in Rheb KO microglia leads to their 
upregulation. This observation is difficult to reconcile with the upregulation of mTOR 
signalling in aged microglia. It is possible to speculate that the upregulation of mTOR 
with age is not responsible for the increased expression levels of inflammatory and age-
related genes but rather is an attempt of microglia cells to counteract the pro-
inflammatory phenotype associated with age.  
 
5.11 Possible regulators of inflammation affected by mTOR 
inhibition   
 
It has been shown previously that mTOR inhibition with rapamycin in human 
monocytes leads to an upregulation of inflammatory genes through an activation of NF-
κB, suggesting that mTOR is a negative regulator of NF-κB129. I observed a similar 
upregulation of inflammatory genes when the pathway was inhibited by Rheb deletion. 
Therefore, I monitored the expression of the NF-κB gene, Rela, which encodes p65, to 
assess whether it was deregulated in Rheb KO microglia. P65 forms a complex with 
p50 and IKβα. Once IKβα becomes phosphorylated, it is targeted for degradation and 
this leads to the translocation of the p65/p50 complex into the nucleus, where it can 
drive the transcription of a number of NF-κB target genes, including inflammatory ones.  
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5.12 mTOR inhibition in vivo leads to an upregulation of regulators of inflammation in 
microglia. Young and old WT and Rheb KO mice were given a peripheral injection of LPS 
5mg/kg or PBS and culled after four hours. Mice were perfused and the brains were removed, 
digested and myelin removed before microglia were isolated using magnetic beads. The 
induction of A) Rela (encoding p65) and B) Mir-155 was determined using qPCR. The data 
shown are representative of 2 independent experiments, * p<0.05,  ***p<0.001. Significance 
was calculated using the unpaired two tailed student t-test between individual groups. 
There was a clear upregulation of p65 expression upon LPS injection in microglia from 
young mice when mTOR was inhibited (p<0.001). I did not, however, observe the same 
increase in gene expression in aged mice (Fig. 5.12A).  
 
I also monitored the gene coding for the microRNA, mir-155. I was interested in this 
gene because it was highly upregulated in the RNA sequencing data of microglia from 
the ageing brain and it has been implicated in pro-inflammatory responses in a number 
of models203. Interestingly, it was found to have a similar pattern of expression as many 
of the age-related genes and inflammatory genes, showing to be upregulated upon LPS 
injection in microglia from Rheb KO mice compared to WTs, an effect further 
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5 Discussion 
5.1 Questions to be addressed 
mTOR activation has been observed in a number of tissues with age and overall the 
pathway has been accepted as a major regulator of ageing30. This comes from a long list 
of studies that have shown that both genetic and pharmacological inhibition of the 
pathway leads to lifespan extension in a number of model organisms31. As a result, 
mTOR inhibitors are being considered as potential ageing interventions.  
 
Given the association of mTOR activation with ageing, it is not surprising that this 
pathway appears to be upregulated in microglia from the ageing brain. What remains to 
be addressed is the role played by mTOR activation in microglia, i.e. how is it affecting 
the function of these cells? One suggestion is that it may be involved in regulating 
senescence, particularly the secretion of the SASP, as rapamycin appears to attenuate 
this phenotype in senescent fibroblasts142.  Other studies have shown that inhibiting the 
mTOR pathway in primary human monocytes actually leads to NF-κB activation and an 
increase in inflammatory cytokines129. While these reports appear conflicting, they do 
indicate that mTOR is an important regulator of inflammation, possibly exerting 
different functions depending on the signals it receives. These studies lead us to ask a 
number of questions, such as - what role is mTOR playing in microglia from the ageing 
brain? Could it be regulating some of the transcriptional changes I have observed, 
particularly those relating to inflammation? Could mTOR be involved in microglia 
priming? Could mTOR be important for regulating neuroinflammation in age-associated 
pathologies?   
5.2 Increase in pro-inflammatory cytokine genes in microglia 
from Csf1r-Cre; Rheb f/f mice 
 
In order to answer some of these questions, I decided to use a model of LPS-induced 
brain inflammation via a peripheral injection.  I hypothesised that if mTOR was 
involved in microglia priming and regulating inflammatory responses with age, this 
should be further increased or attenuated in a model of neuroinflammation. I found that 
upon i.p. LPS injection, the mRNA expression of pro-inflammatory cytokines Tnf, Il6, 
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Il12a and Il1b were all upregulated in microglia from Rheb KO mice. The fact that I 
found that phospho-S6 was downregulated in microglia from Rheb KO mice compared 
to WT microglia would give an indication that mTOR was inhibited in these cells and 
that mTOR may play a role in regulating inflammation in microglia. However it cannot 
be ruled out that phospho-S6 might have been downregulated in Rheb KO microglia as 
a consequence of mTOR being inhibited in other myeloid cells and therefore a result of 
changes in peripheral cytokine levels.  
 
One way to address this question in the future is to consider the use of another mouse 
model. I have used the Csfr1-Cre model in my study as it’s well used for the study of 
myeloid cells and it was the most readily available model in my lab. However, this 
model has some disadvantages most notably, not being able to decipher between 
resident macrophage populations in the brain and microglia and also not being able to 
discount perpetuations in the periphery due to the affects on monocyte populations. This 
is because these populations also express Csfr1. Other models used to study specific 
gene deletions in microglia use promoters such as CD11b or CX3CR1, however these 
markers are also expressed by other myeloid population and therefore do not offer a 
better alternative. Goldman et al. recently developed a novel Cre-LoxP-based system 
that can be used to target microglia but not monocyte derived macrophages. This system 
is induced using the estrogen antagonist tamoxifen (TAM)204. While the use of TAM 
will induce the deletion in both microglia and other CX3CR1+ monocytes and 
macrophages, these cells are known to be relatively short lived and constantly replaced 
by the bone marrow whereas microglia remain permanently modified205.  Therefore it 
would be really interesting to cross this model with the Rheb f/f mice in order to 
determine if the results I have observed are microglia specific. This is an important 
consideration for the ageing in vivo studies where is has to be considered that the 
deletion is in all the myeloid cells and also present for the entire lifespan of the mouse.  
It would also be interesting therefore, to delete Rheb in microglia at different points 
during the lifespan to understand if this would lead to similar results.  
 
This work is also consistent with reports that inhibition of the pathway in primary 
monocytes leads to an increase in cytokine production129. I also saw a consistent 
upregulation of these cytokines in microglia isolated from the aged brain, but what is 
really interesting, is that the effect was exaggerated with age. I can speculate that if 
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mTOR activation is important for regulating microglia priming, then it is conceivable 
that the cells become even more primed when the pathway is inhibited and, therefore, 
even more over-responsive to an inflammatory stimulus such as LPS. These 
observations lead to some relevant questions, discussed below: 
 
1) Are the transcriptome changes observed in Rheb KO microglia being translated? 
 
Given that the main function of mTOR is to regulate translation and cell growth in cells, 
it is important to understand if these changes at the transcriptome level are being 
translated. Activation of mTOR leads to phosphorylation of S6 and 4E-BP1, which 
influence initiation and elongation of translation, respectively114.  There are conflicting 
reports about whether rapamycin affects mTOR-mediated translation, since there are 
rapamycin-resistant functions of mTORC1115. This is important, specifically with 
regards to the studies showing that mTOR inhibition with rapamycin leads to an 
increase in inflammatory cytokines129. In this study, the authors show that cytokines are 
upregulated at transcriptome and protein levels129. This may not be the case in our 
model, where the pathway is genetically inhibited through loss of Rheb. This can be 
tested in a variety of ways. Firstly, a protein lysate can be made from the tissues from 
the LPS in vivo study described in this chapter and can be used to perform ELISA to 
quantify the amounts of pro-inflammatory cytokines in KO versus WT tissue. This 
would indicate if there is more tissue inflammation in the Rheb KO mice upon LPS-
stimulation. It would be particularly relevant to use brain lysates. Secondly, I can 
perform in vitro studies with Rheb KO BMDMs or primary microglia, whereby the cells 
are stimulated with LPS and then the amount of pro-inflammatory cytokines are 
measured in the supernatant, also by ELISA. Thirdly, I can measure cytokines in the 
plasma from our LPS in vivo study to assess cytokine production.  
 
Inflammation in elderly people can result in delirium, where the person becomes 
confused and agitated, as well as experiencing a range of other cognitive symptoms. 
Delirium is thought to be mediated by infections in the periphery having secondary 
effects in the brain206. One way of assessing the effect of inflammation in our KO mice 
would be to use the open-field test to assess how sick the mice become. While this 
simple test is not suitable to define delirium, it can give information on locomotor 
activity and anxiety behavior and is a good measure of systemic inflammation87. It 
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would also give an indication of whether these cytokine changes observed on a 
transcriptome level are in fact being translated.  
 
2) What is the potential mechanism regulating these transcriptome changes? 
 
Weichhart et al. showed that mTOR inhibition with rapamycin leads to an increased 
inflammatory phenotype in macrophages via NF-κB activation; the mechanism could be 
different, however, in a model where the pathway is inhibited genetically and therefore 
NF-κB involvement would have to be confirmed. This could be done by staining for the 
NF-κB subunit, p65, in microglia. p65 localises to the nucleus rather than the cytoplasm 
when the pathway is active. Another way to confirm NF-κB activation upon Rheb 
deletion would be performing time-course experiments using BMDMs and looking at 
key proteins involved in NF-κB signalling such as p-IKKα, and p-IKβα207, both should 
be stronger if NF-κB is more strongly activated (followed by an earlier degradation of 
p-IKβα). If it appears that NF-κB is indeed more active in our model, it would be 
interesting to understand the intracellular pathways that link mTOR inhibition and NF-
κB activation, as these remain unclear. Some potential pathways that intersect with 
mTOR could be: 
 
A. Activation of AMP kinase208, which could result in increased p38 activation209, 
leading to NF-κB activation210.  
B. Other potential candidates may include members of the autophagy pathway as 
autophagy activation is a consequence of mTOR inhibition and has also been 
linked to inflammasome activation211. 
 
5.3 Age-related genes 
 
I also examined a number of differentially expressed genes from the RNA sequencing 
data i.e. genes that were deregulated with age in microglia that were not key 
inflammatory genes. Interestingly, I found that 5 out of the 10 genes analysed appeared 
to be regulated by mTOR. Of these 5 genes – Tlr2, Clec7a, Mmp12, Cst7 and Spp1 – 
three are known targets of NF-κB, such as Tlr2, Cst7 and Spp1. This evidence further 
supports the notion that NF-κB activation is increased in Rheb KO microglia and may 
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also support the idea that mTOR activation in microglia in the ageing brain may be a 




When examining our data, it is important to acknowledge some of the limitations of 
both the cells and models used. While BMDMs are an accepted model to look at 
macrophage function and molecular signalling, they may behave differently to 
microglia cells. It was important to confirm that the upregulation of inflammatory 
cytokines upon LPS stimulation in vitro in BMDMs lacking Rheb was also evident in 
primary microglia. I wanted to use adult microglia as they would be the closest model to 
our ageing data but they are difficult to culture. Therefore, I isolated primary microglia 
from the adult brain and stimulated them for a short period of time in vitro. While the 
qPCR data was consistent with the BMDM data, it must be acknowledged that, in the 
un-stimulated microglia cells, there was already a high basal level of inflammatory 
cytokines, particularly Tnf. This indicates that the cells were not in a good condition. It 
would be important to repeat both the signalling experiment with p-S6 and the qPCR in 
primary microglia isolated from neonate mice. These cells are obtained by culturing 
whole brain tissue on poly-d-lysine for 10 days, therefore microglia grow on a feeder 
layer of astrocytes and can then be recovered for in vitro culture experiments. This is a 
more established method for in vitro experiments, using primary microglia, and will be 
carried out in the future to support our current data212.  
 
I must also consider the limitation of using a peripheral injection of LPS as a model of 
inflammation. While this approach was chosen to mimic the effect of a peripheral 
infection in the elderly, it also complicates the interpretation of results. This is 
particularly true for our model, given that the Csf1r-Cre will cause Rheb deletion in 
microglia but also monocytes and macrophages in the organism. There may be more 
peripheral inflammation present in our Rheb KO model that could be contributing to the 
priming of the microglia with age, rather than a direct effect of Rheb deletion on the 
microglia.  In order to assess the relevance of mTOR signalling in microglia from aged 
Rheb KO mice, I performed phospho-flow cytometry analysis, which showed an 
increase in phospho-S6 in aged WT microglia and a reduction in Rheb KO microglia. 
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This evidence supports the notion that the effect on inflammatory cytokines is specific 
to mTOR inhibition in microglia, rather than a secondary affect from the periphery. I 
cannot, however, exclude that the peripheral environment contributes to microglia 
inflammation in our mouse model.  
 
5 Conclusion  
In conclusion, it appears that mTOR inhibition by Rheb deletion leads to an increase in 
inflammatory cytokine gene expression upon LPS stimulation in both BMDMs and 
microglia. This is evident both in vitro and in vivo. This upregulation is further 
increased with age, suggesting that the mTOR pathway plays a role in microglia 
priming. Surprisingly, mTOR inhibition also regulated the gene expression of additional 
age-related genes, suggesting that mTOR regulates at least some of the transcriptome 
changes observed in our RNA sequencing analysis. While more work is needed to 
clarify the role of mTOR in microglia with age, this data would support the hypothesis 
that it is a key player of inflammation in ageing.  
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Chapter 6: Sickness behaviour and cytokine 
production in Csf1r-Cre; Rheb f/f mice  
 
As described in the previous chapter, Csf1r-Cre; Rheb f/f (Rheb KO) mice showed 
increased expression of inflammatory genes upon LPS stimulation compared to WT 
controls. Thus, I wanted to investigate if these changes were also observed at protein 
level and whether the increased inflammation in the brain had an impact on neurological 
functions. 
6.1 Increased gene expression of pro-inflammatory genes in 
Rheb KO BMDMs is not accompanied by an increase at 
protein level 
 
In order to assess if the increase in gene expression of inflammatory genes was 
translated into the corresponding proteins, I used BMDMs derived from both WT and 
Rheb KO mice.  Bone marrow cells were purified from adult mice and differentiated 
into macrophages by a 6-day culture in the presence of M-Csf. Once differentiated, cells 
were re-plated and treated with LPS at three different time points; 3, 6 and 24 hours. 
Following LPS stimulation, secreted cytokines were measured by ELISA in the culture 
supernatant, whereas cells were lysed, RNA was extracted and quantitative PCR 
(qPCR) was carried out on key inflammatory genes.   
 
The genes measured were Tnf, Il1b, Il6 and Il12. TNF is one of the first cytokines to be 
produced under inflammatory conditions and can amplify and prolong the inflammatory 
response by activating other cytokines such as IL-1213. By qPCR analysis of mRNA 
levels, I found that in WT cells this gene was induced at 3 hours post LPS treatment, 
with similar levels observed at 6 hours before a decline by 24 hours (Fig. 6.1A). As 
expected, there was considerably more Tnf production in the Rheb KO BMDMs at 3 
hours post LPS, however, its levels were comparable to WT cells at 6 and 24 hours 
(Fig. 6.1A), similarly to what I observed in Rheb KO microglia after in vivo LPS 
stimulation. Surprisingly, measurement of Tnf protein by ELISA showed an opposite 
trend to that observed by qPCR analysis. While protein levels were similar at 3 hours, 
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the Rheb KO BMDMs were producing considerably less Tnf at 6 hours post LPS 
treatment compared with WT controls (Fig. 6.1B). By 24 hours, Tnf levels were again 
similar in WT and Rheb KO cells.  
 
I also assessed levels of the cytokine gene Il1b. Again, as expected, Rheb KO BMDMs 
stimulated with LPS had an increased expression of Il1b compared to WTs, as measured 
by qPCR, with a peak of expression for both WTs and Rheb KO BMDMs at 6 hours 
(Fig. 6.1C). An ELISA on Il-1β in the supernatant was also carried out. It is well 
documented that macrophages must first be primed with interferon-γ overnight before 
being treated with LPS in order to stimulate the production of Il-1β. This is because two 
distinct steps, priming and activation, are required for the generation of Il-1β. First, 
expression of the proform of Il-1β is induced, which is subsequently cleaved by 
caspase-1 activated by the inflammasome, into its active form214. However, in my 
experimental conditions, I stimulated cells with LPS only and as such I expected to see 
much less Il-1β production compared to Tnf. Nevertheless, IL-1β levels were 
comparable to Tnf, with less Il-1β in Rheb KO BMDMs compared to WTs at 6 hours 
post LPS stimulation (Fig. 6.1D).  
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Figure 6.1 Increases in gene expression of pro-inflammatory genes Tnf and Il1b in 
Rheb KO BMDMs are not consistent with secreted protein levels. Rheb KO and WT 
macrophages were obtained from the bone marrow and differentiated for 6 days with 20 ng/ml 
of M-Csf to generate BMDMs. BMDMs were then re-plated on day 6 and left to rest overnight. 
The following day, they were stimulated with 200 ng/ml of LPS for 3, 6 and 24 hours. The 
induction of A) Tnf and C) Il1b was determined using qPCR, results are shown as fold change 
over the housekeeping gene Hprt1. B) Tnf and D) Il-1β secreted in the culture supernatants 
were assessed by ELISA. Data shown is from one experiment, where n=2 for all time-points 
and conditions shown. 
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Figure 6.2 Increased gene expression of pro-inflammatory genes IL6 and IL12a in 
Rheb KO BMDMs is not consistent with secreted protein levels. Cells were obtained 
from the bone marrow of WT and Rheb KO mice and differentiated in culture for 6 days with 
20 ng/ml of M-Csf, in order to generate BMDMs. BMDMs were then re-plated on day 6 and 
stimulated with 200 ng/ml of LPS for 3, 6 and 24 hours. The induction of A) Il6 and C) Il12a 
was determined by qPCR, results are shown as fold change relative to the housekeeping gene 
Hprt1. B) Il-6 and D) Il12p40 secreted in the culture supernatant were assessed by ELISA. Data 
shown is from one experiment, where n=2 for all time-points and conditions shown. 
Given that this result was quite striking, I next assessed whether Il-6 and Il-12p40 
behaved in a similar fashion. Il6 was only slightly increased in Rheb KO cells compared 
to WT, whereas Il12a was significantly increased at both 6 and 24 hours, as measured 
by qPCR (Fig. 6.2A and 6.2C). Proteins secreted in the supernatant were measured, and 
both Il6 and Il12p40 were decreased in the supernatant of Rheb KO cells at 6 and 24 
hours (Fig 6.2B and 6.2D), a result in direct contrast to the gene expression data. 
Statistical analysis could not be carried out on this set of data as the n number only 
equalled two and therefore additional replicates would be needed to test significance. 
Nonetheless, this experiment indicated that Rheb KO macrophages behaved differently 
to rapamycin-inhibited macrophages129 upon LPS stimulation.   
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6.2 Inflammation was not induced above baseline in Rheb KO 
mice after in vivo LPS stimulation compared to WT controls 
 
Given that cytokine production appeared to be decreased in Rheb KO BMDMs, despite 
the increase in gene expression, I wanted to test if this was also the case in vivo. To this 
end, I took lung tissue from mice, which had received a single intraperitoneal injection 
of LPS at a dose of 5 mg/kg. I selected the lung as this organ is known to contain a high 
number of macrophages. Protein lysates from frozen lung tissue were prepared and used 
for ELISA in order to measure Tnf.  Indeed, there was decreased Tnf in the lungs of 
Rheb KO mice compared to WT controls (Fig. 6.3). Differences were evident in both 
young and aged mice, although they appeared more striking in the younger age group. 
However, differences were not significant, perhaps because of the variability observed 
in the Rheb KO samples.  
 
Figure 6.3 Reduced Tnf protein levels in the lungs of Rheb KO mice treated with 
LPS. Young and old Rheb KO and WT mice were given an i.p. injection of LPS, 5mg/kg and 
culled 4 hours later. Protein lysates were prepared from the lung tissue and Tnf was measured 
by ELISA. Data are from one experiment, where  n=3 for each group. 
Both the in vitro and in vivo data suggested that cytokines were not being translated in 
the Rheb KO mice. I wanted to further confirm this finding in vivo.  To this end, I used 
a new cohort of Rheb KO and WT mice and gave them an i.p. injection of LPS (5 
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mg/kg). However, instead of perfusing the animals as in previous experiments, mice 
were culled by cardiac puncture in order to collect blood. This way, I was able to 
quantify the amount of Tnf (Fig. 6.4A) and Il12p70 (Fig. 6.4B) in the plasma from both 
young (4 month) and old (22 month) Rheb KO and WT mice. While it appeared that 
there was less Tnf (Fig. 6.4A) and Il12p70 (Fig. 6.4B) in young Rheb KO mice 
compared to controls, the differences were not significant (Tnf, p=0.08 and Il12p70, 
p=0.09).  On the other hand, there was a robust induction of both cytokines with age in 
the WT control groups, which was not observed in the aged Rheb KO mice. This result 
was striking for both cytokines (Fig. 6.4A and Fig. 6.4B) and was highly significant in 
both cases with a p value <0.001.  
 
Figure 6.4 Cytokines are not translated in aged Rheb KO mice upon LPS 
stimulation. Young and old Rheb KO and WT mice were given an i.p. injection of LPS, 
5mg/kg and culled 4 hours later by cardiac puncture. Plasma was obtained from blood and then 
cytokines were measured using the legendplex mouse inflammatory panel from Biolegend. The 
amount of A) Tnf and B) Il12p70 is shown. Data shown are from one experiment, where n=3 
for all groups and ***p<0.001. Significance was calculated using the unpaired two tailed 
student t-test between individual groups. 
6.3 Optimisation of an in vivo experiment to assess sickness 
behaviour  
 
The in vitro and in vivo results so far suggested that Rheb KO mice may have less 
overall inflammation upon LPS stimulation compared to WT mice, the opposite of what 
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I hypothesised based on the increased transcription levels of pro-inflammatory 
cytokines. In order to elucidate the overall effect on the host response, I carried out an 
additional experiment with a lower dose of LPS of 0.33 mg/kg. Mice are not terminally 
sick with this dose of LPS87 and behavioural tests can be carried out after the LPS 
injection, in order to measure sickness behaviour. If overall inflammation was decreased 
in Rheb KO mice upon LPS stimulation, mice should be less sick.  
 
Sickness behaviour was measured with an open-field test. The test was carried out by 
placing each mouse into an empty 15-square gridded box and observing its behaviour 
for 5 minutes. Several parameters can be measured: the distance travelled and number 
of rears, which give an indication of the locomotor ability. The time spent in the middle 
of the box, and time delay before the mouse enters the squares in the middle of the box, 
which provide a measurement of stress and anxiety215. Sicker mice are expected to have 
impaired locomotion and increased anxiety, resulting in reduced movement, rears and 
time spent in the middle of the box.  
 
I could not use the 5 mg/kg high dose of LPS previously described, as the mice became 
too sick too quickly, therefore I chose a lower dose of LPS (0.33 mg/kg), as previously 
reported216. I carried out a pilot experiment using this dose of LPS and simultaneously 
measured a number of different parameters in WT mice, in order to assess the feasibility 
of the experimental design. Mice were given an i.p. injection of 0.33 mg/kg LPS and the 
open-field test was conducted at 6 hours.  
 
Figure 6.5 Locomotor activity is measurable at 6 hours post low dose LPS 
treatment. WT mice were given a peripheral injection of either a low dose of LPS (0.33 
mg/kg) or PBS before being assessed in an open-field test 6 hours post injection. During the 5-
minute test in a 15-square gridded box, locomotor activity was determined by A) distance 
travelled, measured as the number of squares the mouse passes through (with all four paws) and 
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I found that at 6 hours post LPS injection, there was a clear difference in the locomotor 
activity of LPS injected mice compared to PBS injected mice. This was measured by 
two parameters. Firstly, the distance travelled was calculated based on the number of 
squares each mouse passed through (all four paws had to be in each square).  There was 
a clear decrease in this parameter with LPS (Fig. 6.5A). Secondly, locomotor activity 
was calculated based on the number of times the mouse reared up, both paws, which 
was also decreased with LPS (Fig. 6.5B). Therefore, LPS-treated mice, as expected, 
were sicker and consequently moved less than the PBS control group. 
 
I could adequately measure sickness behaviour using this dose of LPS and I 
subsequently wanted to determine if I could still measure some inflammatory 
parameters after 48 hours with such a low dose of LPS, since it would have been helpful 
to repeat the open-field test also at a later time-point. I isolated microglia from the brain 
of these mice (48 hours post LPS) and carried out qPCR analysis on key inflammatory 
genes. I also isolated Ly6C monocytes from the spleen; I was interested in this cell type 
because these are the inflammatory cells in the blood that are recruited into the brain 
during neuroinflammation217.  I found there were still detectable levels of both Tnf and 
Il1b in microglia measured by qPCR (Fig. 6.6A and 6.6C). This was not the case for Il6 
and Il12a, which were not much expressed at this time point relative to the house 
keeping gene (Fig. 6.6E and 6.6G). These observations were not consistent between 
microglia isolated from the brain and Ly6C monocytes isolated from the spleen, which 
showed little difference between the LPS and PBS groups (Fig. 6.6B, 6.6D, 6.6F and 
6.6H). Furthermore, it appeared that after 48-hours low-dose LPS stimulation, there was 
still some persistent inflammation in the microglia that was not present in the 
monocytes. 
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Figure 6.6 Tnf and Il1b gene expression are still detectable in microglia 48 hours 
post low dose LPS challenge. WT mice were given a peripheral injection of LPS, 0.33 
mg/kg, or PBS for 48 hours. Mice were culled by cardiac puncture and the brains were removed 
and digested before microglia were isolated using magnetic beads. The spleens were also 
removed and Ly6C monocytes were isolated with magnetic beads similarly to microglia. The 
induction of inflammatory genes was determined using qPCR for both microglia and splenic 
monocytes with fold changes relative to the housekeeping gene Hprt for Tnf (A and B), Il1b (C 
and D), IL6 (E and F) and IL12a (G and H).  Data shown are from one experiment, where n=3 
for LPS group and n=2 for PBS group. 
 
I also monitored at the expression of the activation markers CD11b and Tlr2 on 
microglia using flow cytometry analysis and found that both markers were still 
detectably upregulated with this dose of LPS after 48 hours as shown by their MFI (Fig. 
6.7A and 6.7B). 
 
 
Figure 6.7 Flow cytometry analysis of markers of microglia activation. WT mice 
were given a peripheral injection of LPS, 0.33 mg/kg, or PBS for 48 hours. Mice were culled by 
cardiac puncture and the brains were removed and digested before microglia were isolated using 
magnetic beads. Microglia were then stained with the activation markers A) CD11b and B) 
Tlr2. Data shown are from one experiment where, n=3 for LPS treated group, and n=2 for PBS 
group. 
 
6.4 Less pronounced sickness behaviour in Rheb KO mice 
 
I decided to use the low dose of LPS 0.33 mg/kg to study sickness behaviour in the 
Rheb KO mice as I was able to detect markers of inflammation (either by qPCR or 
FACS) in microglia using this dose and time frame. The experimental design used for 
these experiments is depicted in Fig. 6.8. I first had to carry out a baseline open-field, 
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size and gender when designing these behavioural experiments. Ideally, a large sample 
size is required and using mice of the same gender is desirable. This is why I carried out 
these experiments at first in males and then in females. All mice received an LPS 
challenge, rather than splitting them into the two groups LPS and PBS, in order to keep 
the sample size large.  Following 0.33 mg/kg LPS injection, the open-field test was 
carried out at 6 hours, as in my pilot study. I also choose an additional time point of 30 
hour post LPS, in order to gain information about sickness behaviour in Rheb KO mice 
during the recovery phase. After 48 hours, all mice were culled by cardiac puncture, and 
plasma was obtained from the blood. Microglia were isolated from the brain but I did 
not isolate monocytes from the spleen, given that I found it difficult to detect changes in 








Figure 6.8 Experimental design for low dose LPS experiments, using Rheb KO and 
WT mice.  All mice were subjected to a 5-minute open-field test, two weeks prior to the start 
of the experiment to assess baseline locomotion. Rheb KO and WT mice were then given a 
peripheral injection of 0.33 mg/kg of LPS. The open-field test was carried out 6-hours and 30-
hours post LPS challenge and all mice were culled at 48 hours. 
 
6.5 Baseline results 
 
I found that Rheb KO mice and WT mice appeared to travel approximately the same 
distance during the 5-minute open-field test, passing through between 40 and 60 squares 
(Fig. 6.9A). Overall, I found no difference in the number of rears (Fig. 6.9B) or in the 
time it took for each mouse to rear (Fig. 6.9C), with each mouse rearing at 
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The open-field test can also give an indication of stress, measured by the number of 
times a mouse enters the three central squares of the gridded box. Mice go into the 
centre when they are less stressed and less fearful of their environment. I therefore 
assessed at which point the mice first passed through any of the three central squares. I 
found that, in general, Rheb KO mice passed through the centre earlier compared to WT 
controls, suggesting that these mice may have a lower baseline for stress. However, this 
was not statistically significant (p=0.17, Fig. 6.9D).  I also found no difference in how 
often mice go into the central squares (Fig. 6.9E). As a result, I can conclude that there 
are no major differences in behaviour associated with either movement or stress 
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Figure 6.9 Baseline analysis of sickness behaviour parameters in Rheb KO vs. WT 
mice as measured by the open-field test. Mice were placed into a 15-square gridded rat 
cage for a 5-minute period. Each test was recorded and later analysed blind. The overall 
movements of each mouse were assessed by three parameters; A) the distance travelled 
measured by the number of squares each mouse passes through during the test, B) locomotor 
activity measured by the number of times the mouse rears (both paws) during the test and C) the 
first time the mouse rears. The overall amount of stress experienced by each mouse was also 
measured by two parameters; D) Time to centre: the first time the mouse passes though any of 
the 3-centre squares, and E) Time in Centre: number of times the mouse passes through these 3-
centre squares. All mice used were male and between the ages of 3 and 6 months, n=6 for WT 
group and n=7 for Rheb KO group. 
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6.6 Sickness behaviour following in vivo LPS stimulation 
6.6.1 Males 
 
Two weeks following the assessment of the baseline parameters with the open-field test, 
I injected mice with a low dose of LPS (0.33 mg/kg) as described in Fig. 6.8. I found 
that, at 6 hours post LPS challenge, Rheb KO mice appeared more mobile (Fig. 6.10A). 
Consistent with this finding, Rheb KO mice also appeared to rear more (Fig. 6.10D). 
The differences for both these parameters were significantly different. These results 
show that the Rheb KO mice move more than their WT counterparts, indicating they 
were less sick. This is perhaps not surprising, given that pro-inflammatory cytokines 
such as Il-6 and Tnf are known to be important in inducing sickness behaviour. 
Therefore, this data is consistent with the hypothesis that Rheb KO mice appear to have 
less overall inflammation after in vivo LPS challenge. 
 
In addition, I observed a similar trend at 30 hours post LPS-treatment, with the Rheb 
KO mice continuing to travel through more squares (Fig. 6.10C) and rear more than 
WT controls (Fig. 6.10D). However, neither of these parameters was significantly 
different at this time point (distance travelled p=0.2, locomotor activity p=0.3).  
 
 




Figure 6.10 Male Rheb KO mice appear less sick compared to WT controls after 
low dose LPS treatment. Sickness behaviour was measured by assessing locomotor activity 
6 and 30 hours post LPS treatment (0.33 mg/kg). Mice were subjected to a 5-minute open-field 
test in a 15-square gridded box at these two time points. Locomotor activity was determined by 
distance travelled at A) 6-hours and B) 30-hours post LPS challenge. Locomotor activity was 
also determined by the number of times the mouse rears during the 5-minute period at D) 6-
hours and E) 30-hrs post LPS challenge. The experiment was carried out on male mice between 
the ages of 3 and 6 months, n=6 for WT group and n=7 for Rheb KO group, * p<0.05. 
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6.6.2 Females 
 
I wanted to repeat this study on female mice, in order to understand whether gender was 
a factor contributing to the improved performance of Rheb KO mice after LPS 
challenge. I found that, consistent with the male study, female Rheb KO mice appeared 
to move more during the open-field test at 6-hours post injection. This was not 
statistically significant for the distance travelled (p=0.17, Fig. 6.11A) but significant for 
the number of rears (p<0.05, Fig. 6.11B).  I also observed a similar trend at 30-hours 
post LPS, however, these differences were not statistically significant for either 
parameters (Fig. 6.11A and 6.11B). Overall, it appeared that Rheb KO female mice 
were less sick compared to their WT counterparts, which was consistent with what was 






Figure 6.11 Female Rheb KO mice appear less sick compared to WT controls after 
low-dose LPS treatment. Sickness behaviour was measured by assessing locomotor activity 
6 and 30 hours post LPS treatment (0.33 mg/kg). Mice were subjected to a 5-minute open-field 
test in a 15-square gridded box at these two time points. Locomotor activity was determined by 
distance travelled at A) 6-hours and 30-hours post LPS challenge. This was assessed by 
calculating the number of squares the mouse passes through during the 5-minute test. B) 
Locomotor activity was also determined by the number of times the mouse rears during the 5-
minute period at 6-hours and 30-hours post LPS challenge. The experiment was carried out on 
female mice between the ages of 3 and 6 months, n=5 for WT group and n=7 for Rheb KO 
group, * p<0.05. Significance was calculated using the unpaired two tailed student t-test 
between individual groups. 
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6.7 Stress/anxiety in males and females 
 
With the open-field test I assessed also at which point the mice went into any of the 
three central squares, termed here “time to centre” and found that there was no 
difference between male Rheb KO and WT mice post LPS challenge (Fig. 6.12A).  
Female Rheb KO mice did appear to go into the centre more quickly than WTs, 
although this observation was not statistically significant (Fig. 6.12B). The finding that 
mice move into the centre more quickly could indicate that the mice are less stressed, 
although more behavioural tests would be needed to establish this point unequivocally. 
 
Additionally, I measured how many times each mouse passed through any of the three 
central squares, termed “time in centre” and found that there was no difference at either 
time points for the male mice (Fig. 6.12C) or the female mice (Fig.  6.12D).  
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Figure 6.12 No differences in stress behaviour between Rheb KO and WT mice 
post LPS challenge.  Mice were placed into a 15-square gridded rat cage for a 5-minute 
period. Each test was recorded and later analysed blind. The overall amount of stress 
experienced by each mouse was measured by two parameters; The first time the mouse passes 
though any of the 3-centre squares, shown in seconds for A) males and B) females and the 
number of times the mouse passed through the 3-centre squares, measured for C) males and D) 
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6.8 Rheb KO microglia appear to have an increase in the 
transcription of inflammatory genes at low dose in vivo LPS 
challenge 
 
Sickness behaviour results for both male and female Rheb KO mice appeared to be 
consistent, indicating that the mice had less overall inflammation. These findings are 
not that surprising, given the lower inflammatory cytokines measured by ELISA. 
Nonetheless, I wanted to confirm if in this cohort of mice and using this dose and 
timeframe of LPS, I still observed an increase in inflammatory gene expression in Rheb 
KO microglia. I carried out qPCR analysis on key inflammatory genes and age related 
genes, as previously described in chapter 5. I found that for Tnf (Fig. 6.13A), Il1b (Fig. 
6.13B) and Il12b (Fig. 6.13C) there was a statistically significant upregulation in Rheb 
KO microglia, consistent with previous findings (p<0.05 for all three genes). I also 
measured Il10 expression. I expected it to be downregulated in Rheb KO microglia 
cells. This is due to the fact that it has been reported in the literature that mTOR 
positively regulates Stat3 and Il10 production129, thus Il10 production should be 
inhibited in the absence of Rheb. Consistent with the literature, I found there was a 
significant downregulation of the Il10 gene in Rheb KO microglia (p<0.01, Fig. 6.13D).  
On the other hand, there were no significant differences in expression of Il6 or Il12a 
(Fig. 6.13F and Fig. 6.13G). This was similar to what I observed in the pilot study (Fig.  
6.5E and Fig. 6.5F). Furthermore, I found that there was an upregulation of the age-
related genes Spp1 and Cst7 in the Rheb KO microglia, as previously observed (Fig. 
6.13G and Fig. 6.13H). These differences were highly significant for both genes 
(p<0.001). 
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Figure 6.13 Inflammatory and age-related genes are upregulated in microglia from 
Rheb KO mice upon low-dose LPS challenge. WT and Rheb KO mice were given a 
peripheral injection of LPS, 0.33 mg/kg. Mice were culled by cardiac puncture 48 hours later 
and the brains were removed and digested before microglia were isolated using magnetic beads. 
The induction of inflammatory genes was determined using qPCR with fold changes being 
expressed relative to the housekeeping gene Hprt. A-F) inflammatory genes and G-I) age-
related genes. The data are from one experiment, where n=4 for both groups, * p<0.05, 
**p<0.01, ***p<0.001. Significance was calculated using the unpaired two tailed student t-test 
between individual groups. 
 
 
Finally, I measured the induction of the NF-κB subunit, p65, as I was interested in the 
association between the mTOR pathway and NF-κB activation and found that this gene 
was significantly upregulated in Rheb KO microglia (p<0.01, Fig 6.13I).  These data 
are consistent with what I observed with higher doses of LPS described in Chapter 5 
and show that despite the Rheb KO mice appearing to be less sick, likely as a 
consequence of having reduced overall cytokine production, there is a stronger 
upregulation of inflammatory genes at transcription level. 
 
Finally, I measured the expression of CD11b and Tlr2 by flow cytometry, as they are 
associated with microglia activation.  I found that microglia from Rheb KO mice 
expressed significantly less CD11b (p<0.01) compared with WT controls (Fig. 6.14A). 
Nonetheless, there did not appear to be a difference between the two groups for Tlr2 
expression (Fig.  6.14B). 
 
 
Figure 6.14 Flow cytometry analysis of markers of microglia activation after low-
dose LPS challenge.  WT and Rheb KO mice were given a peripheral injection of LPS, 0.33 
mg/kg for 48 hours. Mice were culled by cardiac puncture and the brains were removed and 
digested before microglia were isolated using magnetic beads. Microglia were then stained with 
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WT group, n= 8 for Rheb KO group and **p<0.01. Significance was calculated using the 
unpaired two tailed student t-test between individual groups. 
6 Discussion 
 
The main question I wanted to address in this chapter was; what are the potential 
consequences of the increased microglia-mediated inflammation in the Rheb KO mice?  
Before approaching this question, I had to confirm that the transcriptional changes 
observed in microglia and BMDMs from Rheb KO mice were also observed at a protein 
level. The most straightforward way to measure cytokines produced by BMDMs from 
Rheb KO and WT mice treated with LPS was by ELISA. Surprisingly, protein levels 
were very different to gene expression changes. While there was a clear upregulation of 
the transcripts for pro-inflammatory cytokines such as Tnf and Il6, there were 
significantly lower levels of cytokines being produced and released from these cells. 
This was a very interesting result as it was in contrast to Weichhart et al. where they 
observed the same changes at transcript and protein level when mTOR was inhibited in 
BMDMs or peripheral human monocytes129. The major difference between our 
experimental approaches is the mode by which mTORC1 is inhibited. Weichhart et al. 
use the mTORC1 inhibitor rapamycin to inhibit the pathway, while in our model the 
pathway is inhibited by genetic loss of the positive regulator of mTORC1, Rheb. 
Therefore, it is conceivable that the downstream consequences could be very different. 
 
6.1 Effects on translation 
One of the major functions of mTORC1 is to regulate translation through its two main 
substrates, 4E-BP1 and S6, which mediate the initiation and elongation stages of cap-
dependent translation, respectively. There has been a lot of controversy regarding 
whether rapamycin inhibits mTOR-mediated translation, and if so, to what extent. In 
2009, the Sabatini lab reported the development of a small molecule inhibitor called 
Torin1, an ATP-competitive inhibitor of both mTORC1 and mTORC2. They showed 
that a number of mTORC1 functions were rapamycin resistant. They mainly focused on 
cap-dependent translation and used 35S methionine/cysteine incorporation to show that 
protein synthesis was inhibited by Torin1 to a greater extent than by rapamycin115.  
While S6K activity is completely inhibited by rapamycin115, this is not the case for the 
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other main mTORC1 substrate 4E-BP1. 4E-BP1, when phosphorylated at four residues 
(Thr-37, Thr-46, Ser-65 and Thr-70), can dissociate from its binding partner eIf4E, 
allowing it to form complexes with other eIf proteins and initiate translation32. Thoreen 
et al. found that some of these phosphorylation events, mainly the phosphorylation at 
T37/46, were not affected by rapamycin treatment, however, they were completely 
inhibited by Torin1, suggesting this mechanism is behind the increased potency of 
Torin1 in inhibiting protein translation114. 
 
This paper was further supported by a follow-up study conducted by the same group 
and published in 2012, which showed that a subset of mRNAs specifically regulated by 
mTORC1 contained 5’terminal oligopyrimidine (TOP) motifs. Loss of 4E-BP1 was 
sufficient to inhibit the translation of these TOP and TOP-like transcripts. Again these 
findings were only observed in the presence of Torin1 but not rapamycin115. 
 
These studies may shed light on why I observe reduced cytokine production in our Rheb 
KO cells compared to the Weichhart et al. paper.  In this paper, the authors used 
relatively low doses of rapamycin (10-100 nM) and for relatively short periods of time 
(20-22 hours in vitro, 3 days in vivo)129. As a result, it is possible that rapamycin was 
sufficient to activate NF-κB (through a yet to be identified mechanism). However, given 
its lack of effect on protein initiation through 4E-BP1, it was not affecting protein 
synthesis and therefore cytokine production. Alternatively, in our model, deletion of 
Rheb caused a stronger inhibition of mTORC1, with consequences also on protein 
translation. Indeed, Rheb has been shown to be essential for the regulation of 
translation218. It is likely that in our model the initiation of cap-dependent translation is 
impaired, causing a reduction in translation of pro-inflammatory cytokines. There are 
several ways I could test this hypothesis. Similarly to Thoreen et al. I could measure 
35S methionine/cysteine incorporation in Rheb KO cells, as this would give an idea of 
the extent of inhibition of protein synthesis. I could also measure the level of 
phosphorylation of 4E-BP1 at the different phosphorylation sites, particularly T37/46, 
to see if these are inhibited in the Rheb KO cells compared to WT or rapamycin treated 
BMDMs. Lastly, I could investigate the binding of 4E-BP1 to eIF-4E in Rheb KO cells 
as this binding will prevent eIF-4E forming a complex with other eIF proteins to initiate 
translation. Perhaps the best way to assess this would be to measure polysome 
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associated transcripts (which are the ones being translated into proteins) and check if 
there is a reduction in inflammatory cytokines in Rheb KO cells.  
 
While these experiments could answer the question concerning why I observe 
significantly reduced protein levels of Tnf, Il6 and Il12p40 compared WT controls, it 
does not address why I observe the opposite on a transcript level. As discussed in the 
previous chapter, Weichhart et al. showed that the increase in cytokine production upon 
mTOR inhibition was mediated by activation of NF-κB, specifically showing increased 
DNA binding of NF-κB subunit p65. It is possible that in Rheb KO mice, a similar 
increase in NF-κB activation is taking place. In spite of this, I cannot exclude that given 
the impairment in protein synthesis; the mechanism responsible for changes in mRNA 
levels may be different. For example, is there a compensatory mechanism that causes an 
upregulation of mRNA inflammatory genes if proteins are not produced? If this was the 
case, I would expect to observe differences in the kinetics of mRNA upregulation, i.e. 
that the upregulation of mRNA in Rheb KO cells occurred at a later time point, in 
response to loss of a feedback mechanism initiated by increased protein levels. 
However, this does not appear to be the case, as the peak of cytokine mRNA expression 
is similar in WT and Rheb KO cells. In order to test if the mechanism responsible for 
increased NF-κB activation following mTOR inhibition is the same, whether the 
inhibition is mediated by rapamycin or genetic loss of Rheb, BMDMs could be treated 
with rapamycin and an inhibitor of protein synthesis such as cycloheximide, in order to 
assess if NF-κB activation is dependent on new protein synthesis or not.  
 
It’s also important to acknowledge that measuring the cytokines present in the 
supernatant may not be the most optimal way of determining the inflammatory capacity 
of Rheb KO cells. This is because this is a measurement of only what is secreted by the 
cell. Therefore if there is a defect in the secretion in the Rheb KO BMDMs this could be 
a potential reason why I observed less production of Tnf, Il-6 and ll-12. To try to 
understand if the decrease of these inflammatory genes on a protein level is due to a 
defect in translation rather than secretion, it would be important to carry out an ELISA 
on protein lysates obtained from Rheb KO and WT BMDMs stimulated with LPS and 
measure how much of these cytokines are present within the cell. If I still observed less 
of these cytokines it would be a clearer indication that the cell is not able to make these 
cytokines as efficiently as WT cells.  
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6.2 Sickness behaviour 
 
After observing that reduced overall cytokine production was occurring in Rheb KO 
BMDMs and that this was also evident in vivo upon LPS stimulation, I wanted to assess 
the consequences of impaired cytokine production and decided to study sickness 
behaviour.  
 
Communication between the immune system and the brain is necessary for responses to 
pathogens and adequate immune activation. As previously discussed, the ability of the 
immune system to respond to pathogens has been shown to decline with age, 
furthermore and possible as a consequence, infections in the elderly are associated with 
alterations in both behaviour and cognition219. For example, it has been shown that 
peripheral infections such as those affecting the urinary tract can cause a state of 
delirium in the elderly, often resulting in a more pronounced sickness behaviour206.  
 
Sickness behaviour occurs during a peripheral infection when cells of the innate 
immune system are activated and produce inflammatory cytokines such as Tnf, Il6 and 
Il1b. These signals are then transmitted across the blood brain barrier (BBB), where 
they activate glia cells such as microglia. These cells then produce an array of 
cytokines, prostaglandins and secondary mediators, which will then act on neuronal 
cells to elicit the symptoms of sickness behaviour220.  
 
Accordingly, in our model of low dose LPS in vivo stimulation, I hypothesised that 
lower levels of cytokines would be produced in Rheb KO mice and, for this reason, they 
would exhibit reduced sickness behaviour. Indeed, this was what I observed: mice 
appeared less lethargic and moved more, as measured in the open-field test. 
 
I must consider that the open-field test is not a comprehensive way of measuring 
sickness behaviour. Sickness behaviour is characterised by a variety of symptoms that 
include fever, reduced locomotor activity, depressive-like behaviour, reduction in social 
exploratory behaviour, increased sleep and reduced appetite221. Consequently, it would 
have been more powerful if more tests were carried out, for example using a rectal 
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probe to measure changes in body temperature or by performing a social exploratory 
test, in which a test mouse is placed in a cage with a subject mouse and the amount of 
time the test mouse spends investigating the subject mouse is measured. 
 
Although I was able to assess that sickness behaviour in Rheb KO was not affected by 
gender, it would have been extremely interesting to carry out this experiment also in 
elderly Rheb KO mice. Given that I observed an increase in the transcript levels of the 
pro-inflammatory cytokines in old Rheb KO microglia compared to young Rheb KO 
microglia, as described in chapter 5, it would have been important to understand if this 
increase in gene transcripts had any effect on the overall inflammation in the brain. 
Considering that there were significantly less Tnf and Il12p70 in the plasma of aged 
Rheb KO mice, I could hypothesise that elderly Rheb KO mice would be even more 
protected from the induction of sickness behaviour than their younger counterparts. 
Nonetheless, this point will need to be tested.  
6.3 Relevance for immune responses to infections 
 
It is important to consider the overall consequences of having reduced cytokine 
production, particularly in an ageing context. Cytokine production is an important part 
of clearing an infection. For example, Balb/c mice are unable to mount an effective Th1 
response and are therefore more susceptible to infections such as L. major, which can be 
rescued by the administration of IL-12. Fakao et al. showed that inhibition of PI3K in 
DCs led to an increase in IL-12 production, and PI3K-/- mice infected with L. major 
had enhanced resistance to the infection, confirmed by a significant reduction in the 
number of parasites in the popliteal lymph nodes 6 weeks post infection126. This is 
consistent with a report by Aksoy et al. who showed that DCs from mice with a knock-
in mutation in the p110δ isoform of PI3K had augmented cytokine production128. The 
authors went on to explain that this is due to differences in Tlr4 internalisation and 
downstream consequences on alternative TLR signalling. Whether a similar mechanism 
contributes to the effect observed in Rheb KO mice remains to be elucidated. Weichhart 
et al. showed that rapamycin treated Balb/c mice were protected from infection with 
L.monocytogenes through an increase in the production of IL-12129. Therefore in Rheb 
KO mice, I may hypothesise that they are more susceptible to similar infections 
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compared to WT controls, however, they would be protected from endotoxic shock 
during sepsis.  
 
It would be interesting to challenge older mice with infectious agents such as L. Major 
or influenza, in order to mimic what happens in elderly individuals and assess the 
overall impact of mTORC1 inhibition in this context. Would it cause an improvement in 
cognitive and locomotion functions during infections? In elderly rodents, LPS injections 
cause an amplified cytokine response216 and a decline in both spatial memory222 and 
contextual memory223. Nonetheless, could it increase susceptibility to succumb to 
infections? Moreover, could it protect elderly individuals undergoing sepsis? What 
would be the consequences on inflamm-ageing? 
 
Inflamm-ageing is thought to underlie many age-related illnesses such as Alzheimer’s 
and cancer; correspondingly, in the Rheb KO mice, a reduction in the overall production 
of cytokines could reduce inflamm-ageing in older mice. It would be intriguing to 
assess the baseline levels of Tnf, Il6, Il1b and Il12 in the plasma of old Rheb KO mice 
compared to controls, as this would give an overall indication of the systemic 
inflammation that accumulates with age. However, given that the mouse model used 
here has a deletion of Rheb specifically in myeloid cells, I might not be able to observe 
a systemic effect, since the SASP can be produced by other cells in the organism 18 and 




Overall, my data suggest that inhibition of mTORC1 by deletion of Rheb in myeloid 
cells leads to reduced inflammatory cytokine production, which is associated with 
improved sickness behaviour as measured by the open-field test.  These results raise 
further questions, most notably, what could long term mTOR inhibition mean for the 
ageing host? A number of studies have shown that long-term mTOR inhibition 
increases lifespan in a number of model organisms, more recently rapamcyin itself was 
shown to extend lifespan in mice31. I therefore wanted to ask the question; what would 
happen if I treated young and aged mice long-term with rapamycin and then challenged 
them with a peripheral injection of LPS? Would I observe the same transcriptional 
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changes in microglia observed in the Rheb KO mice? Would I see these effects at 
protein level? Would mice be less or more sick after an LPS challenge? 
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Chapter 7: The effect of long-term rapamycin 
treatment on the LPS-induced inflammatory response 
in ageing mice 
 
Given that rapamycin is being considered as an anti-ageing intervention, I wanted to 
understand the impact of long-term rapamycin treatment on the inflammatory response, 
especially in microglia. I also wanted to understand if the effect (if any) of rapamcyin 
treatment was similar in young and aged individuals. At the time of starting this 
experiment, I was aware that Rheb KO microglia expressed higher levels of 
inflammatory cytokines at the mRNA level, with previous reports observing an 
increased inflammatory response in both rapamycin-treated mice and in vitro 
rapamycin-treated macrophages. Therefore, I wanted to assess whether long-term 
rapamycin treatment could result in exaggerated inflammatory responses in the event of 
an infection. I designed an experiment using all female mice as depicted in Fig 7.1, 






Figure 7.1 Experimental design to assess inflammatory responses after long-term 
rapamycin treatment. Mice used were female and either young (6 months) or old (18 
months). These groups were sub divided into two groups; one receiving a diet containing 14 
parts per million (ppm) of encapsulated rapamycin and one receiving only the material used to 
encapsulate the drug, known as eudragit, as the control group. The mice were kept on this diet 
for 22 weeks, after which they were injected i.p. with 2 mg/kg of LPS and culled after five 
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3$ 18Hmonths$ female$ Eudragit$ 7$
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field test was conducted two hours post LPS injection in order to assess changes in sickness 
behaviour. Mice were 11 and 23 months at the time of the LPS injection.  
 
I used both young (6 month) and aged mice (18 months), which were each split into two 
groups that received a diet containing either encapsulated rapamycin or only the 
material used to encapsulate it, known as eudragit, as the control group. Eudragit is a 
polymer used to coat drugs to prevent their premature degradation in the stomach, 
thanks to the fact that the polymer can only be broken down at an adequate pH in the 
gastrointestinal (GI) track. The diet used was similar to the one used in other ageing 
studies, including the 2012 Harrison et al. study in Nature showing that rapamycin 
extended lifespan in mice. The amount of rapamycin incorporated into the diet 
corresponded to 14 parts per million (PPM) that equates to approximately 2.2 mg/kg of 
rapamycin per day.  Mice were placed on both diets at 6 and 18-months of age and 22 
weeks later they were challenged with a dose of LPS of 2mg/kg, then culled 5 hours 
later. The open-field test was conducted two weeks prior to this challenge, to assess 
changes in baseline behaviour and was also conducted two hours post LPS injection, in 
order to determine the effect of rapamycin on LPS-induced sickness behaviour.  
7.1 Rapamycin treatment did not affect baseline behaviour of 
young or aged mice  
 
Firstly, I determined if there were any differences in the baseline behaviour of mice 
treated with rapamycin before challenging them with LPS. To this end, I carried out an 
open-field test after 20 weeks of rapamycin/eudragit diet, when mice were 11 months 
(middle aged) and 23 months old (old). I measured a number of parameters associated 
with both locomotion and stress. I found that the distance travelled, i.e. the number of 
squares each mouse passed through during the 5-minute test, was similar between 
eudragit and rapamycin-treated groups, in both age groups (Fig. 7.2A). This result was 
consistent with other measurements of locomotor ability, including rearing (Fig. 7.2B) 
and time to first rear (Fig. 7.1C).  
 
It appeared that for the 11-month old rapamycin-treated mice, the time interval before 
traversing one of the three central squares was shorter than the eudragit-treated group, 
although this difference was not statistically significant (p=0.07). There was no 
difference in this parameter for the older age group (Fig. 7.2D). I also measured how 
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many faecal boli were present in the box at the end of the test, as this is also a measure 




Figure 7.2 Baseline analysis of locomotor ability and stress levels in rapamycin-
treated versus eudragit-treated mice, as measured by the open-field test. Mice were 
placed into a 15-square gridded rat cage for a 5-minute period. Each test was recorded and later 
analysed blind. Locomotor ability was assessed by three parameters; A) distance travelled, 
measured by the number of squares traversed during the test B) number of rears (both paws), C) 
time to first rear. Stress levels were measured by two parameters; D) time delay before the 
mouse crossed one of the 3 squares in the centre E) number of faecal boli present in the box 
after each test. All mice used were female of 11- or 23-months of age, n ≥ 7 for all groups, data 
are representative of one experiment. Eud = Eudragit and Rapa=Rapamycin. 
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7.2 Long-term rapamycin treatment does not affect sickness 
behaviour after LPS challenge  
 
Twenty-two weeks after starting the rapamycin/eudragit diet, mice were challenged 
with a peripheral injection of 2 mg/kg LPS for 5 hours. While I used a higher dose for 
Rheb KO experiments descried in chapter 5 (5 mg/kg), I decided to use a lower dose of 
LPS in order to carry out a sickness behaviour test, as well as assess cytokine levels in 
microglia and in the blood. With 5 mg/kg of LPS, mice rapidly became too unwell and 
would not have been able to withstand an open-field test.   
 
In order to assess if the 2 mg/kg dose of LPS would be suitable for assessing sickness 
behaviour as well as induce a strong cytokine response, I performed a pilot experiment 
with either 1 mg/kg or 2 mg/kg of LPS and found that the latter was the most 
appropriate to measure tissue inflammation and conduct the open-field test two hours 
post LPS injection. Due to the relatively small size of my cohort of mice on the 
rapamycin/eudragit diet, I decided to inject all mice with LPS and not to have PBS-
injected controls. I reasoned that it was better to have a larger sample size as both the 
open-field test and cytokine responses might show a greater variability, compared to 
Rheb KO mice.  
 
Overall, I found no major differences in sickness behaviour in any of the groups tested. 
In terms of locomotor activity, there was a trend for the rapamycin-treated middle-aged 
group (11 month) to cross more squares (Fig. 7.3A) and rear more (Fig. 7.3B), 
suggesting these mice were less sick. The differences, however, were not statistically 
significant.  
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Figure 7.3 Sickness behaviour in rapamycin-treated vs. eudragit-treated mice as 
measured by the open-field test. Mice were placed into a 15-square gridded rat cage for a 
5-minute period. Each test was recorded and later analysed blind. Locomotor ability was 
assessed by three parameters; A) distance travelled, measured by the number of squares 
traversed during the test B) number of rears (both paws), C) time to first rear. Stress levels were 
measured by two parameters; D) time delay before the mouse crossed one of the 3 squares in the 
centre E) number of faecal boli present in the box after each test. All mice used were female of 
11- or 23-months of age, n ≥ 7 for all groups, data are representative of one experiment. Eud = 
Eudragit and Rapa=Rapamycin. 
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No differences were observed in the older age group for distance travelled or the 
number of rears (Fig. 7.3A and 7.3B). I also found there were no differences between 
any of the groups for the last parameter of locomotion measured, time to first rear (Fig. 
7.3C).   
 
I also measured the two parameters relating to stress and anxiety and found again that 
there were no differences for any of the groups: all mice appeared to traverse one of the 
3-centre squares at the same time (Fig. 7.3D) and also the number of faecal boli was 
similar across all groups (Fig. 7.3E).  
 
7.3 Middle-aged rapamycin-treated mice but not older ones 
show a minor reduction in pro-inflammatory genes  
I next assessed inflammatory genes induced in microglia after LPS injection. Since 
Weichhart et al.129 reported that a short treatment with rapamycin induced a stronger 
inflammatory response and given the observation in Rheb KO mice, which showed an 
increase of inflammatory cytokines at transcript level, I hypothesised that rapamycin 
treatment would cause an increase in pro-inflammatory genes at least at mRNA levels. 
Furthermore, given the evidence that microglia from old mice appear to be primed, I 
expected the inflammatory response to be further exaggerated with age. Therefore, I 
isolated microglia from all four groups of mice and performed qPCR analysis similar to 
Rheb KO experiments described in chapter 4.  Surprisingly, the results were quite 
different to what I expected. There was a clear downregulation of pro-inflammatory 
cytokines in microglia from the middle-aged rapamycin-treated group. This trend was 
just below the significance threshold for Tnf (p=0.06, Fig. 7.4A) but was significant for 
both Il6 (p<0.05, Fig. 7.4E) and Tlr2 (p<0.05, Fig. 7.4F). A similar trend was observed 
for Il1b (Fig. 7.4D) but differences were not statistically significant.  
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Figure 7.4 Downregulation of inflammatory genes in microglia isolated from 
middle-aged mice treated with rapamycin.  Young (6 month) and aged mice (18 month) 
mice were fed a diet containing 14 ppm of rapamycin or eudragit control for 22 weeks, prior to 
being challenged with a peripheral injection of LPS (2 mg/kg). After five hours, mice were 
culled by cardiac puncture and brains were removed. Microglia were isolated using magnetic 
beads. The induction of inflammatory genes was determined using qPCR and results are 
reported as fold change relative to the housekeeping gene Hprt1. Genes analysed were A) Tnf, 
B) Il12a C) Il12b, D) Il1b, E) Il6, F) Tlr2. All mice used were female and n≥7 for all groups, * 
p<0.05, **p<0.01, data are from one individual experiment. Significance was calculated using 
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the unpaired two tailed student t-test between individual groups. Eud = Eudragit and 
Rapa=Rapamycin. 
While the rapamycin diet seemed to be anti-inflammatory in middle-aged mice, no 
differences were observed in older mice (Fig. 7.4 A-D and Fig. 7.4F).  Nonetheless, 
there was a significant upregulation of the Il6 gene in the older mice (23 month) after 
rapamycin treatment (p<0.05), which was in direct contrast to what was observed in the 
11-month age group, in which the gene appeared to be downregulated (Fig. 7.4E).  
 
The most striking result was the difference between the two different eudragit control 
groups post LPS injection. As explained earlier, it has been reported in the literature that 
microglia become primed with age, i.e. they become over responsive to an LPS 
challenge and produce more inflammatory cytokines compared to their younger 
counterparts224. As a result, in this experiment, I expected to see a stronger induction of 
pro-inflammatory cytokines in the 23-month old control group compared to the 11-
month one. I observed the opposite; there was a clear down regulation of key 
inflammatory genes with age in the eudragit-treated group after LPS injection. This was 
evident for Tnf and Il12b (Fig 7.4A and 7.4C), for which differences were statistically 
significant (p<0.05). The downregulation was even more striking for Il6 (p<0.01, Fig 
7.4E).  
 
Finally, there were also differences between the 11 and 23-month old rapamycin-treated 
groups. These differences were not consistent across the different genes tested. For 
example, Il12b was reduced in the old group after rapamycin treatment (p<0.05, Fig. 
7.4C), whereas the opposite was true for Il1b, which was enriched in the rapamycin-
treated old mice compared to middle-aged mice (p<0.05, Fig 7.4D).  
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7.4 Middle-aged rapamycin-treated mice exhibited reduced 
cytokine production at protein level  
	  
	  
I further assessed cytokine production in rapamycin-treated mice by ELISA, in order to 
verify whether the protein levels correlated with the mRNA levels measured in 
microglia. To this end, I analysed the plasma for TNFα and IL-12p40 by ELISA. 
Similarly to what I observed in microglial mRNAs, inflammatory cytokines were lower 
in middle-aged rapamycin-treated mice compared to those on the eudragit control diet. 
TNFα  and IL12p40 followed this trend, although the decrease in middle-aged 
rapamycin-treated mice was only significant for IL12p40 (p<0.05, Fig. 7.5A and 7.5B). 
There were no differences between the rapamcyin and eudragit treatments in the 23-
month old groups. Furthermore, there were also no differences between the control 
groups (middle aged vs. old) and rapamycin-treated group ( middle-aged vs. old, Fig. 
7.5A and 7.5B) at protein level.  
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Figure 7.5 Rapamycin-treated middle-aged mice showed reduced levels of IL-
12p40 in plasma. Plasma levels of A) TNFα and B) IL12p40 as measured by ELISA using 
the plasma of middle-aged and old mice on rapamycin or eudragit diets injected with 2mg/kg 
LPS i.p. and culled five hours later. All mice were female, n≥7 for all groups, * p<0.05, data are 
from one individual experiment. Eud = Eudragit and Rapa=Rapamycin. Significance was 
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7.5 Is the mTOR pathway inhibited in older (23 months) 
rapamycin-treated mice? 
	  
Given that I only observed changes in cytokine transcript levels (microglia) and 
cytokine protein levels (plasma) in the younger 11-month old group of mice and not in 
the older group following rapamycin treatment, I asked the question; is the mTOR 
pathway inhibited in these older mice? To answer this, I carried out phospho flow 
cytometry analysis assessing the status of p-S6. Staining was done on the whole blood, 
using CD11b and CD45 as markers for myeloid (CD11b) and immune cells (CD45). I 
found that there was a reduction in the phosphorylation of S6 in CD11b+ myeloid cells 
(Fig. 7.6A) and in CD45+ immune cells (Fig. 7.6B) in the 11-month age group, 
although these differences were not statistically significant. In the old mice (23 months), 
the levels of phospho-S6 appeared lower overall, however, no differences were 
observed between the rapamycin-treated and control groups. This was the case for both 
CD11b+ cells (Fig. 7.6A) and for CD45+ immune cells (Fig. 7.6B).  
 
To assess if the mTOR pathway was inhibited in the older age group of mice, protein 
lysates were made from the heart tissue of both rapamycin- and eudragit-treated groups. 
No difference in p-S6 levels between these two groups were observed (Fig. 7.6C), 
however, p-S6 levels were not assessed in the 11-month old mice, therefore it was not 
possible to make a comparison.  
 
These results do not clarify if the mTOR pathway was inhibited in the 23-month 
rapamycin-treated group. It is possible that the pathway was not inhibited because 
mTOR activation is already reduced in aged peripheral myeloid cells and heart tissue, 
therefore cannot be reduced further by rapamycin treatment. Furthermore, the heart may 
not be the most appropriate tissue to test p-S6 levels and it would be important to check 
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Figure 7.6 The mTOR pathway may not have been inhibited in 23-month old 
rapamycin treated group. Young (6 month) and aged mice (18 month) mice were fed a diet 
containing 14 ppm of rapamycin or eudragit control for 22 weeks, prior to being challenged 
with a peripheral injection of LPS (2 mg/kg). After five hours, mice were culled by cardiac 
puncture and 100 ul of blood was fixed immediately in PFA and later stained for p-S6, CD11b 
and CD45. The median fluorescence intensity (MFI) for p-S6 is shown for A) CD11b+ myeloid 
cells and B) CD45+ immune cells from whole blood. C) Protein lysates were prepared from the 
heart tissue of seven 23-month eudragit-treated mice and eight 23-month rapamycin-treated 
mice and immunoblot for p-S6 was carried out. Eud = Eudragit and Rapa=Rapamycin. 
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7 Discussion  
 In this chapter, I describe my efforts to understand if long-term rapamycin treatment 
would have an effect on the inflammatory response. To this end, I fed mice with a 
rapamycin-containing diet for 22 weeks and then challenged them with a peripheral 
injection of 2 mg/kg of LPS. I hypothesised that the mice on rapamycin would have a 
stronger inflammatory response compared to eudragit controls and that this effect might 
be further increased in the older age groups. The results were quite different to what I 
expected and they raise a number of questions that will need to be addressed in the 
future.  
7.1 Length of rapamycin treatment and effect on mTOR 
signalling  
The most striking observation in this data set is that the only difference due to 
rapamycin was observed in the group that received it from 6 months of age, with 
relatively no differences in any of the parameters measured in the older group. This 
observation leads to the question; was the pathway equally inhibited in both age groups 
of mice? Was 22-weeks on rapamycin a sufficiently long treatment? Our preliminary 
data would suggest that the pathway may be at least be partly inhibited in myeloid cells 
from the younger group of mice, but this did not seem to be the case from the older age 
group. P-S6 levels in the heart tissue obtained from the older group of mice also further 
support the idea that the pathway was not inhibited in this group. To try to reconcile 
these findings and to determine if the heart was the best tissue to test levels of p-S6, I 
examined the literature on mTOR activation in different tissues with ageing.  
 
It has been generally thought that mTORC1 signalling increases with age and that 
rapamycin exerts some, if not all, of its anti-ageing properties by inhibiting mTOR225. 
Recent evidence, however, has suggested this may not be entirely true. Indeed, 
Houtkooper et al. showed that there was a reduction in mTORC1 signalling with age (2 
v 24 month mice) as marked by a decrease in phosphorylation of S6K1 in muscle 
tissue226. This was similar to a human study that profiled transcriptional changes in the 
blood between young and aged individuals and found a general decrease in mTOR 
related transcripts with age227. However, a number of studies with C57BL/6 mice have 
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reported an increase in mTORC1 signalling with age, for example in the lung228 and the 
liver229. It is possible that the discrepancies in the literature are linked to sex differences, 
age groups or models used.  
 
Baar et al. conducted a study that is most relevant to our research. The authors 
examined both mTORC1 and mTORC2 signalling in male and female C57BL/6J at 6 
months and 22 to 26 months. From the different organs examined, it was found that 
there was a 30% decrease in mTORC1 signalling in the liver in both male and female 
mice with age, as measured by phosphorylation of S6. In the skeletal muscle, there was 
twice as much phosphorylation of S6 in males with age but no changes were observed 
in the skeletal muscle of females. There was no increase in mTORC1 signalling in the 
heart with age in either males or females. The most striking increases in pS6 was in the 
adipose tissue, where a 3-fold increase was observed in males and a 6-fold increase was 
observed in females with age230. Based on this evidence, I should check if the pathway 
was inhibited in the adipose tissue in my cohort of mice after rapamycin treatment, as 
this appears to be the only tissue majorly affected in female C57BL/6J mice. This could 
be tested by carrying out a western blot with the adipose tissue cell lysate and 
measuring phosphorylation of S6, similarly to what I have shown with the heart tissue. 
In the Harrison et al. Nature paper that first showed an extension of lifespan in mice 
with rapamycin, the authors show a clear inhibition of phosphorylation of S6 in the 
visceral fat pads of both male and female mice. However, these mice were fed 
rapamcyin for 420 days31. It would also be important to clarify if therapeutic levels of 
rapamycin were present in the blood of these mice. This could be done similarly to the 
Harrison et al. study that used high performance liquid chromatography to quantify the 
amount of rapamycin in the blood of each animal.  
	  
Could it be that longer treatment is needed to fully inhibit the pathway in the older age 
group? Given that lower levels are observed in p-S6 in myeloid cells from older mice?  
 
It would also be important to determine what affect the rapamycin diet had on mTOR 
signalling in microglia from the ageing brain. I have previously described in chapter 4 
that the mTOR pathway is upregulated in microglia from 23-month old female mice, as 
determined by RNA sequencing. An important question would be; even if mTOR 
inhibition is not evident in the tissues from the 23-month rapamycin-treated mice, could 
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rapamycin levels be sufficient to inhibit the mTOR pathway in microglia? The best way 
to test this would be to look at the levels of pS6 in the microglia by 
immunofluorescence in the brains of these mice.  
7.2 Microglia priming  
 
Regarding the qPCR analysis of inflammatory genes, when comparing the middle-aged 
and old eudragit control groups I expected to observe a clear upregulation of 
inflammatory genes in the old group upon LPS challenge. This was not the case, as I 
observed many of the inflammatory genes to be downregulated in the old control group, 
compared to the middle-aged one. This is not in line with what has previously been 
reported in the literature, showing microglia are primed with age and tend to be over 
responsive to inflammatory stimuli3. In our experiment, microglia appeared to be 
tolerised rather than primed with age. Tolerance and priming are well-described 
mechanisms in macrophages and depend on which stimuli the cells are exposed to and 
the order of exposure. For example, macrophages exposed to LPS become tolerised and 
respond to a second inflammatory stimulus with a reduced production of inflammatory 
cytokines, compared to “naïve macrophages”. On the other hand, if macrophages are 
exposed to beta-glucan, they become primed and produce more inflammatory cytokines 
when later challenged with a second stimulus. These responses were shown to be due to 
epigenetic reprogramming231.  Given what I observed in my experiment, in which 
microglia appear to produce lower levels of inflammatory cytokines with age, it is 
possible to speculate that these mice were exposed to a pathogen or endotoxin, which 
lead them to become tolerised and less responsive. Mice were purchased from Charles 
River prior to commencing the experiment; therefore the old group had spent a 
considerable length of time in a different environment, before being transferred to our 
facility.   
	  
While this is one possible explanation, it also cannot be ruled out that the material used 
to encapsulate the rapamycin, eudragit, could be having an effect on the inflammatory 
response in the microglia. Therefore, it would be important to repeat this experiment 
with a group of mice that do not receive the eudragit control diet, to rule out any 
potential effects. It would also be important to use PBS controls if the experiment was 
repeated, in order to see if rapamycin affected the baseline levels of inflammatory genes 
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in microglia and systemically in ageing. Unfortunately, I did not have sufficient mice to 
include PBS controls in this experiment, as I thought it would be more important to 
have a larger cohort of mice to examine sickness behaviour and be certain about the 
LPS results. This is a major limitation in interrupting the results presented in this 
chapter as not having PBS controls means I could not determine changes from the 
baseline. This is true for example when trying to understand if LPS has induced an 
inflammatory response, as this is also difficult to determine without having a baseline 
reference. Another limitation is not being able to determine the affect of the Eudragit (if 
any) on this cohort of mice, as again we cannot compare it to baseline.  
 
Although I still need to verify that rapamcyin was administered at a sufficiently high 
concentration to attain mTOR inhibition, I did observe an affect in the middle-aged 
group of mice, which suggests that, at least in the middle-aged group, rapamycin 
concentrations were therapeutically relevant. However, as a result of rapamycin 
treatment I observed a decrease in the inflammatory response, both at transcript (in 
microglia) and protein levels (in the plasma). The fact that I detected a decrease in gene 
expression indicates that a different mechanism is in place, compared to Rheb KO mice, 
possibly rapamycin is causing inhibition of NF-κB, rather than its activation or there is 
a different effect on FOXO1, another transcription factor implicated in the 
inflammatory response that is regulated by mTOR137. Our results are in direct contrast 
to Weichhart et al. who showed that rapamycin treatment in vivo lead to a stronger 
inflammatory response to L. monocytogenes pathogen in Balb/c mice. It is possible that 
differences in mouse strains used or the extent of rapamycin treatment plays an 
important role. It remains unknown what is the effect of inhibiting both mTORC1 and 
mTORC2 complexes for such a long period of time on the downstream signalling and 
global changes at organism level, such as changes in whole body metabolism.   
 
The idea that treatment with rapamycin in an ageing context may be anti-inflammatory 
is supported by other reports in the literature. In one study, Flynn et al. showed a 
reduction in heart-related inflammation when mice were treated with rapamycin in a 
similar fashion to our study232.  An overall reduction in both the induction of SASP-
related genes and secreted proteins was reported with in vitro treatment of senescent 
cells with rapamycin. Importantly, in this paper, SASP-related genes, including Il6 and 
Il1b, were downregulated in the liver of mice treated with rapamycin long term233. In 
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these studies, the molecular mechanism governing these changes were not described 
and more work regarding the effect on downstream signalling with long-term rapamycin 
treatment is needed to clarify this point.   
 
7 Conclusion 
Overall, our results suggest that rapamycin treatment starting at a relatively young age 
(6 months) may lead to a reduction in the inflammatory response when mice are later 
challenged with LPS, whereas rapamycin treatment starting in old age (18 month) does 
not seem to have any significant effect. It is important to carry out control experiments 
to verify the validity of these findings and repeat this work in both male and female 
mice to see if their responses are similar.  
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8: Discussion and plans for future work  
	  
The main aim of this thesis was to understand how microglia change with age and to 
use this information to decipher the molecular mechanisms underpinning these changes. 
The work presented in this thesis has lead to a number of novel findings summarised 
below:  
 
1. Microglia from the ageing brain have a very distinct transcriptome 
signature;  
2. The mTOR and inflammatory pathways are deregulated in microglia with 
age; 
3. Inhibition of the mTOR pathway in microglia by Rheb deletion leads to an 
upregulation of key inflammatory genes at mRNA level; 
4. This is further exaggerated with age;  
5. These transcriptome changes are not translated into protein both in vitro or 
in vivo;  
6. As a consequence, Csf1r-Cre; Rheb f/f mice appear to have less overall 
inflammation; 
7. Long-term treatment with rapamcyin in vivo leads to a very different 
phenotype, with a decrease in inflammation at transcript and protein level 
but the effect is evident in middle-aged and not old mice;  
8. These results differ from previously published evidence in which mTOR 
inhibition by short-term rapamycin treatment results in increased 
inflammation129.  
 
8.1 Role of mTOR in inflammation  
	  
While activation of NF-κB is a well-established event occurring downstream of TLR or 
cytokine receptor signalling, the role of the mTOR pathway in NF-κB activation and 
more broadly its role in inflammation is less well defined. It has been suggested that 
mTORC1 is a negative regulator of NF-κB and therefore can increase the inflammatory 
response when inhibited234 but the results presented in this thesis may indicate that the 
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mechanism of action of how mTORC1 co-ordinates the inflammatory response in 
myeloid cells can vary depending on how mTORC1 inhibition is achieved.	  	  
	  
Figure 8.1 Schematic depicting the potential mechanisms governing the 
inflammatory response in microglia following mTOR inhibition. A) mTORC1 
negatively regulates NF-κB and therefore is inhibited when mTORC1 is active and cytokine 
production is limited. B) Rapamycin inhibits mTORC1 leading to activation of NF-κB and 
production of cytokines, both at transcript and protein levels. C) Hypothesised effect of Rheb 
deletion on mTORC1 functions regulating NF-κB and protein translation.  
 
Based on previous findings234, we hypothesised that inhibition of mTORC1 would 
result in activation of NF-κB, however, it seems that if the mode of inhibition is 
rapamycin, it does not affect mTORC1 regulation of translation and, as result, more NF-
κB dependent cytokines may be produced at a protein level, causing a stronger 
inflammatory response (Fig. 8.1B). On the other hand, if the mode of inhibition is the 
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severely, as well as causing activation of NF-κB, therefore although there is an increase 
in the gene expression of cytokines, they seem to be not translated into proteins: overall 
this results in a weaker inflammatory response (Fig. 8.1C). As discussed in the 
discussion in chapter 6, I hypothesised that in Rheb KO cells both 4E-BP1 and S6 
phosphorylation are inhibited and this could be the reason for the impairment in the 
translation of cytokines. One study indicates that Rheb may be very important for the 
regulation of protein synthesis218. In this study, Tyagi et al. showed that deletion of 
Rheb by small hairpin RNA (shRNA) in HEK293 cells lead to a reduction in p-4E-BP1 
and p-S6 and speculate that this would inhibit protein synthesis. However, they also 
elucidate another molecular pathway by which Rheb can regulate protein synthesis, 
through the phosphorylation of another eukaryotic initiation factor called eIF2α. When 
Rheb was over expressed, it increased the phosphorylation of this factor and inhibited 
protein synthesis. Therefore both Rheb downregulation and Rheb overexpression can 
impair protein synthesis. The authors suggest that Rheb may act as a molecular switch 
between the stimulation and inhibition of protein synthesis218. It would be interesting in 
my model to check the phosphorylation state of eIF2α although the fact that I observed 
an inhibition of protein synthesis when Rheb is deleted suggests the effect is 4E-BP1 
mediated. Nevertheless this study does highlight the importance of Rheb in regulating 
protein synthesis.  These findings are important as they may shed light on the 
contradictory results on whether mTOR inhibition leads to a pro versus an anti-
inflammatory response. They also provide useful information about the effect of 
targeting different arms of the pathway. mTOR inhibitors are under investigation as a 
treatment for a number of diseases with an inflammatory component and to extend 
lifespan, therefore understanding what affect these drugs would have on inflammation is 
very important.  
 
Overall, my results show that mTOR is a key regulator of the inflammatory response of 
macrophages and microglia.  
 
8.2 Role of mTOR in ageing  
My results may have implications also for the use of mTOR inhibitors to extend 
lifespan. Rapamycin was recently shown to boost immune responses, specifically 
antibody titres, after influenza vaccinations in a group of elderly people235.  However, a 
	   203	  
6-week pre-treatment with rapamycin may have very different effects compared to long-
term chronic use of the drug. The rapamycin data presented in my study would suggest 
that long-term use of this drug could result in a reduction in the inflammatory response. 
This could have both positive and negative implications for the ageing host. It is well 
documented that the immune system declines with age and that elderly people can often 
succumb to basic infections. Therefore if rapamycin treatment was to result in a 
defective ability to produce important inflammatory cytokines, this could potentially 
have deleterious consequences for the clearance of basic bacterial or viral infections.  
 
Analogs of rapamcyin (rapalogs) are being investigated as potential anti ageing 
treatments as well as other possible mTORC1 inhibitors. It would be important to 
investigate the specific effect of each of them on the inflammatory response. For 
example, too much inflammation in the elderly could lead to an increase in age-related 
diseases, endotoxic shock or tissue damage.  In my data obtained with rapamycin, it 
appeared that the effects on the inflammatory response only occurred when mice were 
fed the drug from an early age. While these experiments would need to be repeated, 
they do indicate that giving rapamycin later in life may not affect inflammatory 
responses.  
 
It must be considered that the majority of ageing studies conducted in mice using the 
drug rapamycin have been done in a relatively clean environment. This is true for the 
Harrison et al. study where specific pathogen free (SPF) mice were used at three 
independent sites to assess the affects of rapamycin on lifespan31. While there have been 
many other studies to date where both age and age-related illness have been assessed in 
mice treated long-term with rapamycin, these studies would also have been carried out 
on WT laboratory mice housed in clean conditions. This therefore leads to the question 
would the anti-ageing affect of rapamycin be observed in mice in a “dirtier” 
environment. This is perhaps a particularly important question when studying the 
immune system, in the context of rapamycin treatment, given a recent publication in 
Nature that showed that standard laboratory housing conditions had profound effects on 
the immune system236. The most striking observation was that laboratory mice lacked 
effector-differentiated memory T cells, a compartment that was present in WT mice 
obtained from pet shops and barns. This compartment could be induced effectively in 
laboratory mice by co-habiting them with these pet shop/barn mice. Given that many 
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age-related illnesses are believed to have a strong immune component, it must be 
considered that rapamycin given to these types of WT mice could have very different 
results to there SPF WT counterparts. One study that might overcome the 
environmental bias associated with laboratory mice is a study being conducted by 
Kaeberlein et al. in which dogs are being treated with rapamycin237. The dogs that have 
been recruited in these studies are pets and therefore share the same environment as 
their human owners including, for example, contaminants in the water or exposure to 
pathogens. Therefore the results of these types of studies will be extremely informative. 
Early results reported suggest that rapamycin has lead to improvements in heart 
function, however it will be several years till it is clear if it has similar effects on canine 
longevity237. 
 
The use of rapamycin has been associated with a long list of side effects including 
ulcers, rash, hair and nail disorders, alopecia and reduced male fertility238. While the 
majority of these side effects have been described in transplant or renal cell carcinoma 
patients, they do raise the important question of whether a drug with these side effects is 
a valid treatment to prevent ageing238. However, it must also be considered that the 
doses used in transplant and renal cell carcinoma of rapamycin is considerably higher 
than the doses that are being proposed for human ageing studies. For example, in renal 
cell carcinoma patients are routinely given approximately 25 mg/kg of rapamycin or a 
rapamycin analog239 whereas the proposed dose for human studies is considered to be 
within the 0.5-5 mg/kg range235. 
8.3 Implications of mTOR inhibition in microglia cells on 
neurodegeneration  
 
One of the most interesting results from my data was that the mTOR pathway appeared 
to be upregulated in microglia with age. However, it is important to confirm this 
upregulation at protein level in order to show that the changes observed are not an 
artefact of the RNA sequencing experiment. I am therefore, currently trying to validate 
that the mTOR pathway is upregulated with age in microglia by using 
immunofluorescence staining of p-S6 and Iba-1, a microglia-specific marker. 
Considering my hypothesis that mTOR is activated with age to limit excessive 
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inflammation, it would also be important to look at the nuclear localisation of NF-κB 
p65 in aged microglia, as a measure of NF-κB activation. These experiments are 
important for understanding my rapamycin experiment data, especially in order to 
understand how much rapamycin is therapeutically necessary to inhibit the mTOR 
pathway in microglia with age.  
 
The first indication that rapamycin could be beneficial in the treatment of Alzheimer’s 
was published in 2010 by Caccamo et al. The authors used the 3 x Tg-AD mouse 
model, which develops the key features of the disease such as the build up of amyloid 
plagues and tau tangles. Using this model, it was shown that a 13-week treatment with 
rapamycin was sufficient to protect Tg mice from cognitive decline, as measured by the 
morris water maze240. The finding that rapamycin could improve cognition was 
confirmed by a second group in another model of Alzheimer’s, the hAPP model241. In 
both studies, the authors showed that rapamycin treatment lead to the induction of 
autophagy and this was suggested as the potential mechanism behind the beneficial 
effects.  
 
While there is no clear agreement on the role of inflammation in the pathogenesis of 
Alzheimer’s disease, it is generally accepted that the number of microglia increases in 
the disease and that these cells present a more activated phenotype242. Majumder et al. 
showed that there was a clear reduction in the number of activated microglia in the 
hippocampus of 3 x Ttg-AD mice that had received rapamycin, compared to 3 x Tg-AD 
control mice, suggesting that rapamcyin was also having an effect on microglia 
activation243. However it is still relatively unknown to what extent the microglia 
phenotype is affected in these models. It has been suggested that this reduction in 
microglia activation may correlate with a decrease in brain inflammation244 but this has 
not been shown conclusively.  
 
These studies provide evidence for the use of rapamyin as an anti ageing therapy, since 
age is a major risk factor for Alzheimer’s. Using a drug like rapamycin as a preventable 
measure for neurodegenerative diseases would be an attractive prospect. However, it is 
plausible to speculate from my data from Rheb KO mice that microglia from the ageing 
brain upregulate the mTOR pathway to try and limit excessive inflammation, which is 
further supported by the fact that many of the age-related genes altered in aged 
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microglia were regulated by mTOR. If this hypothesis was true, then using a drug that 
inhibits this pathway in microglia could potentially have negative consequences, 
causing excessive inflammation. However, this is not supported by my results from the 
in vivo rapamycin experiment. Therefore, it remains to be elucidated how mTOR 
inhibition would affect inflammation in ageing and if different mTOR inhibitors are 
likely to play different roles.  
 
There are several lines of evidence in the data described in this thesis that may indicate 
that mTOR activation is important to limit inflammation in microglia with age. The 
changes in the transcriptome of microglia with age suggests that the mTOR pathway is 
upregulated and the fact that a number of transcription factors with a known association 
to mTOR are implicated using the differentially expressed genes, again would suggest a 
possible role of mTOR in microglia with age. However based on the transcriptome data 
alone it is not apparent if mTOR is activated as a consequence of age in microglia or if 
it plays a role in the transcriptome changes itself. The data I have obtained using the 
Rheb KO model may partly answer this question. This data showed that on a transcript 
level, inhibition of mTOR led to an upregulation of many inflammatory and age-related 
genes suggesting that mTOR may be used as a control mechanism for some 
inflammatory and age-related factors. The fact that Rheb KO macrophages display these 
changes on RNA but not protein level adds another layer of complexity to how mTOR 
may potentially control these responses. However while these findings may indicate that 
mTOR in ageing microglia may be controlling some of the transcriptome changes, 
without protein data from microglia in the ageing brain it is difficult to conclusively say 
how much mTOR may be controlling these changes. Also it would be important to 
validate that mTOR is actually active in these cells with age.  
 
Evidence in the past suggested that microglia become more inflammatory with age and 
this was generally associated with more of a neurotoxic phenotype224. However the 
Hickman et al. study where microglia were isolated from young and aged mice and 
directly RNA sequenced suggested otherwise. They suggest that microglia upregulate 
pathways associated with neuroprotection and downregulated those associated with 
neurotoxicity96. This would indicate that the changes they observe could be a reflection 
of an adaptive response. The hypothesis presented in this thesis that the mTOR pathway 
is upregulated to try and limit excessive inflammation may also suggest a potentially 
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protective response. It has been reported in the literature that microglia become primed 
due to a change in the brain microenvironment as it ages. Therefore it could be 
hypothesised that the changes observed on the transcriptome level both in my study and 
the Hickman et al. study could be a reflection of the microglia trying to cope with a 
changing environment. This is supported by the fact that microglia with age 
downregulate receptors that would be activated by endogenous ligands and upregulate 
those that sense exogenous ligands potentially trying to limit their activation to changes 
in the brain environment while also maintaining an immune-vigilant state96,97. However, 
it must also be considered that these cells do appear to be more inflammatory and that 
this can have negative consequences for example triggering apoptosis in neurons55. The 
production of inflammatory mediators could be a direct consequence of a changing 
environment and therefore influenced by age-related changes. However they could also 
potentially be due to intrinsic changes within the cells or a combination of both. It was 
shown recently that macrophages undergo epigenetic modifications that had a profound 
affect on the macrophage phenotype determining if the cells became primed or 
tolerised. This ultimately led to an effect on the cytokines produced by the cells in 
response to a number of ligands231. It is therefore conceivable that during lifespan, 
microglia become epigenetically modified depending on the endogenous/exogenous 
ligands they encounter. This may explain how the microglia become primed and are 
then over responsive in the changing environment of the brain. Therefore it is possible 
that both intrinsic and extrinsic factors influence how microglia change with age.  
 
 
8.4 Future work  
 
My work still leaves many questions unanswered; most notably the molecular 
mechanisms that are responsible for the phenotype observed in Rheb KO mice after 
LPS stimulation. I have attempted to carry out experiments to define the signalling in 
Rheb KO myeloid cells, however, they have been technically challenging, due to 
inconsistent growth of BMDMs derived from Rheb KO mice. There are a number of 
alternative ways to study cell signalling and they will be discussed below. I would also 
like to answer the following questions: 
 
1. Does mTOR inhibition in microglia affect neurotoxicity?  
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2. What are the effects of inhibiting mTOR at different levels on the host’s ability 
to clear infections? How is age affecting this process?  
3. Are the results obtained from my long-term rapamycin ageing study 
reproducible? Could the effect depend on variables such as mice being tolerized 
or their microbiota? 
 
8.4.1 Molecular mechanism of increased NF- κB. activation 
 
The main aim of my future work is to understand the molecular mechanisms that govern 
the phenotype of Rheb KO mice. As described in Fig. 8.1B, I want to understand if the 
transcript changes we observe are due to NF-κB activation and if the cytokines are not 
translated because of broad or specific block in translation, most likely linked to 4E-
BP1 phosphorylation.  Since the growth of BMDMs appears to be affected by the 
deletion of Rheb, as well as using BMDMs, which require a differentiation step in vitro, 
I will use primary microglia obtained from neonatal mice. These cells are grown on a 
feeder layer of astrocytes for 10 days and it is possible that their growth may not be as 
affected as BMDMs. I will also use macrophages already differentiated, obtained from 
the peritoneum. Given that the growth of myeloid cells did not appear to be affected in 
vivo, peritoneal macrophages may be a useful alternative to cultured cells.  
 
I plan to compare the signalling events that occur after LPS stimulation in Rheb KO 
cells and cells treated with rapamycin or Torin1, in order to understand their different 
effects on signalling and NF-κB activation.  
8.4.2 mTOR inhibition and neurotoxicity  
 
I will also generate neuronal cultures from day 18 embryonic tissue by dissecting the 
hippocampus and establishing cultures for 10-12 days on poly-D-lysine.  I will treat 
Rheb KO microglia, rapamycin-treated, Torin1-treated or WT microglia with 200 ng/ml 
of LPS for 20-24 hours in order to induce the production and secretion of pro-
inflammatory and neurotoxic factors. I will then use this culture media to assess if 
different modes of mTOR inhibition in microglia lead to more or less neurotoxicity. 
Neuronal cell death can be assessed using the MTT assay. I can also use blocking 
antibodies or inhibitors to block certain neurotoxic factors, if more neurotoxicity was 
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observed. For example, I could use an inhibitor for Il-1β, in order to see if blocking 
this cytokine could reverse a potential increased neurotoxicity when mTOR is inhibited 
in microglia.  
8.4.3 The effect of mTOR inhibition on clearing infections in the 
elderly  
 
It would be really interesting and relevant to ageing research to understand what effect 
the different modes of mTOR inhibition would have on the ability of the host to clear 
infections. To answer this question, I could use young and aged Rheb KO or WT mice 
pre-treated with rapamycin/Torin 1 and then expose them to a basic infection often 
encountered by the elderly, for example influenza. It has been well documented that 
elderly people have increased susceptibility to this disease and it has been shown that 
elderly mice infected with the virus have increased mortality compared to their younger 
counterparts.  I could then measure overall survival, as well as viral titers in the lungs 
and overall inflammation. It would be more relevant to do this study using long-term 
treatments with rapamycin or Torin1, however using a short 3-day pre-treatment similar 
to other studies might be necessary to distinguish the effect of long-term and short-term 
mTOR inhibition.  
 
8.4.4 Questions unanswered from the rapamycin in vivo experiment 
 
It would also be important to understand if the results obtained in my long-term 
rapamycin ageing study are reproducible, since it is possible that they are affected by 
the past history of infections in mice (if there was one) and/or by their microbiota. To 
this end, it would be important to repeat the experiment on a new cohort of young and 
aged mice. It would also be important to use both male and female mice to eliminate 
any gender-specific differences and to include both LPS and PBS treated groups, in 
order to gain information about changes to the baseline level of inflammatory cytokines 
when rapamycin is used long term.  
 
I also need to establish if all the mice used in my original study received equal amounts 
of rapamycin, by measuring it in the blood using targeted mass spectrometry.  If my 
results are reproducible and an overall reduction in the inflammatory response occurs at 
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transcript and protein level when rapamycin is used long term, it would be interesting to 
understand why this differs to short-term rapamycin treatment, which caused a more 
pronounced inflammatory response in Balb/c mice234. Why does long-term rapamycin 
treatment result in the opposite response? Could it be through and additional effect on 
mTORC2 or PI3K signalling as discussed above? Or an overall systemic adaptation to 
rapamycin treatment, i.e. are the metabolic changes caused by rapamycin affecting the 
inflammatory response? Are these differences strain specific? 
 
In this respect, it would be useful to have an in vitro system to mimic long-term 
rapamycin treatment, which might be technically challenging.  One potential strategy 
could be to inhibit the mTOR pathway in a macrophage-like cell line, for example the 
RAW 264.7. It would be interesting to compare long-term inhibition, for example 14 
days, with short-term inhibition (24 hours) and see if the two treatments cause similar 
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